Publikationen

Die Klinik für Stammzelltransplantation ist eine sehr forschungsaktive Klinik. In den letzten 25 Jahren seit Ihres Bestehens hat die Klinik wesentliche Beiträge in der Grundlagenforschung und der klinischen Forschung geleistet. Mehr als 700 Arbeiten in internationalen Fachjournalen (peer-reviewed) wurden in dieser Zeit veöffentlicht.

Buckdeckel "Allogene Stammzelltherapie"
Lupe zum Vergrößern des Bildes
Allogene Stammzelltherapie (zum Vergrößern bitte anklicken)

Allogene Stammzelltherapie -
Grundlagen, Indikationen und Perspektiven

Prof. Dr. Nicolaus Kröger und Prof. Dr. Dr. h.c. Axel R. Zander (Hrsg.)

Interdisziplinäre Klinik für Stammzelltransplantation, Universitätsklinikum Hamburg-Eppendorf

UNI-MED, 4., neubearb. Auflage 2015, 212 Seiten, Hardcover, ISBN 978-3-8374-2346-4

Wissenschaftliche Publikationen unserer Mitarbeiter

isTab: true
Zurück
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1987
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
Vor

Umstellung häufig verordneter Kapselrezepturen in der Pädiatrie und Neonatologie auf flüssige Oralia im Krankenhaus
Albrecht S, Scherließ R, Baehr M, Goerke A, Langebrake C
Krankenhauspharmazie. 2017;38(10):459-68.

Wenn dem Blut der Sauerstoff ausgeht... Bisherige Erkenntnisse und Besonderheiten der Pharmakotherapie bei erwachsenen ECMO-Patienten
Alihodzic D, Kluge S, Langebrake C
Krankenhauspharmazie. 2017;38(2):77-85.

Genetic barcodes facilitate competitive clonal analyses in vivo
Aranyossy T, Thielecke L, Glauche I, Fehse B, Cornils K
HUM GENE THER. 2017;28(10):926-937.

Coupled Proliferation and Apoptosis Maintain the Rapid Turnover of Microglia in the Adult Brain
Askew K, Li K, Olmos-Alonso A, Garcia-Moreno F, Liang Y, Richardson P, Tipton T, Chapman M, Riecken K, Beccari S, Sierra A, Molnár Z, Cragg M, Garaschuk O, Perry V, Gomez-Nicola D
CELL REP. 2017;18(2):391-405.

Coinhibitory molecule PD-1 as a therapeutic target in the microenvironment of Multiple Myeloma
Atanackovic D, Luetkens T, Steinbach M, Kröger N
CURR CANCER DRUG TAR. 2017 [Epub ahead of print].

Cetuximab resistance in head and neck cancer is mediated by EGFR-K521 polymorphism
Braig F, Kriegs M, Habel B, Voigtländer M, Grob T, Biskup K, Blanchard V, Sack M, Thalhammer A, Ben Batalla I, Braren I, Laban S, Danielczyk A, Goletz S, Jakubowicz E, Märkl B, Trepel M, Knecht R, Riecken K, Fehse B, Loges S, Bokemeyer C, Binder M
CANCER RES. 2017;77(5):1188–1199.

Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT
Brissot E, Labopin M, Stelljes M, Ehninger G, Schwerdtfeger R, Finke J, Kolb H, Ganser A, Schäfer-Eckart K, Zander A, Bunjes D, Mielke S, Bethge W, Milpied N, Kalhs P, Blau I, Kröger N, Vitek A, Gramatzki M, Holler E, Schmid C, Esteve J, Mohty M, Nagler A
J HEMATOL ONCOL. 2017;10(1):130.

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)
Bug G, Burchert A, Wagner E, Kröger N, Berg T, Güller S, Metzelder S, Wolf A, Hünecke S, Bader P, Schetelig J, Serve H, Ottmann O
LEUKEMIA. 2017 [Epub ahead of print].

High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation
Cook G, Iacobelli S, van Biezen A, Ziagkos D, LeBlond V, Abraham J, McQuaker G, Schoenland S, Rambaldi A, Halaburda K, Rovira M, Sica S, Byrne J, Sanz R, Nagler A, van de Donk N, Sinisalo M, Cook M, Kröger N, De Witte T, Morris C, Garderet L
HAEMATOLOGICA. 2017;102(1):160-167.

Clonal competition in BcrAbl-driven leukemia: how transplantations can accelerate clonal conversion
Cornils K, Thielecke L, Winkelmann D, Aranyossy T, Lesche M, Dahl A, Roeder I, Fehse B, Glauche I
MOL CANCER. 2017;16(1):120.

Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, Mufti G, Fenaux P, Sanz G, Martino R, Alessandrino E, Onida F, Symeonidis A, Passweg J, Kobbe G, Ganser A, Platzbecker U, Finke J, van Gelder M, van de Loosdrecht A, Ljungman P, Stauder R, Volin L, Deeg H, Cutler C, Saber W, Champlin R, Giralt S, Anasetti C, Kröger N
BLOOD. 2017;129(13):1753-1762.

Investigating the temporal course, relevance and risk factors of fatigue over 5 years: a prospective study among patients receiving allogeneic HSCT
Esser P, Kuba K, Mehnert A, Schwinn A, Schirmer L, Schulz-Kindermann F, Kruse M, Koch U, Zander A, Kröger N, Schilling G, Götze H, Scherwath A
BONE MARROW TRANSPL. 2017;52(5):753-758.

Stability and priority of symptoms and symptom clusters among allogeneic HSCT patients within a 5-year longitudinal study
Esser P, Kuba K, Scherwath A, Johansen C, Schwinn A, Schirmer L, Schulz-Kindermann F, Kruse M, Koch U, Zander A, Kröger N, Götze H, Mehnert A
J PAIN SYMPTOM MANAG. 2017;54(4):493-500.

Posttraumatic stress disorder symptomatology in the course of allogeneic HSCT: a prospective study
Esser P, Kuba K, Scherwath A, Schirmer L, Schulz-Kindermann F, Dinkel A, Balck F, Koch U, Kröger N, Götze H, Mehnert A
J CANCER SURVIV. 2017;11(2):203-210.

CHO cells engineered for fluorescence read out of cell cycle and growth rate in real time
Fuge G, Hong Y, Riecken K, Zeng A, Jandt U
BIOTECHNOL PROGR. 2017 [Epub ahead of print].

Comparison of Different Rabbit Anti-Thymocyte Globulin Formulations in Allogeneic Stem Cell Transplantation: Systematic Literature Review and Network Meta-Analysis
Gagelmann N, Ayuk F, Wolschke C, Kröger N
BIOL BLOOD MARROW TR. 2017 [Epub ahead of print].

Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting
Garderet L, Cook G, Auner H, Bruno B, Lokhorst H, Perez-Simon J, Sahebi F, Scheid C, Morris C, van Biezen A, Sobh M, Michallet M, Gahrton G, Schönland S, Kröger N
LEUKEMIA LYMPHOMA. 2017;58(4):797-808.

Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances
Garderet L, D'Souza A, Jacobs P, van Biezen A, Schönland S, Kroeger N, Morris C, Hari P
BIOL BLOOD MARROW TR. 2017;23(7):1193-1202.

Alloreactivity: the Janus-face of hematopoietic stem cell transplantation
Gratwohl A, Sureda A, Cornelissen J, Apperley J, Dreger P, Duarte R, Greinix H, Mc Grath E, Kroeger N, Lanza F, Nagler A, Snowden J, Niederwieser D, Brand R
LEUKEMIA. 2017;31(8):1752-1759.

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival
Hartwell M, Özbek U, Holler E, Renteria A, Major-Monfried H, Reddy P, Aziz M, Hogan W, Ayuketang F, Efebera Y, Hexner E, Bunworasate U, Qayed M, Ordemann R, Wölfl M, Mielke S, Pawarode A, Chen Y, Devine S, Harris A, Jagasia M, Kitko C, Litzow M, Kröger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rösler W, Weber D, Wudhikarn K, Yanik G, Levine J, Ferrara J
JCI Insight. 2017;2(3):e89798.

Reduction of Relapse after Unrelated Donor Stem Cell Transplantation by KIR-Based Graft Selection
Heidenreich S, Kröger N
Front Immunol. 2017;8:41.

Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT
Heidenreich S, Ziagkos D, de Wreede L, van Biezen A, Finke J, Platzbecker U, Niederwieser D, Einsele H, Bethge W, Schleuning M, Beelen D, Tischer J, Nagler A, Glass B, Maertens J, Yáñez L, Beguin Y, Sill H, Scheid C, Stelljes M, Ganser A, Zachée P, Selleslag D, de Witte T, Robin M, Kröger N
BIOL BLOOD MARROW TR. 2017;23(1):44-52.

Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation
Heuser M, Gabdoulline R, Löffeld P, Dobbernack V, Kreimeyer H, Pankratz M, Flintrop M, Liebich A, Klesse S, Panagiota V, Stadler M, Wichmann M, Shahswar R, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Geffers R, Schlegelberger B, Göhring G, Kreipe H, Germing U, Ganser A, Kröger N, Koenecke C, Thol F
ANN HEMATOL. 2017;96(8):1361-1372.

Impact of non-transferrin-bound iron (NTBI) in comparison to serum ferritin on outcome after allogeneic stem cell transplantation (ASCT)
Hilken A, Langebrake C, Wolschke C, Kersten J, Rohde H, Nielsen P, Kröger N
ANN HEMATOL. 2017;96(8):1379-1388.

PTEN mediates the cross talk between breast and glial cells in brain metastases leading to rapid disease progression
Hohensee I, Chuang H, Grottke A, Werner S, Schulte A, Horn S, Lamszus K, Bartkowiak K, Witzel I, Westphal M, Matschke J, Glatzel M, Jücker M, Pukrop T, Pantel K, Wikman H
ONCOTARGET. 2017;8(4):6155-6168.

Maximizing the benefit of allogeneic stem cell transplantation in myelodysplastic syndromes
Kröger N
SEMIN HEMATOL. 2017;54(3):154-158.

Raising the bar for chronic GVHD trials
Kröger N
BLOOD. 2017;130(3):241-242.

Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)
Kröger N, Iacobelli S, Franke G, Platzbecker U, Uddin R, Hübel K, Scheid C, Weber T, Robin M, Stelljes M, Afanasyev B, Heim D, Deliliers G, Onida F, Dreger P, Pini M, Guidi S, Volin L, Günther A, Bethge W, Poiré X, Kobbe G, van Os M, Brand R, de Witte T
J CLIN ONCOL. 2017;35(19):2157-2164.

Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation
Kröger N, Panagiota V, Badbaran A, Zabelina T, Triviai I, Araujo Cruz M, Shahswar R, Ayuketang F, Gehlhaar M, Wolschke C, Bollin R, Walter C, Dugas M, Wiehlmann L, Lehmann U, Koenecke C, Chaturvedi A, Alchalby H, Stadler M, Eder M, Christopeit M, Göhring G, Koenigsmann M, Schlegelberger B, Kreipe H, Ganser A, Stocking C, Fehse B, Thol F, Heuser M
BIOL BLOOD MARROW TR. 2017;23(7):1095-1101.

Depression and anxiety following hematopoietic stem cell transplantation: a prospective population-based study in Germany
Kuba K, Esser P, Mehnert A, Johansen C, Schwinn A, Schirmer L, Schulz-Kindermann F, Kruse M, Koch U, Zander A, Kröger N, Götze H, Scherwath A
BONE MARROW TRANSPL. 2017 [Epub ahead of print].

Cancer-and-treatment-specific distress and its impact on posttraumatic stress in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT)
Kuba K, Esser P, Scherwath A, Schirmer L, Schulz-Kindermann F, Dinkel A, Balck F, Koch U, Kröger N, Götze H, Mehnert A
PSYCHO-ONCOLOGY. 2017;26(8):1164-1171.

CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
Locke F, Pidala J, Storer B, Martin P, Pulsipher M, Chauncey T, Jacobsen N, Kröger N, Walker I, Light S, Shaw B, Beato F, Laport G, Nademanee A, Keating A, Socie G, Anasetti C
BIOL BLOOD MARROW TR. 2017;23(3):405-411.

Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Malard F, Labopin M, Stuhler G, Bittenbring J, Ganser A, Tischer J, Michallet M, Kröger N, Schmid C, Huynh A, Hallek M, Savani B, Mohty M, Nagler A
BIOL BLOOD MARROW TR. 2017;23(2):278-284.

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations
Marchetti M, Barosi G, Cervantes F, Birgegård G, Griesshammer M, Harrison C, Hehlmann R, Kiladjian J, Kröger N, McMullin M, Passamonti F, Vannucchi A, Barbui T
LEUKEMIA. 2017;31(4):882-888.

Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes
Martino R, Henseler A, van Lint M, Schaap N, Finke J, Beelen D, Vigouroux S, Alessandrino E, Mufti G, Veelken J, Bruno B, Yakoub-Agha I, Volin L, Maertens J, Or R, Leblond V, Rovira M, Kalhs P, Alvarez A, Vitek A, Sierra J, Wagner E, Robin M, de Witte T, Kröger N
BONE MARROW TRANSPL. 2017;52(8):1107-1112.

Optical Barcoding for Single-Clone Tracking to Study Tumor Heterogeneity
Mohme M, Maire C, Riecken K, Zapf S, Aranyossy T, Westphal M, Lamszus K, Fehse B
MOL THER. 2017;25(3):621-633.

Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT
Neuenhahn M, Albrecht J, Odendahl M, Schlott F, Dössinger G, Schiemann M, Lakshmipathi S, Martin K, Bunjes D, Harsdorf S, Weissinger E, Menzel H, Verbeek M, Uharek L, Kröger N, Wagner E, Kobbe G, Schroeder T, Schmitt M, Held G, Herr W, Germeroth L, Bonig H, Tonn T, Einsele H, Busch D, Grigoleit G
LEUKEMIA. 2017 [Epub ahead of print].

Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection
Oberle A, Brandt A, Alawi M, Langebrake C, Janjetovic S, Wolschke C, Schütze K, Bannas P, Kröger N, Koch-Nolte F, Bokemeyer C, Binder M
HAEMATOLOGICA. 2017;102(9):e368-e370.

Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
Onida F, de Wreede L, van Biezen A, Eikema D, Byrne J, Iori A, Schots R, Jungova A, Schetelig J, Finke J, Veelken H, Johansson J, Craddock C, Stelljes M, Theobald M, Holler E, Schanz U, Schaap N, Bittenbring J, Olavarria E, Chalandon Y, Kröger N
BRIT J HAEMATOL. 2017;177(5):759-765.

In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review
Oostvogels R, Uniken Venema S, de Witte M, Raymakers R, Kuball J, Kröger N, Minnema M
BONE MARROW TRANSPL. 2017;52(9):1233-1240.

Mutations in EXTL3 Cause Neuro-immuno-skeletal Dysplasia Syndrome
Oud M, Tuijnenburg P, Hempel M, van Vlies N, Ren Z, Ferdinandusse S, Jansen M, Santer R, Johannsen J, Bacchelli C, Alders M, Li R, Davies R, Dupuis L, Cale C, Wanders R, Pals S, Ocaka L, James C, Müller I, Lehmberg K, Strom T, Engels H, Williams H, Beales P, Roepman R, Dias P, Brunner H, Cobben J, Hall C, Hartley T, Le Quesne Stabej P, Mendoza-Londono R, Davies E, de Sousa S, Lessel D, Arts H, Kuijpers T
AM J HUM GENET. 2017;100(2):281-296.

Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT)
Passweg J, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte R, Dufour C, Kuball J, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Nagler A, Sureda A, Mohty M
BONE MARROW TRANSPL. 2017;52(2):191-196.

Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report
Passweg J, Baldomero H, Bader P, Bonini C, Duarte R, Dufour C, Gennery A, Kröger N, Kuball J, Lanza F, Montoto S, Nagler A, Snowden J, Styczynski J, Mohty M
BONE MARROW TRANSPL. 2017;52(6):811-817.

ГЕННАЯ КЛЕТОЧНАЯ ТЕРАПИЯ ВИЧ И ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ КРОВЕТВОРНОЙ И ЛИМФАТИЧЕСКОЙ ТКАНИ НА ОСНОВЕ ТРАНСПЛАНТАЦИИ ГЕМОПОЭТИЧЕСКИХ СТВОЛОВЫХ КЛЕТОК С ИСПОЛЬЗОВАНИЕМ САЙТ-СПЕЦИФИЧЕСКОГО РЕДАКТИРОВАНИЯ ГЕНОМА
Popova M, Sergeev V, Lepik K, Shakirova A, Potter A, Barkhatov I, Fehse B, Afanasyev B
Zhurnal infektologii. 2017;9(1):31-39.

IL-33-Mediated Expansion of Type 2 Innate Lymphoid Cells Protects from Progressive Glomerulosclerosis
Riedel J, Becker M, Kopp K, Düster M, Brix S, Meyer-Schwesinger C, Kluth L, Gnirck A, Attar M, Krohn S, Fehse B, Stahl R, Panzer U, Turner J
J AM SOC NEPHROL. 2017;28(7):2068-2080.

Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT
Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N
BONE MARROW TRANSPL. 2017;52(7):1081.

Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT
Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N
BONE MARROW TRANSPL. 2017;52(2):209-215.

The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis
Ruutu T, Gratwohl A, Niederwieser D, de Witte T, van der Werf S, van Biezen A, Mohty M, Kröger N, Rambaldi A, McGrath E, Sureda A, Basak G, Greinix H, Duarte R
BONE MARROW TRANSPL. 2017;52(3):357-362.

Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party
Scheid C, de Wreede L, van Biezen A, Koenecke C, Göhring G, Volin L, Maertens J, Finke J, Passweg J, Beelen D, Cornelissen J, Itälä-Remes M, Chevallier P, Russell N, Petersen E, Milpied N, Richard Espiga C, Peniket A, Sierra J, Mufti G, Crawley C, Veelken J, Ljungman P, Cahn J, Alessandrino E, de Witte T, Robin M, Kröger N
BONE MARROW TRANSPL. 2017 [Epub ahead of print].

Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT)
Schetelig J, de Wreede L, Andersen N, Moreno C, van Gelder M, Vitek A, Karas M, Michallet M, Machaczka M, Gramatzki M, Beelen D, Finke J, Delgado J, Volin L, Passweg J, Dreger P, Schaap N, Wagner E, Henseler A, van Biezen A, Bornhäuser M, Iacobelli S, Putter H, Schönland S, Kröger N
BRIT J HAEMATOL. 2017;178(4):521-533.

Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation
Schetelig J, de Wreede L, van Gelder M, Andersen N, Moreno C, Vitek A, Karas M, Michallet M, Machaczka M, Gramatzki M, Beelen D, Finke J, Delgado J, Volin L, Passweg J, Dreger P, Henseler A, van Biezen A, Bornhäuser M, Schönland S, Kröger N
BONE MARROW TRANSPL. 2017;52(4):552-560.

Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party
Sobh M, Michallet M, Dubois V, Iacobelli S, Koster L, Van Biezen A, Fegueux N, Tabrizi R, Finke J, El-Cheikh J, Schipperus M, Meijer E, von dem Borne P, Petersen E, Russell N, Tholouli E, Passweg J, Garban F, Maertens J, Chevalier P, Maillard N, Volin L, Francois S, Lioure B, Beguin Y, Gluckman E, Ruggeri A, Garderet L, Kröger N
HAEMATOLOGICA. 2017;102(7):e271-e274.

Limitations and challenges of genetic barcode quantification
Thielecke L, Aranyossy T, Dahl A, Tiwari R, Roeder I, Geiger H, Fehse B, Glauche I, Cornils K
SCI REP-UK. 2017;7:43249.

Efficient gene editing via non-viral delivery of CRISPR-Cas9 system using polymeric and hybrid microcarriers
Timin A, Muslimov A, Lepik K, Epifanovskaya O, Shakirova A, Mock U, Riecken K, Okilova M, Sergeev V, Afanasyev B, Fehse B, Sukhorukov G
NANOMED-NANOTECHNOL. 2017 [Epub ahead of print].

Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation
van Gelder M, de Wreede L, Bornhäuser M, Niederwieser D, Karas M, Anderson N, Gramatzki M, Dreger P, Michallet M, Petersen E, Bunjes D, Potter M, Beelen D, Cornelissen J, Yakoub-Agha I, Russell N, Finke J, Schoemans H, Vitek A, Urbano-Ispízua Á, Blaise D, Volin L, Chevallier P, Caballero D, Putter H, van Biezen A, Henseler A, Schönland S, Kröger N, Schetelig J
BONE MARROW TRANSPL. 2017;52(3):372-380.

Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT
van Gelder M, Ziagkos D, de Wreede L, van Biezen A, Dreger P, Gramatzki M, Stelljes M, Andersen N, Schaap N, Vitek A, Beelen D, Lindström V, Finke J, Passweg J, Eder M, Machaczka M, Delgado J, Krüger W, Raida L, Socié G, Jindra P, Afanasyev B, Wagner E, Chalandon Y, Henseler A, Schoenland S, Kröger N, Schetelig J
Clin Lymphoma Myeloma Leuk. 2017 [Epub ahead of print].

Evaluation des Quantos-Dosiersystems für die Kapselherstellung in der Klinikapotheke: Ein Vergleich zur DAC-Methode
Vitt M, Will N, Goerke A, Löbering M, Laukart J, Baehr M, Langebrake C
Krankenhauspharmazie. 2017;38(5):220-227.

High bone turnover in mice carrying a pathogenic Notch2-mutation causing Hajdu-Cheney syndrome
Vollersen N, Hermans-Borgmeyer I, Cornils K, Fehse B, Rolvien T, Triviai I, Jeschke A, Oheim R, Amling M, Schinke T, Yorgan T
J BONE MINER RES. 2017 [Epub ahead of print].

Gene and Cell Therapy in Germany
von Kalle C, Fehse B, Büning H
HUM GENE THER. 2017;28(10):781.

Mesenchymal stem cells and myoblast differentiation under HGF and IGF-1 stimulation for 3D skeletal muscle tissue engineering
Witt R, Weigand M, Boos A, Cai A, Dippold D, Boccaccini A, Schubert D, Hardt M, Lange C, Arkudas A, Horch R, Beier J
BMC CELL BIOL. 2017;18(1):15.

Impact of molecular residual disease post allografting in myelofibrosis patients
Wolschke C, Badbaran A, Zabelina T, Christopeit M, Ayuketang F, Triviai I, Zander A, Alchalby H, Bacher U, Fehse B, Kröger N
BONE MARROW TRANSPL. 2017 [Epub ahead of print].

Mesenchymal Stromal/Stem Cells Do Not Ameliorate Experimental Autoimmune Encephalomyelitis and Are Not Detectable in the Central Nervous System of Transplanted Mice
Abramowski P, Krasemann S, Ernst T, Lange C, Ittrich H, Schweizer M, Zander A, Martin R, Fehse B
STEM CELLS DEV. 2016;25(15):1134-48.

Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis
Alchalby H, Yunus D, Zabelina T, Ayuketang F, Kröger N
BONE MARROW TRANSPL. 2016;51(9):1223-7.

β-MSCs: successful fusion of MSCs with β-cells results in a beta-cell like phenotype
Azizi-Varzaneh Z, Lange C, Paroni F, Ardestani A, Meyer A, Wu Y, Zander A, Westenfelder C, Maedler K
ONCOTARGET. 2016;7(31):48963-48977.

Digital-PCR assay for screening and quantitative monitoring of calreticulin (CALR) type-2 positive patients with myelofibrosis following allogeneic stem cell transplantation
Badbaran A, Fehse B, Christopeit M, Aranyossy T, Ayuketang F, Wolschke C, Kröger N
BONE MARROW TRANSPL. 2016;51(6):872-3.

Runx1 downregulates stem cell and megakaryocytic transcription programs that support niche interactions.
Behrens K, Triviai I, Schwieger M, Nilgun T, Alawi M, Spohn M, Indenbirken D, Ziegler M, Müller U, WS A, Stocking C
BLOOD. 2016;127(26):3369-81.

Primary Human Hepatocytes Repopulate Livers of Mice After In Vitro Culturing and Lentiviral-Mediated Gene Transfer
Bierwolf J, Volz T, Lütgehetmann M, Allweiss L, Riecken K, Warlich M, Fehse B, Kalff J, Dandri-Petersen M, Pollok J
TISSUE ENG. 2016;22(9-10):742-53.

Investigation of the Mesenchymal Stem Cell Compartment by Means of a Lentiviral Barcode Library
Bigildeev A, Cornils K, Aranyossy T, Sats N, Petinati N, Shipounova I, Surin V, Pshenichnikova O, Riecken K, Fehse B, Drize N
BIOCHEMISTRY (MOSC). 2016;81(4):373-81.

Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting)
Bruno B, Auner H, Gahrton G, Garderet L, Festuccia M, Ladetto M, Lemoli R, Massaia M, Morris C, Palumbo A, Schönland S, Boccadoro M, Kröger N
LEUKEMIA LYMPHOMA. 2016;57(6):1256-1268.

When is second allogeneic HSCT for relapse of acute leukaemia an option?
Christopeit M
BONE MARROW TRANSPL. 2016;51(2):184-5.

Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with MDS
Christopeit M, Badbaran A, Alawi M, Zabelina T, Zeck G, Wolschke C, Ayuketang F, Kröger N
EUR J HAEMATOL. 2016;97(3):288-96.

Similar outcome of calreticulin type I and calreticulin type II mutations following RIC allogeneic haematopoietic stem cell transplantation for myelofibrosis
Christopeit M, Badbaran A, Zabelina T, Zeck G, Fehse B, Ayuketang F, Wolschke C, Kröger N
BONE MARROW TRANSPL. 2016;51(10):1391-1393.

Suspected encephalitis with Candida tropicalis and Fusarium detected by unbiased RNA sequencing
Christopeit M, Grundhoff A, Rohde H, Belmar-Campos C, Grzyska U, Fiehler J, Wolschke C, Kröger N, Fischer N
ANN HEMATOL. 2016;95(11):1919-1921.

Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia
Craddock C, Labopin M, Robin M, Finke J, Chevallier P, Yakoub-Agha I, Bourhis J, Sengelov H, Blaise D, Luft T, Hallek M, Kröger N, Nagler A, Mohty M
HAEMATOLOGICA. 2016;101(7):879-83.

Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT
Cremers E, van Biezen A, de Wreede L, Scholten M, Vitek A, Finke J, Platzbecker U, Beelen D, Schwerdtfeger R, Volin L, Harhalakis N, Blijlevens N, Nagler A, Kröger N, de Witte T
ANN HEMATOL. 2016;95(12):1971-1978.

Microglia regulate hippocampal neurogenesis during chronic neurodegeneration
De Lucia C, Rinchon A, Olmos-Alonso A, Riecken K, Fehse B, Boche D, Perry V, Gomez-Nicola D
BRAIN BEHAV IMMUN. 2016;55:179-190.

Serial 18F-FDG PET for Monitoring Treatment Response After Allogeneic Stem Cell Transplantation for Myelofibrosis
Derlin T, Alchalby H, Bannas P, Laqmani A, Ayuketang F, Triviai I, Kreipe H, Bengel F, Kröger N
J NUCL MED. 2016;57(10):1556-1559.

Complementarity determining region-independent recognition of a superantigen by B-cell antigen receptors of mantle cell lymphoma
Fichtner M, Spies E, Seismann H, Riecken K, Engels N, Gösch B, Dierlamm J, Gerull H, Nollau P, Klapper W, Dreyling M, Binder M, Trepel M
HAEMATOLOGICA. 2016;101(9):e378-81.

Indication of Horizontal DNA Gene Transfer by Extracellular Vesicles
Fischer S, Cornils K, Speiseder T, Badbaran A, Reimer R, Indenbirken D, Grundhoff A, Brunswig-Spickenheier B, Alawi M, Lange C
PLOS ONE. 2016;11(9):e0163665.

Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study
Gratwohl A, Iacobelli S, Bootsman N, van Biezen A, Baldomero H, Arcese W, Arnold R, Bron D, Cordonnier C, Ernst P, Ferrant A, Frassoni F, Gahrton G, Richard C, Kolb H, Link H, Niederwieser D, Ruutu T, Schattenberg A, Schmitz N, Torres-Gomez A, Zwaan F, Apperley J, Olavarria E, Kröger N
ANN HEMATOL. 2016;95(6):967-72.

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia-A randomized comparison of stem cell transplantation with drug treatment
Gratwohl A, Pfirrmann M, Zander A, Kröger N, Beelen D, Novotny J, Nerl C, Scheid C, Spiekermann K, Mayer J, Sayer H, Falge C, Bunjes D, Döhner H, Ganser A, Schmidt-Wolf I, Schwerdtfeger R, Baurmann H, Kuse R, Schmitz N, Wehmeier A, Fischer J, Ho A, Wilhelm M, Goebeler M, Lindemann H, Bormann M, Hertenstein B, Schlimok G, Baerlocher G, Aul C, Pfreundschuh M, Fabian M, Staib P, Edinger M, Schatz M, Fauser A, Arnold R, Kindler T, Wulf G, Rosselet A, Hellmann A, Schäfer E, Prümmer O, Schenk M, Hasford J, Heimpel H, Hossfeld D, Kolb H, Büsche G, Haferlach C, Schnittger S, Müller M, Reiter A, Berger U, Saußele S, Hochhaus A, Hehlmann R
LEUKEMIA. 2016;30(3):562-9.

Acute effects of exercise on the inflammatory state in patients with idiopathic pulmonary arterial hypertension
Harbaum L, Renk E, Yousef S, Glatzel A, Lüneburg N, Hennigs J, Oqueka T, Baumann H, Atanackovic D, Grünig E, Böger R, Bokemeyer C, Klose H
BMC PULM MED. 2016;16(1):145.

International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium
Harris A, Young R, Devine S, Hogan W, Ayuketang F, Bunworasate U, Chanswangphuwana C, Efebera Y, Holler E, Litzow M, Ordemann R, Qayed M, Renteria A, Reshef R, Wölfl M, Chen Y, Goldstein S, Jagasia M, Locatelli F, Mielke S, Porter D, Schechter T, Shekhovtsova Z, Ferrara J, Levine J
BIOL BLOOD MARROW TR. 2016;22(1):4-10.

Intrinsic Deregulation of Vascular Smooth Muscle and Myofibroblast Differentiation in Mesenchymal Stromal Cells from Patients with Systemic Sclerosis
Hegner B, Schaub T, Catar R, Kusch A, Wagner P, Essin K, Lange C, Riemekasten G, Dragun D
PLOS ONE. 2016;11(4):e0153101.

Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas
Heinzelmann F, Bethge W, Beelen D, Engelhard M, Kröger N, Dreger P, Niederwieser D, Finke J, Bunjes D, Tischer J, Kobbe G, Holler E, Bornhäuser M, Stelljes M, Baurmann H, Müller A, Haubitz I, Schrezenmeier H, Müller C, Ottinger H
BONE MARROW TRANSPL. 2016;51(5):654-62.

Late acute graft versus host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors
Holtan S, Khera N, Levine J, Chai X, Storer B, Liu H, Inamoto Y, Chen G, Mayer S, Arora M, Palmer J, Flowers M, Cutler C, Lukez A, Arai S, Lazaryan A, Newell L, Krupski C, Jagasia M, Pusic I, Wood W, Renteria A, Yanik G, Hogan W, Hexner E, Ayuketang F, Holler E, Watanaboonyongcharoen P, Efebera Y, Ferrara J, Panoskaltsis-Mortari A, Weisdorf D, Lee S, Pidala J
BLOOD. 2016;128(19):2350-2358.

Lentiviral HSV-Tk.007-mediated suicide gene therapy is not toxic for normal brain cells
Hossain J, Ystaas L, Mrdalj J, Välk K, Riecken K, Fehse B, Bjerkvig R, Grønli J, Miletic H
J GENE MED. 2016;18(9):234-43.

Cytokine Expression Pattern in Bone Marrow Microenvironment after Allogeneic Stem Cell Transplantation in Primary Myelofibrosis
Hussein K, Stucki-Koch A, Alchalby H, Triviai I, Kröger N, Kreipe H
BIOL BLOOD MARROW TR. 2016;22(4):664-650.

Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation
Jaekel N, Lieder K, Albrecht S, Leismann O, Hubert K, Bug G, Kröger N, Platzbecker U, Stadler M, de Haas K, Altamura S, Muckenthaler M, Niederwieser D, Al-Ali H
BONE MARROW TRANSPL. 2016;51(1):89-95.

Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors
Kanate A, Mussetti A, Kharfan-Dabaja M, Ahn K, DiGilio A, Beitinjaneh A, Chhabra S, Fenske T, Freytes C, Gale R, Ganguly S, Hertzberg M, Klyuchnikov E, Lazarus H, Olsson R, Perales M, Rezvani A, Riches M, Saad A, Slavin S, Smith S, Sureda A, Yared J, Ciurea S, Armand P, Salit R, Bolaños-Meade J, Hamadani M
BLOOD. 2016;127(7):938-47.

Tedizolid susceptibility in linezolid- and vancomycin-resistant Enterococcus faecium isolates
Klupp E, Both A, Belmar Campos C, Büttner H, König C, Christopeit M, Christner M, Aepfelbacher M, Rohde H
EUR J CLIN MICROBIOL. 2016;35(12):1957-1961.

Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working Party
Koenecke C, Heim D, van Biezen A, Heuser M, Aljurf M, Kyrcz-Krzemien S, Volin L, de Souza C, Gedde-Dahl T, Sengeloev H, Schanz U, Komarnicki M, Arroyo C, Tholouli E, Gluckman E, Esquirol A, Yakoub-Agha I, Gürman G, Olavarria E, Kröger N
BONE MARROW TRANSPL. 2016;51(9):1259-61.

Outcome Improvement After Allogeneic Stem-Cell Transplantation in Myelofibrosis
Kröger N
J Oncol Pract. 2016;12(7):629-31.

Antilymphocyte Globulin for Chronic Graft-versus-Host Disease
Kröger N, Solano C, Bonifazi F
NEW ENGL J MED. 2016;374(19):1894-5.

Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease
Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, Nagler A, Selleri C, Risitano A, Messina G, Bethge W, Pérez de Oteiza J, Duarte R, Carella A, Cimminiello M, Guidi S, Finke J, Mordini N, Ferra C, Sierra J, Russo D, Petrini M, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuketang F, Ruutu T, Bonifazi F
NEW ENGL J MED. 2016;374(1):43-53.

Alpharetroviral self-inactivating vectors produced by a superinfection-resistant stable packaging cell line allow genetic modification of primary human T lymphocytes
Labenski V, Suerth J, Barczak E, Heckl D, Levy C, Bernadin O, Charpentier E, Williams D, Fehse B, Verhoeyen E, Schambach A
BIOMATERIALS. 2016;97:97-109.

Генная терапия на основе трансплантации гемопоэтичеcких стволовых клеток с использованием сайт-специфического редактирования генома
Lepik K, Popova M, Shakirova A, Sergeev V, Potter A, Barkhatov I, Fehse B, Afanasyev B
Genes & Cells (гены & клетки) . 2016;XI(2):21-31.

Long-term in vivo single-cell tracking reveals the switch of migration patterns in adult-born juxtaglomerular cells of the mouse olfactory bulb
Liang Y, Li K, Riecken K, Maslyukov A, Gomez-Nicola D, Kovalchuk Y, Fehse B, Garaschuk O
CELL RES. 2016;26(7):805-21.

Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation
Merz M, Jansen L, Castro F, Hillengass J, Salwender H, Weisel K, Scheid C, Luttmann S, Emrich K, Holleczek B, Katalinic A, Nennecke A, Straka C, Langer C, Engelhardt M, Einsele H, Kröger N, Beelen D, Dreger P, Brenner H, Goldschmidt H
EUR J CANCER. 2016;62:1-8.

Digital PCR to assess gene-editing frequencies (GEF-dPCR) mediated by designer nucleases
Mock U, Hauber I, Fehse B
NAT PROTOC. 2016;11(3):598-615.

Treosulfan based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicentre experience
Morillo-Gutierrez B, Beier R, Rao K, Burroughs L, Schulz A, Ewins A, Gibson B, Sedlacek P, Krol L, Strahm B, Zaidman I, Kalwak K, Talano J, Woolfrey A, Fraser C, Meyts I, Müller I, Wachowiak J, Bernardo M, Veys P, Sykora K, Gennery A, Slatter M
BLOOD. 2016;128(3):440-8.

Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually
Passweg J, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte R, Dufour C, Kuball J, Farge-Bancel D, Kröger N, Gennery A, Lanza F, Nagler A, Sureda A, Mohty M
BONE MARROW TRANSPL. 2016;51(6):786-92.

Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT
Paviglianiti A, Xavier E, Ruggeri A, Ceballos P, Deconinck E, Cornelissen J, Nguyen-Quoc S, Maillard N, Sanz G, Rohrlich P, Garderet L, Volt F, Rocha V, Kroeger N, Gluckman E, Fegueux N, Mohty M
HAEMATOLOGICA. 2016;101(9):1120-7.

Blood-borne Hepatitis E Virus Transmission: A Relevant Risk for Immunosuppressed Patients
Pischke S, Hiller J, Lütgehetmann M, Polywka S, Rybczynski M, Ayuketang F, Lohse A
CLIN INFECT DIS. 2016;63(4):569-570.

Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research
Potter V, Iacobelli S, van Biezen A, Maertens J, Bourhis J, Passweg J, Yakhoub-Agha I, Tabrizi R, Bay J, Chevallier P, Chalandon Y, Huynh A, Cahn J, Ljungman P, Craddock C, Lenhoff S, Russell N, Fegueux N, Socié G, Benedetto B, Meijer E, Mufti G, de Witte T, Robin M, Kröger N
BIOL BLOOD MARROW TR. 2016;22(9):1615-1620.

Fracture Healing Is Delayed in Immunodeficient NOD/scid‑IL2Rγcnull Mice
Rapp A, Bindl R, Recknagel S, Erbacher A, Müller I, Schrezenmeier H, Ehrnthaller C, Gebhard F, Ignatius A
PLOS ONE. 2016;11(2):e0147465.

Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis
Robin M, Porcher R, Wolschke C, Sicre de Fontbrune F, Alchalby H, Christopeit M, Cassinat B, Zabelina T, Peffault de Latour R, Ayuketang F, Socié G, Kröger N
BIOL BLOOD MARROW TR. 2016;22(7):1206-11.

The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party
Rubio M, Savani B, Labopin M, Polge E, Niederwieser D, Ganser A, Schwerdtfeger R, Ehninger G, Finke J, Renate A, Craddock C, Kröger N, Hallek M, Jindra P, Mohty M, Nagler A
J HEMATOL ONCOL. 2016;9(1):65.

Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study
Ruggeri A, Battipaglia G, Labopin M, Ehninger G, Beelen D, Tischer J, Ganser A, Schwerdtfeger R, Glass B, Finke J, Michallet M, Stelljes M, Jindra P, Arnold R, Kröger N, Mohty M, Nagler A
J HEMATOL ONCOL. 2016;9(1):89.

Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT
Savani B, Labopin M, Kröger N, Finke J, Ehninger G, Niederwieser D, Schwerdtfeger R, Bunjes D, Glass B, Socié G, Ljungman P, Craddock C, Baron F, Ciceri F, Gorin N, Esteve J, Schmid C, Giebel S, Mohty M, Nagler A
HAEMATOLOGICA. 2016;101(6):773-80.

A transplant “immunome” screening platform defines a targetable epitope fingerprint of multiple myeloma
Schieferdecker A, Oberle A, Thiele B, Hofmann F, Göthel M, Miethe S, Hust M, Braig F, Voigt M, Pein U, Nolte F, Haag F, Alawi M, Indenbirken D, Grundhoff A, Bokemeyer C, Bacher U, Kröger N, Binder M
BLOOD. 2016;127(25):3202-14.

Potent in vitro and in vivo effects of polyclonal anti-human-myeloma globulins
Schieferdecker A, Shoshani O, Westner B, Zipori D, Fehse B, Kröger N, Ayuketang F
ONCOTARGET. 2016;7(41):67061-67070.

CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation)-Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
Schmidt-Hieber M, Silling G, Schalk E, Heinz W, Panse J, Penack O, Christopeit M, Buchheidt D, Meyding-Lamadé U, Hähnel S, Wolf H, Ruhnke M, Schwartz S, Maschmeyer G
ANN ONCOL. 2016;27(7):1207-25.

Massive Clonal Selection and Transiently Contributing Clones During Expansion of Mesenchymal Stem Cell Cultures Revealed by Lentiviral RGB-Barcode Technology
Selich A, Daudert J, Hass R, Philipp F, von Kaisenberg C, Paul G, Cornils K, Fehse B, Rittinghausen S, Schambach A, Rothe M
STEM CELL TRANSL MED. 2016;5(5):591-601.

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party
Sobh M, Michallet M, Gahrton G, Iacobelli S, van Biezen A, Schönland S, Petersen E, Schaap N, Bonifazi F, Volin L, Meijer E, Niederwieser D, El Cheikh J, Tabrizi R, Fegeux N, Finke J, Bunjes D, Cornelissen J, Einsele H, Bruno B, Potter M, Fanin R, Mohty M, Garderet L, Kröger N
LEUKEMIA. 2016;30(10):2047-2054.

Efficient transformation of primary human mesenchymal stromal cells by adenovirus early region 1 oncogenes
Speiseder T, Hofmann-Sieber H, Rodríguez E, Schellenberg A, Akyüz N, Dierlamm J, Spruss T, Lange C, Dobner T
J VIROL. 2016;91(1):e01782-16.

Digital PCR Panel for Sensitive Hematopoietic Chimerism Quantification after Allogeneic Stem Cell Transplantation
Stahl T, Rothe C, Böhme M, Kohl A, Kröger N, Fehse B
INT J MOL SCI. 2016;17(9):E1515.

Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation
Styczynski J, Tridello G, Gil L, Ljungman P, Hoek J, Iacobelli S, Ward K, Cordonnier C, Einsele H, Socie G, Milpied N, Veelken H, Chevallier P, Yakoub-Agha I, Maertens J, Blaise D, Cornelissen J, Michallet M, Daguindau E, Petersen E, Passweg J, Greinix H, Duarte R, Kröger N, Dreger P, Mohty M, Nagler A, Cesaro S
J CLIN ONCOL. 2016;34(19):2212-20.

Increasing the sensitivity for stem cell monitoring in system-function based magnetic particle imaging
Them K, Salamon J, Szwargulski P, Sequeira S, Kaul M, Lange C, Ittrich H, Knopp T
PHYS MED BIOL. 2016;61(9):3279-90.

Community acquired respiratory virus infections in cancer patients-Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology
von Lilienfeld-Toal M, Berger A, Christopeit M, Hentrich M, Heussel C, Kalkreuth J, Klein M, Kochanek M, Penack O, Hauf E, Rieger C, Silling G, Vehreschild M, Weber T, Wolf H, Lehners N, Schalk E, Mayer K
EUR J CANCER. 2016;67:200-212.

Potentially Inappropriate Medication Use in Multimorbid Elderly Inpatients: Differences Between the FORTA, PRISCUS and STOPP Ratings
Wickop B, Härterich S, Sommer C, Daubmann A, Baehr M, Langebrake C
Drugs Real World Outcomes. 2016;3(3):317-325.

Übersicht - Gentherapeutische Konzepte in der Onkologie
Abramowski P, Fehse B
Tumor Diagnostik & Therapie. 2015;36(06):333-336.

Combined Application of RGB Marking and Mass Spectrometric Imaging Facilitates Detection of Tumor Heterogeneity
Abramowski P, Kraus O, Rohn S, Riecken K, Fehse B, Schlüter H
Cancer Genomics & Proteomics. 2015;12(4):179-187.

Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma
Auner H, Garderet L, Kröger N
BRIT J HAEMATOL. 2015;171(4):453-62.

Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria
Ayuketang F, Veit R, Zabelina T, Bussmann L, Christopeit M, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander A, Kröger N
ANN HEMATOL. 2015;94(10):1727-32.

Monitoring of Minimal Residual Disease After Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia Allows for the Identification of Impending Relapse: Results of the ALL-BFM-SCT 2003 Trial
Bader P, Kreyenberg H, von Stackelberg A, Eckert C, Salzmann-Manrique E, Meisel R, Poetschger U, Stachel D, Schrappe M, Alten J, Schrauder A, Schulz A, Lang P, Müller I, Albert M, Willasch A, Klingebiel T, Peters C
J CLIN ONCOL. 2015;33(11):1275 - 84.

How we manage JAK inhibition in allogeneic transplantation for myelofibrosis
Ballinger T, Savani B, Gupta V, Kröger N, Mohty M
EUR J HAEMATOL. 2015;94(2):115-119.

SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation
Bartels S, Lehmann U, Büsche G, Schlue J, Mozer M, Stadler J, Triviai I, Alchalby H, Kröger N, Kreipe H
LEUKEMIA. 2015;29(1):253-5.

Allogeneic Hematopoietic Stem Cell Transplantation in Solid Organ Transplant Recipients: A Retrospective, Multicenter Study of the EBMT
Basak G, Wiktor-Jedrzejczak W, Labopin M, Schoemans H, Ljungman P, Kobbe G, Beguin Y, Lang P, Koenecke C, Sykora K, Te Boome L, van Biezen A, van der Werf S, Mohty M, de Witte T, Marsh J, Dreger P, Kröger N, Duarte R, Ruutu T
AM J TRANSPLANT. 2015;15(3):705-14.

Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs
Ben-Batalla I, Cubas-Cordova M, Udonta F, Wroblewski M, Waizenegger J, Janning M, Sawall S, Gensch V, Zhao L, Martinez-Zubiaurre I, Riecken K, Fehse B, Pantel K, Bokemeyer C, Loges S
ONCOTARGET. 2015;6(8):6341-58.

Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer
Braig F, März M, Schieferdecker A, Schulte A, Voigt M, Stein A, Grob T, Alawi M, Indenbirken D, Kriegs M, Engel E, Vanhoefer U, Grundhoff A, Loges S, Riecken K, Fehse B, Bokemeyer C, Binder M
ONCOTARGET. 2015;6(14):12035-47.

Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia
Brissot E, Labopin M, Beckers M, Socié G, Rambaldi A, Volin L, Finke J, Lenhoff S, Kröger N, Ossenkoppele G, Craddock C, Yakoub-Agha I, Gürman G, Russell N, Aljurf M, Potter M, Nagler A, Ottmann O, Cornelissen J, Esteve J, Mohty M
HAEMATOLOGICA. 2015;100(3):392-9.

Epigenetic reprogramming and blood development
Christopeit M
EPIGENOMICS-UK. 2015;7(1):9-11.

Assessment of bone marrow inflammation in patients with myelofibrosis: an (18)F-fluorodeoxyglucose PET/CT study
Derlin T, Alchalby H, Bannas P, Veldhoen S, Apostolova I, Triviai I, Bengel F, Kröger N
EUR J NUCL MED MOL I. 2015;42(5):696-705.

Diagnostic value of 18F-FDG-PET/CT for monitoring myelofibrosis after allogeneic stem cell transplantation
Derlin T, Büsche G, Kröger N
Nucl Med Rev Cent East Eur. 2015;18(1):35-6.

18F-FDG PET/CT for Detection of Leukemic Transformation in Myelofibrosis
Derlin T, Clauditz T, Kröger N
CLIN NUCL MED. 2015;40(6):521-2.

Magnetic resonance enterography for assessment of intestinal graft-versus-host disease after allogeneic stem cell transplantation
Derlin T, Laqmani A, Veldhoen S, Apostolova I, Ayuketang F, Adam G, Kröger N, Bannas P
EUR RADIOL. 2015;25(5):1229-1237.

Gentherapie - zurück in die Zukunft?
Fehse B
BioSpektrum. 2015;15(4):448.

Genetische Manipulation: klinische Anwendung.
Fehse B, Cornils K
2015. Hämatopoetische Stammzellen. Herr W, Theobald M, Ehninger G, Einsele H, Meyer R (Hrsg.). 1. Aufl. Köln: Deutscher Ärzte-Verlag, 21-24.

Themenbereich somatische Gentherapie: Translationale und klinische Forschung
Fehse B, Domasch S
2015. Dritter Gentechnologiebericht: Analyse einer Hochtechnologie. Müller-Röber B, Budisa N, Diekämper J, Domasch S, Fehse B, Hampel J, Hucho F, Hümpel A, Köchy K, Marx-Stölting L, Reich J, Rheinberger H, Ropers H, Taupitz J, Walter J, Zenke M (Hrsg.). 1. Aufl. Baden Baden: Nomos, 211-308.

Evaluation of Unbiased Next-Generation Sequencing of RNA (RNA-seq) as a Diagnostic Method in Influenza Virus-Positive Respiratory Samples
Fischer N, Indenbirken D, Meyer T, Lütgehetmann M, Lellek H, Spohn M, Aepfelbacher M, Alawi M, Grundhoff A
J CLIN MICROBIOL. 2015;53(7):2238-50.

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen H, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre C, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E
BIOL BLOOD MARROW TR. 2015;21(12):2039-51.

Multicolor RGB Marking Allows Morphometric and Functional Analysis of Hippocampal Granule Neurons at the Single-Cell Level
Gomez-Nicola D, Riecken K, Perry V, Fehse B
HUM GENE THER. 2015;26(6):332-333.

Economics and Outcome After Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study
Gratwohl A, Sureda A, Baldomero H, Gratwohl M, Dreger P, Kröger N, Ljungman P, McGrath E, Mohty M, Nagler A, Rambaldi A, de Elvira C, Snowden J, Passweg J, Apperley J, Niederwieser D, Stijnen T, Brand R
EBioMedicine. 2015;2(12):2101-9.

Retroviral insertional mutagenesis in telomerase-immortalized hepatocytes identifies RIPK4 as novel tumor suppressor in human hepatocarcinogenesis
Heim D, Cornils K, Schulze K, Fehse B, Lohse A, Brümmendorf T, Wege H
ONCOGENE. 2015;34(3):385-393.

Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q
Heuser M, Meggendorfer M, Cruz M, Fabisch J, Klesse S, Köhler L, Göhring G, Ganster C, Shirneshan K, Gutermuth A, Cerny-Reiterer S, Krönke J, Panagiota V, Haferlach C, Koenecke C, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Ehrlich S, Stamer K, Döhner K, Valent P, Schlegelberger B, Kroeger N, Ganser A, Haase D, Haferlach T, Thol F
LEUKEMIA. 2015;29(9):1942-45.

Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial
Iacobelli S, de Wreede L, Schönland S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella A, Beksac M, Bosi A, Milone G, Corradini P, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N, Gahrton G
BONE MARROW TRANSPL. 2015;50(4):505-510.

Activation of Cell Surface Bound 20S Proteasome Inhibits Vascular Cell Growth and Arteriogenesis
Ito W, Lund N, Zhang Z, Buck F, Lellek H, Horst A, Machens H, Schunkert H, Schaper W, Meinertz T
BIOMED RES INT . 2015;2015:719316.

Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Kharfan-Dabaja M, Labopin M, Bazarbachi A, Socie G, Kroeger N, Blaise D, Veelken H, Bermudez A, Or R, Lioure B, Beelen D, Fegueux N, Hamladji R, Nagler A, Mohty M
LEUKEMIA RES. 2015;39(9):933-7.

Risk of Rotavirus Vaccination for Children with SCID
Klinkenberg D, Blohm M, Hoehne M, Mas Marques A, Malecki M, Schildgen V, Schneppenheim R, Müller I, Schildgen O, Kobbe R
PEDIATR INFECT DIS J. 2015;34(1):114-5.

Stammzelltransplantation bei malignen Lymphomen Hat sie noch eine Bedeutung?
Klyuchnikov E, Bacher U
ONKOLOGE. 2015;21(10):925-935.

Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors
Klyuchnikov E, Bacher U, Kröger N, Hari P, Ahn K, Carreras J, Bachanova V, Bashey A, Cohen J, D'Souza A, Freytes C, Gale R, Ganguly S, Hertzberg M, Holmberg L, Kharfan-Dabaja M, Klein A, Ku G, Laport G, Lazarus H, Miller A, Mussetti A, Olsson R, Slavin S, Usmani S, Vij R, Wood W, Maloney D, Sureda A, Smith S, Hamadani M
BIOL BLOOD MARROW TR. 2015;21(12):2091-2099.

Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma
Klyuchnikov E, Bacher U, Woo Ahn K, Carreras J, Kröger N, Hari P, Ku G, Ayala E, Chen A, Chen Y, Cohen J, Freytes C, Gale R, Kamble R, Kharfan-Dabaja M, Lazarus H, Martino R, Mussetti A, Savani B, Schouten H, Usmani S, Wiernik P, Wirk B, Smith S, Sureda A, Hamadani M
BONE MARROW TRANSPL. 2015;51(1):58-66.

Extracellular Vesicles from MSC Modulate the Immune Response to Renal Allografts in a MHC Disparate Rat Model
Koch M, Lemke A, Lange C
Stem Cells Int. 2015;2015:486141.

Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation
Koenecke C, Göhring G, de Wreede L, van Biezen A, Scheid C, Volin L, Maertens J, Finke J, Schaap N, Robin M, Passweg J, Cornelissen J, Beelen D, Heuser M, de Witte T, Kröger N
HAEMATOLOGICA. 2015;100(3):400-8.

Current Challenges in Stem Cell Transplantation in Myelofibrosis
Kröger N
Curr Hematol Malig Rep. 2015;10(4):344-50.

Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL)
Kröger N, Bornhäuser M, Stelljes M, Pichlmeier U, Trenschel R, Schmid C, Arnold R, Martin H, Heinzelmann M, Wolschke C, Meyer R, Bethge W, Kobbe G, Ayuketang F, Gökbuget N, Hölzer D, Zander A, Beelen D
BONE MARROW TRANSPL. 2015;50(12):1503-7.

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group
Kröger N, Deeg J, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, Rambaldi A, Mesa R, Tefferi A, Griesshammer M, Gupta V, Harrison C, Alchalby H, Vannucchi A, Cervantes F, Robin M, Ditschkowski M, Fauble V, McLornan D, Ballen K, Popat U, Passamonti F, Rondelli D, Barosi G
LEUKEMIA. 2015;29(11):2126-33.

Impact of allogeneic stem cell transplantation on survival of patients less than 65 years with primary myelofibrosis
Kröger N, Giorgino T, Scott B, Ditschkowski M, Alchalby H, Cervantes F, Vannucchi A, Cazzola M, Morra E, Zabelina T, Maffioli M, Pereira A, Beelen D, Deeg H, Passamonti F
BLOOD. 2015;125(21):3347-3350.

Donor choice in haploidentical stem cell transplantation: fetal microchimerism is associated with better outcome in pediatric leukemia patients
Kruchen A, Stahl T, Gieseke F, Binder T, Özcan Z, Meisel R, Kreyenberg H, Bader P, Gruhn B, Greil J, Pfeiffer M, Döring M, Handgretinger R, Fehse B, Müller I
BONE MARROW TRANSPL. 2015;50(10):1367-1370.

Impaired bone remodeling and its correction by combination therapy in a mouse model of mucopolysaccharidosis-I
Kühn S, Koehne T, Cornils K, Markmann S, Riedel C, Pestka J, Schweizer M, Baldauf C, Yorgan T, Krause M, Keller J, Neven M, Breyer S, Stücker R, Muschol N, Busse B, Braulke T, Fehse B, Amling M, Schinke T
HUM MOL GENET. 2015;24(24):7075-7086.

Cancer-testis antigen MAGEC2 promotes proliferation and resistance to apoptosis in Multiple Myeloma
Lajmi N, Luetkens T, Yousef S, Templin J, Cao Y, Hildebrandt Y, Bartels K, Kröger N, Atanackovic D
BRIT J HAEMATOL. 2015;171(5):752-62.

Nationwide Evaluation of Day-to-Day Clinical Pharmacists' Interventions in German Hospitals
Langebrake C, Ihbe-Heffinger A, Leichenberg K, Kaden S, Kunkel M, Lueb M, Hilgarth H, Hohmann C
PHARMACOTHERAPY. 2015;35(4):370-9.

Mesenchymal Stromal Cells Protect From Acute Radiation Syndromes: Insights into Possible Mechanisms
Lange C
Medico-Biological and Socio-Psychological Problems of Safety in Emergency Situations. 2015;1(1):5-17.

Treatment of Acute Radiation Syndromes with Transplantation of Bone Marrow-derived Mesenchymal Stromal Cells.
Lange C, Reimer R, Zustin J, Brunswig-Spickenheier B
2015. Biological Responses, Monitoring and Protection from Radiation Exposure. Mishra K (Hrsg.). 1.. Aufl. Hauppauge, NY 11788-3619, USA: NOVA SCIENCE PUBLISHERS, 149-164.

Emergence of daptomycin non-susceptibility in colonizing vancomycin-resistant Enterococcus faecium isolates during daptomycin therapy
Lellek H, Franke G, Ruckert C, Wolters M, Wolschke C, Christner M, Büttner H, Alawi M, Kröger N, Rohde H
INT J MED MICROBIOL. 2015;305(8):902-909.

Drosophila homologue of Diaphanous 1 (DIAPH1) controls the metastatic potential of colon cancer cells by regulating microtubule-dependent adhesion
Lin Y, Bhuwania R, Gromova K, Failla A, Lange T, Riecken K, Linder S, Kneussel M, Izbicki J, Windhorst S
ONCOTARGET. 2015;6(21):18577-89.

Lrp1/LDL receptor play critical roles in mannose 6-phosphate-independent lysosomal enzyme targeting
Markmann S, Thelen M, Cornils K, Schweizer M, Brocke-Ahmadinejad N, Willnow T, Heeren J, Gieselmann V, Braulke T, Kollmann K
TRAFFIC. 2015.

Atovaquone for Prophylaxis of Toxoplasmosis after Allogeneic Hematopoietic Stem Cell Transplantation.
Mendorf A, Klyuchnikov E, Langebrake C, Rohde H, Ayuketang F, Regier M, Christopeit M, Zabelina T, Bacher A, Stübig T, Wolschke C, Bacher U, Kroger N
ACTA HAEMATOL-BASEL. 2015;134(3):146-154.

Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen
Michaelis M, Agha B, Rothweiler F, Löschmann N, Voges Y, Mittelbronn M, Starzetz T, Harter P, Abhari B, Fulda S, Westermann F, Riecken K, Spek S, Langer K, Wiese M, Dirks W, Zehner R, Cinatl J, Wass M, Cinatl J
SCI REP-UK. 2015;5:8202.

Gezielter CCR5-Knockout in primären T-Lymphozyten zur Verhinderung der HIV-Infektion
Mock U, Fehse B
2015.

mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5
Mock U, Machowicz R, Hauber I, Horn S, Abramowski P, Berdien B, Hauber J, Fehse B
NUCLEIC ACIDS RES. 2015;43(11):5560-5571.

Efficacy and outcome of allogeneic transplantation in IgD and non secretory myeloma. A report on behalf of the myeloma subcommittee of the Chronic Malignancies Working Party of the EBMT
Morris C, Iacobelli S, Gahrton G, van Biezen A, Drake M, Garderet L, Potter M, Schattenberg A, Cornelissen J, Hamladji R, Martelli M, Petersen E, Rovira M, Bandini G, Kröger N, de Witte T
BIOL BLOOD MARROW TR. 2015;21(6):1054-8.

Targeting species D adenoviruses replication to counteract the epidemic keratoconjunctivitis
Nikitenko N, Speiseder T, Groitl P, Spirin P, Prokofjeva M, Lebedev T, Rubtsov P, Lam E, Riecken K, Fehse B, Dobner T, Prassolov V
BIOCHIMIE. 2015;113:10-16.

New IDH1 mutant inhibitors for treatment of acute myeloid leukemia
Okoye-Okafor U, Bartholdy B, Cartier J, Gao E, Pietrak B, Rendina A, Rominger C, Quinn C, Smallwood A, Wiggall K, Reif A, Schmidt S, Qi H, Zhao H, Joberty G, Faelth-Savitski M, Bantscheff M, Drewes G, Duraiswami C, Brady P, Groy A, Narayanagari S, Antony-Debre I, Mitchell K, Wang H, Kao Y, Christopeit M, Carvajal L, Barreyro L, Paietta E, Makishima H, Will B, Concha N, Adams N, Schwartz B, McCabe M, Maciejewski J, Verma A, Steidl U
NAT CHEM BIOL. 2015;11(11):878-86.

JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms
Parampalli Yajnanarayana S, Stübig T, Cornez I, Alchalby H, Schönberg K, Rudolph J, Triviai I, Wolschke C, Heine A, Brossart P, Kröger N, Wolf D
BRIT J HAEMATOL. 2015;169(6):824-33.

Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants
Passweg J, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte R, Dufour C, Falkenburg J, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Nagler A, Sureda A, Mohty M
BONE MARROW TRANSPL. 2015;50(4):476-482.

УНИВЕРСАЛЬНАЯ МОДУЛЬНАЯ СИСТЕМА СКРИНИНГА IN VITRO ПОТЕНЦИАЛЬНЫХ ИНГИБИТОРОВ РЕПЛИКАЦИИ ВИЧ-1
Prokof'eva M, Orlova N, Gornostaeva A, Shul'gin A, Nikitenko N, Senchenko V, Lebedev T, Spirin P, Riecken K, Fehse B, Stocking C, Prasolov V
MOL BIOL (MOSK). 2015;48(2):344-8.

Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A, Guglielmi C, Bergantini S, Iacobelli S, van Biezen A, Milojkovic D, Gratwohl A, Schattenberg A, Verdonck L, Niederwieser D, de Witte T, Kröger N, Olavarria E
BIOL BLOOD MARROW TR. 2015;21(7):1230-1236.

Systemic mesenchymal stem cell administration enhances bone formation in fracture repair but not load-induced bone formation
Rapp A, Bindl R, Heilmann A, Erbacher A, Müller I, Brenner R, Ignatius A
EUR CELLS MATER. 2015;29:22-34.

Comparison of Unrelated Cord Blood and Peripheral Blood Stem Cell Transplantation in Adults with Myelodysplastic Syndrome after Reduced-Intensity Conditioning Regimen: A Collaborative Study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party
Robin M, Ruggeri A, Labopin M, Niederwieser D, Tabrizi R, Sanz G, Bourhis J, van Biezen A, Koenecke C, Blaise D, Tischer J, Craddock C, Maillard N, Mohty M, Russel N, Schetelig J, Finke J, Gluckman E, de Witte T, Rocha V, Kroger N, Kröger N
BIOL BLOOD MARROW TR. 2015;21(3):489-95.

Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT
Ruutu T, de Wreede L, van Biezen A, Brand R, Mohty M, Dreger P, Duarte R, Peters C, Garderet L, Schönland S, Gratwohl A, Niederwieser D, de Witte T, Kröger N
BONE MARROW TRANSPL. 2015;50(12):1542-50.

Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma
Sahebi F, Iacobelli S, Biezen A, Volin L, Dreger P, Michallet M, Ljungman P, de Witte T, Henseler A, Schaap N, López-Corral L, Poire X, Passweg J, Hamljadi R, Thomas S, Schonland S, Gahrton G, Morris C, Kröger N, Garderet L
BONE MARROW TRANSPL. 2015;50(6):802-807.

Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study
Shouval R, Labopin M, Bondi O, Mishan-Shamay H, Shimoni A, Ciceri F, Esteve J, Giebel S, Gorin N, Schmid C, Polge E, Aljurf M, Kroger N, Craddock C, Bacigalupo A, Cornelissen J, Baron F, Unger R, Nagler A, Mohty M
J CLIN ONCOL. 2015;33(28):3144-51.

Digital PCR to assess hematopoietic chimerism after allogeneic stem cell transplantation
Stahl T, Böhme M, Kröger N, Fehse B
EXP HEMATOL. 2015;43(6):462-468.

Stammzelltransplantation bei Multipler Sklerose. Hamburger Erfahrungen und internationaler Forschungsstand
Stellmann J, Stürner K, Ufer F, Havemeister S, Pöttgen J, Ayuketang F, Kröger N, Friese M, Heesen C
NERVENARZT. 2015;86(8):989-96.

Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015
Sureda A, Bader P, Cesaro S, Dreger P, Duarte R, Dufour C, Falkenburg J, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Marsh J, Nagler A, Peters C, Velardi A, Mohty M, Madrigal A
BONE MARROW TRANSPL. 2015;50(8):1037-56.

Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
Symeonidis A, van Biezen A, de Wreede L, Piciocchi A, Finke J, Beelen D, Bornhäuser M, Cornelissen J, Volin L, Mufti G, Chalandon Y, Ganser A, Bruno B, Niederwieser D, Kobbe G, Schwerdtfeger R, de Witte T, Robin M, Kröger N
BRIT J HAEMATOL. 2015 [Epub ahead of print].

Treatment of multifocal breast cancer by systemic delivery of dual-targeted adeno-associated viral vectors
Trepel M, Körbelin J, Spies E, Heckmann M, Hunger A, Fehse B, Katus H, Kleinschmidt J, Müller O, Michelfelder S
GENE THER. 2015;22(10):840-847.

Treatment of multifocal breast cancer by systemic delivery of dual-targeted adeno-associated viral vectors
Trepel M, Körbelin J, Spies E, Heckmann M, Hunger A, Fehse B, Katus H, Kleinschmidt J, Müller O, Michelfelder S
GENE THER. 2015;22(10):840-7.

CD133 marks a stem cell population that drives human Primary Myelofibrosis
Triviai I, Stübig T, Niebuhr B, Hussein K, Tsiftsoglou A, Fehse B, Stocking C, Kröger N
HAEMATOLOGICA. 2015;100(6):768-79.

Possible role of minor h antigens in the persistence of donor chimerism after stem cell transplantation; relevance for sustained leukemia remission
van der Torren C, van Hensbergen Y, Luther S, Aghai Z, Rychnavská Z, Slot M, Scherjon S, Kröger N, Ganser A, Weissinger E, Goulmy E, Hambach L
PLOS ONE. 2015;10(3):e0119595.

Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Vannucchi A, Barbui T, Cervantes F, Harrison C, Kiladjian J, Kröger N, Thiele J, Buske C
ANN ONCOL. 2015;26 Suppl 5:v85-99.

Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma
Waizenegger J, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Fiedler W, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab M, Pantel K, Bokemeyer C, Loges S
LEUKEMIA. 2015;29(3):696-704.

Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects
Wellbrock J, Latuske E, Köhler J, Wagner K, Stamm H, Vettorazzi E, Vohwinkel G, Klokow M, Uibeleisen R, Ehm P, Riecken K, Loges S, Thol F, Schubert C, Amling M, Jücker M, Bokemeyer C, Heuser M, Krauter J, Fiedler W
CLIN CANCER RES. 2015.

Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Societé Française de Greffe de Moelle et Therapie Cellulaire
Xavier E, Cornillon J, Ruggeri A, Chevallier P, Cornelissen J, Andersen N, Maillard N, Nguyen S, Blaise D, Deconinck E, Veelken H, Milpied N, Van Gelder M, Peffault de Latour R, Gluckman E, Kröger N, Schetelig J, Rocha V
BIOL BLOOD MARROW TR. 2015;21(8):1515-23.

Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma
Yousef S, Heise J, Lajmi N, Bartels K, Kröger N, Luetkens T, Atanackovic D
J TRANSL MED. 2015;13:197.

CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma
Yousef S, Kovacsovics-Bankowski M, Salama M, Bhardwaj N, Steinbach M, Langemo A, Kovacsovics T, Marvin J, Binder M, Panse J, Kröger N, Luetkens T, Atanackovic D
HUM VACC IMMUNOTHER . 2015;11(7):1606-11.

Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients
Yousef S, Marvin J, Steinbach M, Langemo A, Kovacsovics T, Binder M, Kröger N, Luetkens T, Atanackovic D
BLOOD CANCER J. 2015;5:e285.

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder S, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuketang F, Ajib S, de Fontbrune F, Na I, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit G, Kuball J, Flynn R, Ihorst G, Du J, Blazar B, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N
LEUKEMIA. 2015;29(10):2062-8.

A truncation variant of the cation channel P2RX5 is upregulated during T cell activation
Abramowski P, Ogrodowczyk C, Martin R, Pongs O
PLOS ONE. 2014;9(9):e104692.

The orally available, synthetic ether lipid edelfosine inhibits T cell proliferation and induces a type I interferon response
Abramowski P, Otto B, Martin R
PLOS ONE. 2014;9(3):e91970.

Immunomodulatory effects of the ether phospholipid edelfosine in experimental autoimmune encephalomyelitis
Abramowski P, Steinbach K, Zander A, Martin R
J NEUROIMMUNOL. 2014;274(1-2):111-24.

Allogeneic stem cell transplant vs.Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera
Alchalby H, Kröger N
Clin Lymphoma Myeloma Leuk. 2014;14 Suppl:S36-41.

Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation
Alchalby H, Zabelina T, Stübig T, van Biezen A, Bornhäuser M, Di Bartolomeo P, Beelen D, Cahn J, Dreger P, Schroyens W, de Witte T, Olavarria E, Kröger N
BIOL BLOOD MARROW TR. 2014;20(2):279-81.

Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma
Atanackovic D, Luetkens T, Kröger N
LEUKEMIA. 2014;28(5):993-1000.

Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years
Auner H, Szydlo R, Hoek J, Goldschmidt H, Stoppa A, Morgan G, Moreau P, Attal M, Marit G, Russell N, Brune M, Cook G, Sonneveld P, Schönland S, Garderet L, Kröger N
BONE MARROW TRANSPL. 2014;50(2):209-215.

Selected CD34 Stem cells for Graft Engineering: 34 Case Reports in Hematopoietic Stem Cell Transplantation
Aversa F, Kroger N
2014.

Serum albumin level predicts survival of patients with gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation
Ayuketang F, Bussmann L, Zabelina T, Veit R, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander A, Kröger N
ANN HEMATOL. 2014;93(5):855-61.

Kopplung von elektronischer Verordnung und patientenorientierter Logistik
Baehr M, van der Linde A, König R, Melzer S, Langebrake C, Grothe-Tenberge C, Hug M
Krankenhauspharmazie. 2014;35(4):110-117.

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
Barosi G, Tefferi A, Besses C, Birgegard G, Cervantes F, Finazzi G, Gisslinger H, Griesshammer M, Harrison C, Hehlmann R, Hermouet S, Kiladjian J, Kröger N, Mesa R, Mc Mullin M, Pardanani A, Passamonti F, Samuelsson J, Vannucchi A, Reiter A, Silver R, Verstovsek S, Tognoni G, Barbui T
LEUKEMIA. 2014.

TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer
Berdien B, Mock U, Atanackovic D, Fehse B
GENE THER. 2014;21:539–548.

Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT
Chalandon Y, Passweg J, Guglielmi C, Iacobelli S, Apperley J, Schaap N, Finke J, Robin M, Fedele R, Bron D, Yakoub-Agha I, van Biezen A, de Witte T, Kröger N, Olavarria E
HAEMATOLOGICA. 2014;99(9):1492-8.

Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation
Chemaly R, Ullmann A, Stoelben S, Richard M, Bornhäuser M, Groth C, Einsele H, Silverman M, Mullane K, Brown J, Nowak H, Kölling K, Stobernack H, Lischka P, Zimmermann H, Rübsamen-Schaeff H, Champlin R, Ehninger G
NEW ENGL J MED. 2014;370(19):1781-9.

IMWG consensus on risk stratification in multiple myeloma
Chng W, Dispenzieri A, Chim C, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel J, Sonneveld P, Cavo M, Usmani S, Durie B, Avet-Loiseau H
LEUKEMIA. 2014;28(2):269-77.

Epigenetic signatures as prognostic tools in acute myeloid leukemia and myelodysplastic syndromes
Christopeit M, Bartholdy B
EPIGENOMICS-UK. 2014;6(4):371-4.

Relapse assessment following allogeneic SCT in patients with MDS and AML
Christopeit M, Kröger N, Haferlach T, Bacher U
ANN HEMATOL. 2014;93(7):1097-110.

Multiplexing clonality: combining RGB marking and genetic barcoding
Cornils K, Thielecke L, Hüser S, Forgber M, Thomaschewski M, Kleist N, Hussein K, Riecken K, Volz T, Gerdes S, Glauche I, Dahl A, Dandri M, Roeder I, Fehse B
NUCLEIC ACIDS RES. 2014;42(7):e56.

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation
de Lima M, Porter D, Battiwalla M, Bishop M, Giralt S, Hardy N, Kröger N, Wayne A, Schmid C
BIOL BLOOD MARROW TR. 2014;20(1):4-13.

Should patients with high-risk or transformed myelodysplastic syndrome proceed directly to allogeneic transplant without prior cytoreduction by remission-induction chemotherapy or hypomethylating agent therapy?
de Witte T, Bowen D, Robin M, Malcovati L, Mufti G, Niederwieser D, Yakoubagha I, Kröger N
Clin Lymphoma Myeloma Leuk. 2014;14 Suppl:S42-5.

Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study
de Wreede L, Watson M, van Os M, Milligan D, van Gelder M, Michallet M, Dreger P, Dearden C, Homewood J, Dupuis J, Leporrier M, Karas M, Corront B, Baerlocher G, Herr W, Choquet S, Niederwieser D, Sutton L, Kröger N, de Witte T, Schetelig On Behalf Of The Chronic Malignancies Working Party Of The Ebmt And The Uk Medical Research Council J
AM J HEMATOL. 2014;89(2):174-80.

Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation
Döring M, Blume O, Haufe S, Hartmann U, Kimmig A, Schwarze C, Lang P, Handgretinger R, Müller I
EUR J CLIN MICROBIOL. 2014;33(4):629-38.

Neural stem cell-based intraocular administration of ciliary neurotrophic factor attenuates the loss of axotomized ganglion cells in adult mice
Flachsbarth K, Kruszewski K, Jung G, Jankowiak W, Riecken K, Wagenfeld L, Richard G, Fehse B, Bartsch U
INVEST OPHTH VIS SCI. 2014;55(11):7029-7039.

Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms
Fu Y, Schroeder T, Zabelina T, Badbaran A, Bacher U, Kobbe G, Ayuketang F, Wolschke C, Schnittger S, Kohlmann A, Haferlach T, Kröger N
EUR J HAEMATOL. 2014;92(3):189-94.

In-vivo RGB marking and multicolour single-cell tracking in the adult brain
Gomez-Nicola D, Riecken K, Fehse B, Perry V
SCI REP-UK. 2014;4:7520.

Temporal dynamics of hippocampal neurogenesis in chronic neurodegeneration
Gomez-Nicola D, Suzzi S, Vargas-Caballero M, Fransen N, Al-Malki H, Cebrian-Silla A, Garcia-Verdugo J, Riecken K, Fehse B, Perry V
BRAIN. 2014;137(Pt 8):2312-28.

Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis
Gupta V, Gotlib J, Radich J, Kröger N, Rondelli D, Verstovsek S, Deeg H
BIOL BLOOD MARROW TR. 2014;20(9):1274-81.

Selectins mediate small cell lung cancer systemic metastasis
Heidemann F, Schildt A, Schmid K, Bruns O, Riecken K, Jung C, Ittrich H, Wicklein D, Reimer R, Fehse B, Heeren J, Lüers G, Schumacher U, Heine M
PLOS ONE. 2014;9(4):e92327.

Low frequency of calreticulin mutations in MDS patients
Heuser M, Panagiota V, Koenecke C, Fehse B, Alchalby H, Badbaran A, Shahswar R, Stadler M, Eder M, Göhring G, Trummer A, Schroeder T, Kobbe G, Thiede C, Platzbecker U, Schlegelberger B, Kroeger N, Ganser A, Thol F
LEUKEMIA. 2014.

Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: a report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation
Hussein A, Halkes C, Socié G, Tichelli A, von dem Borne P, Schaap M, Foa R, Ganser A, Dufour C, Bacigalupo A, Locasciulli A, Aljurf M, Peters C, Robin M, van Biezen A, Volin L, De Witte T, Marsh J, Passweg J, Kröger N
BIOL BLOOD MARROW TR. 2014;20(9):1448-50.

Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?
Klyuchnikov E, Bacher U, Kroll T, Shea T, Lazarus H, Bredeson C, Fenske T
BONE MARROW TRANSPL. 2014;49(1):1-7.

CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies
Klyuchnikov E, El-Cheikh J, Sputtek A, Lioznov M, Calmels B, Furst S, Chabannon C, Crocchiolo R, Lemarié C, Faucher C, Bacher U, Alchalby H, Stübig T, Wolschke C, Ayuketang F, Reckhaus M, Blaise D, Kröger N
BIOL BLOOD MARROW TR. 2014;20(3):382-6.

Gentherapie
Köchy K, Domasch S, Fehse B
2014. Handbuch Ethik & Recht der Forschung am Menschen. Lenk C, Duttge G, Fangerau H (Hrsg.). 1. Aufl. Berlin, Heidelberg: Springer-Verlag, 427 - 432.

Inhibition of PARP1-dependent end-joining contributes to Olaparib-mediated radiosensitization in tumor cells
Kötter A, Cornils K, Borgmann K, Dahm-Daphi J, Petersen C, Dikomey E, Mansour Khalfallah W
MOL ONCOL. 2014;8(8):1616-25.

Immune-modulating drugs and hypomethylating agents to prevent or treat relapse after allogeneic stem cell transplantation
Kröger N, Stübig T, Atanackovic D
BIOL BLOOD MARROW TR. 2014;20(2):168-72.

Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis
Kröger N, Zabelina T, Alchalby H, Stübig T, Wolschke C, Ayuketang F, von Huenerbein N, Kvasnicka H, Thiele J, Kreipe H, Büsche G
BIOL BLOOD MARROW TR. 2014;20(6):812-5.

Formale Kriterien für eine gute Verordnung im stationären Bereich
Langebrake C, Melzer S, Baehr M
THER UMSCH. 2014;71(6):343-351.

Micafungin as antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell Transplantation: results of different dosage levels in clinical practice
Langebrake C, Rohde H, Lellek H, Wolschke C, Kröger N
CLIN TRANSPLANT. 2014;28(3):286-91.

Treosulfan-based conditioning regimen for children and adolescents with hemophagocytic lymphohistiocytosis
Lehmberg K, Albert M, Beier R, Beutel K, Gruhn B, Kröger N, Meisel R, Schulz A, Stachel D, Woessmann W, Janka G, Müller I
HAEMATOLOGICA. 2014;99(1):180-4.

Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation
Luetkens T, Kobold S, Cao Y, Ristic M, Schilling G, Tams S, Bartels B, Templin J, Bartels K, Hildebrandt Y, Yousef S, Marx A, Haag F, Bokemeyer C, Kröger N, Atanackovic D
CANCER IMMUNOL IMMUN. 2014;63(11):1151-62.

Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
Lussana F, Rambaldi A, Finazzi M, van Biezen A, Scholten M, Oldani E, Carobbio A, Iacobelli S, Finke J, Nagler A, Volin L, Lamy T, Arnold R, Mohty M, Michallet M, de Witte T, Olavarria E, Kröger N
HAEMATOLOGICA. 2014;99(5):916-21.

Novel lentiviral vectors with mutated reverse transcriptase for mRNA delivery of TALE nucleases
Mock U, Riecken K, Berdien B, Qasim W, Chan E, Cathomen T, Fehse B
SCI REP-UK. 2014;4:6409.

Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation
Mohty M, Hübel K, Kröger N, Aljurf M, Apperley J, Basak G, Bazarbachi A, Douglas K, Gabriel I, Garderet L, Geraldes C, Jaksic O, Kattan M, Koristek Z, Lanza F, Lemoli R, Mendeleeva L, Mikala G, Mikhailova N, Nagler A, Schouten H, Selleslag D, Suciu S, Sureda A, Worel N, Wuchter P, Chabannon C, Duarte R
BONE MARROW TRANSPL. 2014;49(7):865-72.

Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide
Morris C, de Wreede L, Scholten M, Brand R, van Biezen A, Sureda A, Dickmeiss E, Trneny M, Apperley J, Chiusolo P, van Imhoff G, Lenhoff S, Martinelli G, Hentrich M, Pabst T, Onida F, Quinn M, Kröger N, de Witte T, Ruutu T
TRANSFUSION. 2014;54(10):2514-22.

Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome
Nagler A, Labopin M, Berger R, Bunjes D, Campos A, Socié G, Kröger N, Goker H, Yakoub-Agha I, Shimoni A, Mohty M, Rocha V
BONE MARROW TRANSPL. 2014;49(5):628-33.

Synergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines
Nitsch E, Mina S, Brammer I, Pace A, Schuch G, Bokemeyer C, Zander A, Kröger N, Ayuketang F
ANTICANCER RES. 2014;34(4):1779-84.

Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism
Oehler N, Volz T, Bhadra O, Kah J, Allweiss L, Giersch K, Bierwolf J, Riecken K, Pollok J, Lohse A, Fehse B, Petersen J, Urban S, Lütgehetmann M, Heeren J, Dandri M
HEPATOLOGY. 2014.

Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party
Onida F, Brand R, van Biezen A, Schaap M, von dem Borne P, Maertens J, Beelen D, Carreras E, Alessandrino E, Volin L, Kuball J, Figuera A, Sierra J, Finke J, Kröger N, de Witte T
HAEMATOLOGICA. 2014;99(10):1582-90.

Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation
Panagiota V, Thol F, Markus B, Fehse B, Alchalby H, Badbaran A, Lehmann U, Koenecke C, Shahswar R, Chaturvedi A, Stadler M, Eder M, Göhring G, Koenigsmann M, Kloos A, Trummer A, Schroeder T, Kobbe G, Thiede C, Platzbecker U, Schlegelberger B, Kreipe H, Ganser A, Kröger N, Heuser M
LEUKEMIA. 2014;28(7):1552-5.

Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation
Passweg J, Baldomero H, Peters C, Gaspar H, Cesaro S, Dreger P, Duarte R, Falkenburg J, Farge-Bancel D, Gennery A, Halter J, Kröger N, Lanza F, Marsh J, Mohty M, Sureda A, Velardi A, Madrigal A
BONE MARROW TRANSPL. 2014;49(6):744-50.

Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO)
Penack O, Becker C, Buchheidt D, Christopeit M, Kiehl M, von Lilienfeld-Toal M, Hentrich M, Reinwald M, Salwender H, Schalk E, Schmidt-Hieber M, Weber T, Ostermann H
ANN HEMATOL. 2014;93(7):1083-95.

Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients
Reinhard H, Yousef S, Luetkens T, Fehse B, Berdien B, Kröger N, Atanackovic D
BLOOD CANCER J. 2014;4:e212.

Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis
Robin M, Giannotti F, Deconinck E, Mohty M, Michallet M, Sanz G, Chevallier P, Cahn J, Legrand F, Rovira M, Passweg J, Sierra J, Nguyen S, Maillard N, Yakoub-Agha I, Linkesch W, Cannell P, Marcatti M, Bay J, Chalandon Y, Kröger N, Gluckman E, Rocha V, Olavarria E, Ruggeri A
BIOL BLOOD MARROW TR. 2014;20(11):1841-6.

Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice
Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A, Dazzi F, Dreger P, Duarte R, Finke J, Garderet L, Greinix H, Holler E, Kröger N, Lawitschka A, Mohty M, Nagler A, Passweg J, Ringdén O, Socié G, Sierra J, Sureda A, Wiktor-Jedrzejczak W, Madrigal A, Niederwieser D
BONE MARROW TRANSPL. 2014;49(2):168-73.

Magnetic resonance imaging of single co-labeled mesenchymal stromal cells after intracardial injection in mice
Salamon J, Wicklein D, Didié M, Lange C, Schumacher U, Adam G, Peldschus K
ROFO-FORTSCHR RONTG. 2014;186(4):367-76.

Fear of recurrence and its impact on quality of life in patients with hematological cancers in the course of allogeneic hematopoietic SCT
Sarkar S, Scherwath A, Schirmer L, Schulz-Kindermann F, Neumann K, Kruse M, Dinkel A, Kunze S, Balck F, Kröger N, Koch U, Mehnert A
BONE MARROW TRANSPL. 2014;49(9):1217-22.

Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL
Schieferdecker A, Voigt M, Riecken K, Braig F, Schinke T, Loges S, Bokemeyer C, Fehse B, Binder M
ONCOTARGET. 2014;5(16):6647-53.

Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions-A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group
Schroeder T, Rachlis E, Bug G, Stelljes M, Klein S, Steckel N, Wolf D, Ringhoffer M, Czibere A, Nachtkamp K, Dienst A, Kondakci M, Stadler M, Platzbecker U, Uharek L, Luft T, Fenk R, Germing U, Bornhäuser M, Kröger N, Beelen D, Haas R, Kobbe G
BIOL BLOOD MARROW TR. 2014.

Cell adhesion molecules in metastatic neuroblastoma models
Schwankhaus N, Gathmann C, Wicklein D, Riecken K, Schumacher U, Valentiner U
CLIN EXP METASTAS. 2014;31(4):483-96.

Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis
Stern M, de Wreede L, Brand R, van Biezen A, Dreger P, Mohty M, de Witte T, Kröger N, Ruutu T
LEUKEMIA. 2014;28(11):2235-40.

JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis
Stübig T, Alchalby H, Ditschkowski M, Wolf D, Wulf G, Zabelina T, Wolschke C, Ayuketang F, Kröger N
LEUKEMIA. 2014;28(8):1736-8.

5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity
Stübig T, Badbaran A, Luetkens T, Hildebrandt Y, Atanackovic D, Binder T, Fehse B, Kröger N
MEDIAT INFLAMM. 2014;2014:418292.

Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia
Thol F, Scherr M, Kirchner A, Shahswar R, Battmer K, Kade S, Chaturvedi A, Koenecke C, Stadler M, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Bug G, Ottmann O, Hofmann W, Kröger N, Fiedler W, Schlenk R, Döhner K, Döhner H, Krauter J, Eder M, Ganser A, Heuser M
HAEMATOLOGICA. 2014.

Endogenous retrovirus induces leukemia in a xenograft mouse model for primary myelofibrosis
Triviai I, Ziegler M, Bergholz U, Oler A, Stübig T, Prassolov V, Fehse B, Kozak C, Kröger N, Stocking C
P NATL ACAD SCI USA. 2014;111(23):8595 - 8600.

Gute Verordnungspraxis bei älteren Patienten
Wickop B, Langebrake C
THER UMSCH. 2014;71(6):366-373.

Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantation
Wolschke C, Zabelina T, Ayuketang F, Alchalby H, Berger J, Klyuchnikov E, Pein U, Schumacher S, Amtsfeld G, Adjallé R, Wortmann F, Lellek H, Randenborgh A, Zander A, Kröger N
BONE MARROW TRANSPL. 2014;49(1):126-30.

Acute psychological stress increases peripheral blood CD3+CD56+ natural killer T cells in healthy men: possible implications for the development and treatment of allergic and autoimmune disorders
Atanackovic D, Nowottne U, Freier E, Weber C, Meyer S, Bartels K, Hildebrandt Y, Cao Y, Kröger N, Brunner-Weinzierl M, Bokemeyer C, Deter H
STRESS. 2013;16(4):421-8.

The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting
Atanackovic D, Reinhard H, Meyer S, Spöck S, Grob T, Luetkens T, Yousef S, Cao Y, Hildebrandt Y, Templin J, Bartels K, Lajmi N, Stoiber H, Kröger N, Atz J, Seimetz D, Izbicki J, Bokemeyer C
HUM VACC IMMUNOTHER . 2013;9(12):2533-42.

Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous Transplantation: a study by the European Group for Blood and Marrow Transplantation
Auner H, Szydlo R, van Biezen A, Iacobelli S, Gahrton G, Milpied N, Volin L, Janssen J, Nguyen Quoc S, Michallet M, Schoemans H, El Cheikh J, Petersen E, Guilhot F, Schönland S, Ahlberg L, Morris C, Garderet L, de Witte T, Kröger N
BONE MARROW TRANSPL. 2013;48(11):1395-400.

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies
Avigan D, Hari P, Battiwalla M, Bishop M, Giralt S, Hardy N, Kröger N, Wayne A, Hsu K
BIOL BLOOD MARROW TR. 2013;19(12):1661-9.

Donor choice according to age for allo-SCT for AML in complete remission
Ayuketang F, Zabelina T, Wortmann F, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander A, Kröger N
BONE MARROW TRANSPL. 2013;48(8):1028-32.

Moderne Bildgebungsverfahren beim Multiplen Myelom
Bannas P, Kröger N, Adam G, Derlin T
ROFO-FORTSCHR RONTG. 2013;185(1):26-33.

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma
Ben Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger J, Riecken K, Binder M, Schewe D, Sawall S, Witzke V, Cubas Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, Krauter J, Ganser A, Lorens J, Fiedler W, Carmeliet P, Pantel K, Bokemeyer C, Loges S
BLOOD. 2013;122(14):2443-52.

Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy
Berdien B, Reinhard H, Meyer S, Spöck S, Kröger N, Atanackovic D, Fehse B
HUM VACC IMMUNOTHER . 2013;9(6):1205-16.

Genome-wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer
Bhattacharyya S, Yu Y, Suzuki M, Campbell N, Mazdo J, Vasanthakumar A, Bhagat T, Nischal S, Christopeit M, Parekh S, Steidl U, Godley L, Maitra A, Greally J, Verma A
NUCLEIC ACIDS RES. 2013;41(16):e157.

Cytogenetics of extramedullary manifestations in multiple myeloma
Billecke L, Murga Penas E, May A, Engelhardt M, Nagler A, Leiba M, Schiby G, Kröger N, Zustin J, Marx A, Matschke J, Tiemann M, Goekkurt E, Heidtmann H, Vettorazzi E, Dierlamm J, Bokemeyer C, Schilling G
BRIT J HAEMATOL. 2013;161(1):87-94.

Myogenic differentiation of mesenchymal stem cells in a newly developed neurotised AV-loop model
Bitto F, Klumpp D, Lange C, Boos A, Arkudas A, Bleiziffer O, Horch R, Kneser U, Beier J
BIOMED RES INT . 2013;2013:935046.

Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic Syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data
Brand R, Putter H, van Biezen A, Niederwieser D, Martino R, Mufti G, Onida F, Symeonidis A, Schmid C, Garderet L, Robin M, van Gelder M, Finke J, Bornhäuser M, Kobbe G, Germing U, de Witte T, Kröger N
PLOS ONE. 2013;8(10):e74368.

The Gonads and their Magic Bullet, Lysophosphatidic Acid: Physiological and Toxicological Functions of Lysophosphatidic Acid (LPA) In Female and Male Reproductive Systems
Budnik L, Brunswig-Spickenheier B, Müller D
2013. Lysophospholipid Receptors: Signaling and Biochemistry. Chun J, Hla T, Spiegel S, Moolenaar W (Hrsg.). Wiley & Sons, Inc , 569-586.

Impact of physiological BM CD10+CD19+ B-cell precursors (haematogones) in the post-transplant period in patients with AML
Christopeit M, Heiland A, Binder M, Zabelina T, Ayuketang F, Horn C, Haferlach T, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2013;48(9):1257-9.

Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change
Christopeit M, Kuss O, Finke J, Bacher U, Beelen D, Bornhäuser M, Schwerdtfeger R, Bethge W, Basara N, Gramatzki M, Tischer J, Kolb H, Uharek L, Meyer R, Bunjes D, Scheid C, Martin H, Niederwieser D, Kröger N, Bertz H, Schrezenmeier H, Schmid C
J CLIN ONCOL. 2013;31(26):3259-71.

Evaluation of BM cytomorphology after allo-SCT in patients with MDS
Christopeit M, Ocheni S, Haferlach T, Miersch K, Zabelina T, Klyuchnikov E, Binder M, Ayuketang F, Schafhausen P, Zander A, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2013;48(3):465-6.

Comparative clonal analysis of reconstitution kinetics after transplantation of hematopoietic stem cells gene marked with a lentiviral SIN or a γ-retroviral LTR vector
Cornils K, Bartholomae C, Thielecke L, Lange C, Arens A, Glauche I, Mock U, Riecken K, Gerdes S, von Kalle C, Schmidt M, Roeder I, Fehse B
EXP HEMATOL. 2013;41(1):28-38.e3.

Comparative diagnostic performance of ¹⁸F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation
Derlin T, Peldschus K, Münster S, Bannas P, Herrmann J, Stübig T, Habermann C, Adam G, Kröger N, Weber C
EUR RADIOL. 2013;23(2):570-8.

Parthenogenetic stem cells for tissue-engineered heart repair
Didié M, Christalla P, Rubart M, Muppala V, Döker S, Unsöld B, El-Armouche A, Rau T, Eschenhagen T, Schwoerer A, Ehmke H, Schumacher U, Fuchs S, Lange C, Becker A, Tao W, Scherschel J, Soonpaa M, Yang T, Lin Q, Zenke M, Han D, Schöler H, Rudolph C, Steinemann D, Schlegelberger B, Kattman S, Witty A, Keller G, Field L, Zimmermann W
J CLIN INVEST. 2013;123(3):1285-98.

Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study
Gahrton G, Iacobelli S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella A, Beksac M, Bosi A, Milone G, Corradini P, Schönland S, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N
BLOOD. 2013;121(25):5055-63.

Syngeneic transplantation in aplastic anemia: pre-transplant conditioning and peripheral blood are associated with improved engraftment: an observational study on behalf of the Severe Aplastic Anemia and Pediatric Diseases Working Parties of the European Group for Blood and Marrow Transplantation
Gerull S, Stern M, Apperley J, Beelen D, Brinch L, Bunjes D, Butler A, Ganser A, Ghavamzadeh A, Koh M, Komarnicki M, Kröger N, Maertens J, Maschan A, Peters C, Rovira M, Sengeløv H, Socié G, Tischer J, Oneto R, Passweg J, Marsh J
HAEMATOLOGICA. 2013;98(11):1804-9.

Stem cell clonality -- theoretical concepts, experimental techniques, and clinical challenges
Glauche I, Bystrykh L, Eaves C, Roeder I
BLOOD CELL MOL DIS. 2013;50(4):232-40.

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation
Gress R, Miller J, Battiwalla M, Bishop M, Giralt S, Hardy N, Kröger N, Wayne A, Landau D, Wu C
BIOL BLOOD MARROW TR. 2013;19(11):1537-45.

Genetically modified neural stem cells for a local and sustained delivery of neuroprotective factors to the dystrophic mouse retina
Jung G, Sun J, Petrowitz B, Riecken K, Kruszewski K, Jankowiak W, Kunst F, Skevas C, Richard G, Fehse B, Bartsch U
STEM CELL TRANSL MED. 2013;2(12):1001-10.

Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib.
Koch M, Graeser C, Lehnhardt A, Pollok J, Kröger N, Verboom M, Thaiss F, Eiermann T, Nashan B
TRANSPL INT. 2013;26(8):64-68.

Isogeneic MSC application in a rat model of acute renal allograft rejection modulates immune response but does not prolong allograft survival
Koch M, Lehnhardt A, Hu X, Brunswig-Spickenheier B, Stolk M, Bröcker V, Noriega M, Seifert M, Lange C
TRANSPL IMMUNOL. 2013;29(1-4):43-50.

Aktuelle Therapieoptionen bei der Myelofibrose
Kröger N
2013. Aktuelle Therapieoptionen bei der Myelofibrose. Döhner K, Griesshammer M (Hrsg.). 2. Aufl. Uni-Med Verlag, 56-63.

From nuclear to a global Family: more donors for MDS
Kröger N
BLOOD. 2013;122(11):1848-50.

Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.
Kröger N, Badbaran A, Zabelina T, Ayuketang F, Wolschke C, Alchalby H, Klyuchnikov E, Atanackovic D, Schilling G, Hansen T, Schwarz S, Heinzelmann M, Zeschke S, Bacher U, Stübig T, Fehse B, Zander A
BIOL BLOOD MARROW TR. 2013;19(3):398-404.

Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings.
Kröger N, Zabelina T, de Wreede L, Berger J, Alchalby H, van Biezen A, Milpied N, Volin L, Mohty M, Leblond V, Blaise D, Finke J, Schaap N, Robin M, de Witte T
LEUKEMIA. 2013;27(3):604-609.

Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.
Kröger N, Zabelina T, Klyuchnikov E, Kropff M, Pflüger K, Burchert A, Stübig T, Wolschke C, Ayuketang F, Hildebrandt Y, Bacher U, Badbaran A, Schilling G, Hansen T, Atanackovic D, Zander A
BONE MARROW TRANSPL. 2013;48(3):403-407.

Rapid activation of monocyte tissue factor by antithymocyte globulin is dependent on complement and protein disulfide isomerase
Langer F, Spath B, Fischer C, Stolz M, Ayuketang F, Kröger N, Bokemeyer C, Ruf W
BLOOD. 2013;121(12):2324-35.

Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs
Löschmann N, Michaelis M, Rothweiler F, Zehner R, Cinatl J, Voges Y, Sharifi M, Riecken K, Meyer J, von Deimling A, Fichtner I, Ghafourian T, Westermann F, Cinatl J
TRANSL ONCOL. 2013;6(6):685-96.

Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT.
Martino R, de Wreede L, Fiocco M, van Biezen A, von Dem Borne P, Hamladji R, Volin L, Bornhäuser M, Robin M, Rocha V, de Witte T, Kröger N, Mohty M
BONE MARROW TRANSPL. 2013;48(6):761-770.

Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms
Nischal S, Bhattacharyya S, Christopeit M, Yu Y, Zhou L, Bhagat T, Sohal D, Will B, Mo Y, Suzuki M, Pardanani A, McDevitt M, Maciejewski J, Melnick A, Greally J, Steidl U, Moliterno A, Verma A
CANCER RES. 2013;73(3):1076-85.

MAGE-C1/CT7 spontaneously triggers a CD4+ T-cell response in multiple myeloma patients
Nuber N, Curioni-Fontecedro A, Dannenmann S, Matter C, von Boehmer L, Atanackovic D, Knuth A, van den Broek M
LEUKEMIA. 2013;27(8):1767-9.

Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Oyekunle A, Zander A, Binder M, Ayuketang F, Zabelina T, Christopeit M, Stübig T, Alchalby H, Schafhausen P, Lellek H, Wolschke C, Müller I, Bacher U, Kröger N
ANN HEMATOL. 2013;92(4):487-496.

Hematopoietic SCT in Europe: data and trends in 2011
Passweg J, Baldomero H, Bregni M, Cesaro S, Dreger P, Duarte R, Falkenburg J, Kröger N, Farge-Bancel D, Gaspar H, Marsh J, Mohty M, Peters C, Sureda A, Velardi A, Ruiz de Elvira C, Madrigal A
BONE MARROW TRANSPL. 2013;48(9):1161-7.

Interaction of magnetically labeled multipotent mesenchymal stromal cells and E-and P-selectins monitored by magnetic resonance imaging in mice
Peldschus K, Salamon J, Wicklein D, Lange C, Ittrich H, Adam G, Schumacher U
MOL IMAGING. 2013;12(2):100-10.

Fucoidans as potential inhibitors of HIV-1
Prokofjeva M, Imbs T, Shevchenko N, Spirin P, Horn S, Fehse B, Zvyagintseva T, Prassolov V
MAR DRUGS. 2013;11(8):3000-14.

A new system for parallel drug screening against multiple-resistant HIV mutants based on lentiviral self-inactivating (SIN) vectors and multi-colour analyses
Prokofjeva M, Riecken K, Spirin P, Yanvarév D, Düsedau A, Ellinger B, Fehse B, Stocking C, Prassolov V
AIDS RES THER. 2013;10(1):1.

Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation.
Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, Arturo I, Arcese W, Beelen D, Cornelissen J, Kröger N, Milone G, Rossi G, Jardin F, Peters C, Rocha V, Sureda A, Mohty M, Dreger P
BLOOD. 2013;121(3):440-446.

Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study.
Scherwath A, Schirmer L, Kruse M, Ernst G, Eder M, Dinkel A, Kunze S, Balck F, Bornhäuser M, Ehninger G, Dolan K, Gramatzki M, Kolb H, Heußner P, Wilhelm H, Beelen D, Schulz-Kindermann F, Zander A, Koch-Gromus U, Mehnert A
PSYCHO-ONCOLOGY. 2013;22(7):1509-1516.

CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell Transplantation: a report from the Acute Leukemia Working Party of EBMT
Schmidt-Hieber M, Labopin M, Beelen D, Volin L, Ehninger G, Finke J, Socié G, Schwerdtfeger R, Kröger N, Ganser A, Niederwieser D, Polge E, Blau I, Mohty M
BLOOD. 2013;122(19):3359-64.

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation
Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T, Giagounidis A, Zohren F, Bruns I, Wolschke C, Rieger K, Fenk R, Germing U, Haas R, Kröger N, Kobbe G
LEUKEMIA. 2013;27(6):1229-35.

Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation
Schroeder T, Fröbel J, Cadeddu R, Czibere A, Dienst A, Platzbecker U, Bug G, Uharek L, Fenk R, Germing U, Kröger N, Haas R, Kobbe G
LEUKEMIA. 2013;27(9):1910-3.

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi A, Gotlib J, Dupriez B, Pardanani A, Harrison C, Hoffman R, Gisslinger H, Kröger N, Thiele J, Barbui T, Barosi G
BLOOD. 2013;122(8):1395-8.

SETBP1 mutation analysis in 944 patients with MDS and AML
Thol F, Suchanek K, Koenecke C, Stadler M, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Kade S, Löffeld P, Banihosseini S, Bug G, Ottmann O, Hofmann W, Krauter J, Kröger N, Ganser A, Heuser M
LEUKEMIA. 2013;27(10):2072-5.

Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia.
van Gelder M, de Wreede L, Schetelig J, van Biezen A, Volin L, Maertens J, Robin M, Petersen E, de Witte T, Kröger N
LEUKEMIA. 2013;27(4):879-888.

Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12
Vater A, Sahlmann J, Kröger N, Zöllner S, Lioznov M, Maasch C, Buchner K, Vossmeyer D, Schwoebel F, Purschke W, Vonhoff S, Kruschinski A, Hübel K, Humphrey M, Klussmann S, Fliegert F
CLIN PHARMACOL THER. 2013;94(1):150-7.

Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
Vehreschild M, Vehreschild J, Hübel K, Hentrich M, Schmidt-Hieber M, Christopeit M, Maschmeyer G, Schalk E, Cornely O, Neumann S
ANN ONCOL. 2013;24(5):1189-202.

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction
Wayne A, Giralt S, Kröger N, Bishop M
BIOL BLOOD MARROW TR. 2013;19(11):1534-6.

Allogeneic hematopoietic stem cell transplantation: an option for long-term survival for patients with simultaneous appearance of myeloid and lymphatic malignancies.
Weber T, Ocheni S, Binder M, Theurich S, Scheid C, Schmid C, Müller L, Christopeit M, Bacher U
ACTA HAEMATOL-BASEL. 2013;129(3):135-136.

Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
Wolschke C, Stübig T, Hegenbart U, Schönland S, Heinzelmann M, Hildebrandt Y, Ayuketang Ayuk F, Atanackovic D, Dreger P, Zander A, Kröger N
EXP HEMATOL. 2013;41(2):133-134.

Production and first-in-man use of T cells engineered to express a HSVTK-CD34 sort-suicide gene
Zhan H, Gilmour K, Chan L, Farzaneh F, McNicol A, Xu J, Adams S, Fehse B, Veys P, Thrasher A, Gaspar H, Qasim W
PLOS ONE. 2013;8(10):e77106.

Discovered on gastrointestinal stromal tumour 1 (DOG1): a useful immunohistochemical marker for diagnosing chondroblastoma.
Akpalo H, Lange C, Zustin J
HISTOPATHOLOGY. 2012;60(7):1099-1106.

Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.
Alchalby H, Yunus D, Zabelina T, Kobbe G, Holler E, Bornhäuser M, Schwerdtfeger R, Bethge W, Kvasnicka H, Büsche G, Ayuketang Ayuk F, Bacher U, Zander A, Kröger N
BRIT J HAEMATOL. 2012;157(1):75-85.

Role of interleukin 16 in multiple myeloma.
Atanackovic D, Hildebrandt Y, Templin J, Cao Y, Keller C, Panse J, Meyer S, Reinhard H, Bartels K, Lajmi N, Sezer O, Zander A, Marx A, Uhlig R, Zustin J, Bokemeyer C, Kröger N
JNCI-J NATL CANCER I. 2012;104(13):1005-1020.

Identification of genetic parameters associated with disease progression in plasma cell myeloma.
Bacher U, Binder M
LEUKEMIA RES. 2012;36(1):23-24.

[Diagnostics of acute leukemias: interaction of phenotypic and genetic methods].
Bacher U, Haferlach C, Schnittger S, Kern W, Ott M, Haferlach T
PATHOLOGE. 2012;33(6):528-538.

The benefit of population-based studies for older patients with acute myeloid leukemia.
Bacher U, Haferlach T
HAEMATOLOGICA. 2012;97(12):1781-1782.

Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course.
Bacher U, Kern W, Alpermann T, Schnittger S, Haferlach C, Haferlach T
LEUKEMIA RES. 2012;36(7):826-831.

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?
Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop M, Bredeson C, Cairo M, Fenske T, Freytes C, Gale R, Gibson J, Isola L, Inwards D, Laport G, Lazarus H, Maziarz R, Wiernik P, Schouten H, Slavin S, Smith S, Vose J, Waller E, Hari P
BLOOD. 2012;120(20):4256-62.

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?
Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop M, Bredeson C, Cairo M, Fenske T, Freytes C, Gale R, Gibson J, Isola L, Inwards D, Laport G, Lazarus H, Maziarz R, Wiernik P, Schouten H, Slavin S, Smith S, Vose J, Waller E, Hari P, Lymphoma W
BLOOD. 2012;120(20):4256-4262.

Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity.
Bacher U, Schnittger S, Macijewski K, Grossmann V, Kohlmann A, Alpermann T, Kowarsch A, Nadarajah N, Kern W, Haferlach C, Haferlach T
BLOOD. 2012;119(20):4719-4722.

Monitoring and prevention of relapse after allogeneic hematopoietic cell transplantation for myeloid malignancies.
Bacher U, Talano J, Bishop M
BIOL BLOOD MARROW TR. 2012;18(1 Suppl):62-73.

TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.
Bacher U, Weissmann S, Kohlmann A, Schindela S, Alpermann T, Schnittger S, Kern W, Haferlach T, Haferlach C
BRIT J HAEMATOL. 2012;156(1):67-75.

Diagnostic performance of whole-body MRI for the detection of persistent or relapsing disease in multiple myeloma after stem cell transplantation.
Bannas P, Hentschel H, Bley T, Treszl A, Zu Eulenburg C, Derlin T, Yamamura J, Adam G, Stübig T, Kröger N, Weber C
EUR RADIOL. 2012;22(9):2007-2012.

Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myeloma.
Billecke L, Murga-Penas E, May A, Engelhardt M, Nagler A, Leiba M, Schiby G, Kröger N, Zustin J, Marx A, Matschke J, Tiemann M, Goekkurt E, Bokemeyer C, Schilling G
ANTICANCER RES. 2012;32(5):2031-2034.

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial
Bornhäuser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M, Baurmann H, Schäfer-Eckart K, Holler E, Kröger N, Schmid C, Einsele H, Kiehl M, Hiddemann W, Schwerdtfeger R, Buchholz S, Dreger P, Neubauer A, Berdel W, Ehninger G, Beelen D, Schetelig J, Stelljes M
LANCET ONCOL. 2012;13(10):1035-44.

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.
Bornhäuser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M, Baurmann H, Schäfer-Eckart K, Holler E, Kröger N, Schmid C, Einsele H, Kiehl M, Hiddemann W, Schwerdtfeger R, Buchholz S, Dreger P, Neubauer A, Berdel W, Ehninger G, Beelen D, Schetelig J, Stelljes M
LANCET ONCOL. 2012;13(10):1035-1044.

The role of regulatory T cells and TH17 cells in multiple myeloma.
Braga W, Atanackovic D, Colleoni G
Clin Dev Immunol. 2012;2012:293479.

Evaluation of BM cytomorphology after allo-SCT in patients with AML.
Christopeit M, Miersch K, Klyuchnikov E, Haferlach T, Binder M, Zabelina T, Ayuketang Ayuk F, Schafhausen P, Zander A, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2012;47(12):1538-1544.

18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation
Derlin T, Weber C, Habermann C, Herrmann J, Wisotzki C, Ayuk F, Wolschke C, Klutmann S, Kröger N
EUR J NUCL MED MOL I. 2012;39(3):493-500.

Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial.
Finke J, Schmoor C, Bethge W, Ottinger H, Stelljes M, Zander A, Volin L, Heim D, Schwerdtfeger R, Kolbe K, Mayer J, Maertens J, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Bertz H, Grishina O, Socié G
BIOL BLOOD MARROW TR. 2012;18(11):1716-1726.

Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial
Finke J, Schmoor C, Bethge W, Ottinger H, Stelljes M, Zander A, Volin L, Heim D, Schwerdtfeger R, Kolbe K, Mayer J, Maertens J, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Bertz H, Grishina O, Socié G, , Kröger N
BIOL BLOOD MARROW TR. 2012;18(11):1716-26.

Critical imbalance of TNF-α and soluble TNF receptor 1 in a patient with macrophage activation syndrome: potential implications for diagnostics and treatment.
Flammiger A, Fiedler W, Bacher U, Bokemeyer C, Schneider M, Binder M
ACTA HAEMATOL-BASEL. 2012;128(2):69-72.

Molecular analysis of RAS-RAF tyrosine-kinase signaling pathway alterations in patients with plasma cell myeloma.
Grossmann V, Bacher U, Artusi V, Kohlmann A, Nadarajah N, Kern W, Schnittger S, Haferlach T, Haferlach C
BLOOD CANCER J. 2012;2:85.

EZH2 mutations and their association with PICALM-MLLT10 positive acute leukaemia.
Grossmann V, Bacher U, Kohlmann A, Artusi V, Klein H, Dugas M, Schnittger S, Alpermann T, Kern W, Haferlach T, Haferlach C
BRIT J HAEMATOL. 2012;157(3):387-390.

Expression of CEBPA is reduced in RUNX1-mutated acute myeloid leukemia.
Grossmann V, Bacher U, Kohlmann A, Butschalowski K, Roller A, Jeromin S, Dicker F, Kern W, Schnittger S, Haferlach T, Haferlach C
BLOOD CANCER J. 2012;2:86.

Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
Haferlach C, Bacher U, Grossmann V, Schindela S, Zenger M, Kohlmann A, Kern W, Haferlach T, Schnittger S
GENE CHROMOSOME CANC. 2012;51(12):1079-1085.

ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
Haferlach C, Bacher U, Schnittger S, Alpermann T, Zenger M, Kern W, Haferlach T
GENE CHROMOSOME CANC. 2012;51(4):328-337.

Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype.
Haferlach T, Bacher U, Alpermann T, Haferlach C, Kern W, Schnittger S
LEUKEMIA RES. 2012;36(1):51-58.

Impact of the NK cell receptor LIR-1 (ILT-2/CD85j/LILRB1) on cytotoxicity against multiple myeloma.
Heidenreich S, Zu Eulenburg C, Hildebrandt Y, Stübig T, Sierich H, Badbaran A, Eiermann T, Binder T, Kröger N
Clin Dev Immunol. 2012;2012:652130.

European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization.
Hübel K, Fresen M, Apperley J, Basak G, Douglas K, Gabriel I, Geraldes C, Jaksic O, Koristek Z, Kröger N, Lanza F, Lemoli R, Mikala G, Selleslag D, Worel N, Mohty M, Duarte R
BONE MARROW TRANSPL. 2012;47(8):1046-1050.

Frequency and prognostic impact of the aberrant CD8 expression in 5,523 patients with chronic lymphocytic leukemia.
Kern W, Bacher U, Haferlach C, Alpermann T, Dicker F, Schnittger S, Haferlach T
CYTOMETRY B CLIN CYTOM. 2012;82(3):145-150.

Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early-stage CLL.
Kern W, Bacher U, Haferlach C, Dicker F, Alpermann T, Schnittger S, Haferlach T
BRIT J HAEMATOL. 2012;157(1):86-96.

SOCS3 promotes interleukin-17 expression of human T cells.
Kleinsteuber K, Heesch K, Schattling S, Sander-Juelch C, Mock U, Riecken K, Fehse B, Fleischer B, Jacobsen M
BLOOD. 2012;120(22):4374-4382.

Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting.
Klyuchnikov E, Holler E, Bornhäuser M, Kobbe G, Nagler A, Shimoni A, Könecke C, Wolschke C, Bacher U, Zander A, Kröger N
BRIT J HAEMATOL. 2012;159(2):172-181.

Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients.
Kobold S, Luetkens T, Bartels B, Cao Y, Hildebrandt Y, Sezer O, Reinhard H, Templin J, Bartels K, Lajmi N, Haag F, Bokemeyer C, Kröger N, Atanackovic D
Clin Dev Immunol. 2012;2012:134081.

Allogene Blutstammzelltransplantation
Kröger N
2012. Multiples Myelom: Moderne Diagnoseverfahren, aktuelle Behandlungsoptionen und Supportivtherapie. Deutscher Ärzte-Verlag: 105-116.

Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome.
Kröger N
BLOOD. 2012;119(24):5632-5639.

Allogene Stammzelltransplantation zur Therapie der Osteomyelofibrose
Kröger N
2012. Blutstammzelltransplantation - Bilanz des aktuellen Wissens. düsseldorf university press: 139-155.

Allogene Stammzelltransplantation bei Myelofibrose
Kröger N, Alchalby H
2012. Aktuelle Therapieoptionen bei der Myelofibrose. UNI-MED Verlag: 47-56.

Replacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis.
Kröger N, Kvasnicka M, Thiele J
Fibrogenesis Tissue Repair. 2012;5 Suppl 1:25.

Immunotherapy for multiple myeloma.
Kröger N, Mohty M, Nagler A, Yi Q
Clin Dev Immunol. 2012;2012:797165.

Basic biology and clinical application of multipotent mesenchymal stromal cells: from bench to bedside
Kuçi S, Henschler R, Müller I, Biagi E, Meisel R
Stem Cells Int. 2012;2012:185943.

Platelet lysate suppresses the expression of lipocalin-type prostaglandin D2 synthase that positively controls adipogenic differentiation of human mesenchymal stromal cells.
Lange C, Brunswig-Spickenheier B, Eissing L, Scheja L
EXP CELL RES. 2012;318(18):2284-2296.

Treatment of Ischemia/Reperfusion Injury of the Kidney with Mesenchymal Stromal Cells
Lange C, Zander A, Westenfelder C
2012. Stem Cells and Cancer Stem Cells,Volume 3. Springer Berlin Heidelberg: 241-250.

Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience
Le Gouill S, Kröger N, Dhedin N, Nagler A, Bouabdallah K, Yakoub-Agha I, Kanouni T, Bulabois C, Tournilhac O, Buzyn A, Rio B, Moles M, Shimoni A, Bacher U, Ocheni S, Milpied N, Harousseau J, Moreau P, Leux C, Mohty M
ANN ONCOL. 2012;23(10):2695-703.

Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience.
Le Gouill S, Kröger N, Dhedin N, Nagler A, Bouabdallah K, Yakoub-Agha I, Kanouni T, Bulabois C, Tournilhac O, Buzyn A, Rio B, Moles M, Shimoni A, Bacher U, Ocheni S, Milpied N, Harousseau J, Moreau P, Leux C, Mohty M
ANN ONCOL. 2012;23(10):2695-2703.

Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
Malard F, Kröger N, Gabriel I, Hübel K, Apperley J, Basak G, Douglas K, Geraldes C, Jaksic O, Koristek Z, Lanza F, Lemoli R, Mikala G, Selleslag D, Worel N, Mohty M, Duarte R
BIOL BLOOD MARROW TR. 2012;18(2):314-317.

Efficient lentiviral transduction and transgene expression in primary human B cells.
Mock U, Thiele R, Uhde A, Fehse B, Horn S
HUM GENE THER METHOD. 2012;23(6):408-415.

Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies.
Preukschas M, Hagel C, Schulte A, Riecken K, Lamszus K, Sievert H, Pällmann N, Bokemeyer C, Hauber J, Balabanov M, Balabanov S
PLOS ONE. 2012;7(8):43468.

Screening of Potential HIV-1 Inhibitors/Replication Blockers Using Secure Lentiviral in Vitro System.
Prokofjeva M, Spirin P, Yanvarev D, Ivanov A, Novikov M, Stepanov O, Gottikh M, Kochetkov S, Fehse B, Stocking C, Prassolov V
Acta Naturae. 2012;3(4):55-65.

Antigen-specificity of oligoclonal abnormal protein bands in multiple myeloma after allogeneic stem cell transplantation.
Rahlff J, Trusch M, Haag F, Bacher U, Horst A, Schlüter H, Binder M
CANCER IMMUNOL IMMUN. 2012;61(10):1639-1651.

RGB marking with lentiviral vectors for multicolor clonal cell tracking.
Riecken K, Thomaschewski M, Benten D, Fehse B
NAT PHYS. 2012;7(5):839-849.

RGB marking : Vielfarbige Zellmarkierung zur klonalen Analyse
Riecken K, Thomaschewski M, Warlich M, Cornils K, Benten D, Fehse B
Laborwelt. 2012;13(1):7-9.

Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation.
Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R, Stadler M, Kuball J, Cornelissen J, Vorlicek J, Socié G, Falda M, Vindeløv L, Ljungman P, Jackson G, Kröger N, Rank A, Polge E, Rocha V, Mohty M, Blood A, Transplantation M
BLOOD. 2012;119(6):1599-1606.

Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases.
Schnittger S, Bacher U, Alpermann T, Reiter A, Ulke M, Dicker F, Eder C, Kohlmann A, Grossmann V, Kowarsch A, Kern W, Haferlach C, Haferlach T
HAEMATOLOGICA. 2012;97(12):1890-1894.

Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow.
Schnittger S, Bacher U, Eder C, Dicker F, Alpermann T, Grossmann V, Kohlmann A, Kern W, Haferlach C, Haferlach T
HAEMATOLOGICA. 2012;97(10):1582-1585.

Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data.
Schnittger S, Bacher U, Haferlach C, Alpermann T, Kern W, Haferlach T
GENE CHROMOSOME CANC. 2012;51(10):910-924.

Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia.
Schnittger S, Bacher U, Haferlach T, Wendland N, Ulke M, Dicker F, Grossmann V, Haferlach C, Kern W
BLOOD. 2012;119(13):3151-3154.

Therapy-related myeloid neoplasms following treatment with radioiodine.
Schroeder T, Kuendgen A, Kayser S, Kröger N, Braulke F, Platzbecker U, Klärner V, Zohren F, Haase D, Stadler M, Schlenk R, Czibere A, Bruns I, Fenk R, Gattermann N, Haas R, Kobbe G, Germing U
HAEMATOLOGICA. 2012;97(2):206-212.

p65-Dependent production of interleukin-1β by osteolytic prostate cancer cells causes an induction of chemokine expression in osteoblasts.
Schulze J, Riecken K, Baranowsky A, Streichert T, Lange T, Spiro A, Albers J, Seitz S, Zustin J, Amling M, Fehse B, Schinke T
CANCER LETT. 2012;317(1):106-113.

Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges.
Shah N, Bacher U, Fry T, Calvo K, Stetler-Stevenson M, Arthur D, Kurlander R, Baird K, Wise B, Giralt S, Bishop M, Hardy N, Wayne A
AM J HEMATOL. 2012;87(9):916-922.

Control of bone formation by the serpentine receptor Frizzled-9.
Albers J, Schulze J, Beil F, Gebauer M, Baranowsky A, Keller J, Marshall R, Wintges K, Friedrich F, Priemel M, Schilling A, Rueger J, Cornils K, Fehse B, Streichert T, Sauter G, Jakob F, Insogna K, Pober B, Knobeloch K, Francke U, Amling M, Schinke T
J CELL BIOL. 2011;192(6):1057-1072.

Circulating CD34(+) cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT.
Alchalby H, Lioznov M, Fritzsche-Friedland U, Badbaran A, Zabelina T, Bacher U, Stübig T, Ayuketang Ayuk F, Zander A, Kröger N
BONE MARROW TRANSPL. 2011;47(1):143-145.

Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
Atanackovic D, Luetkens T, Kloth B, Fuchs G, Cao Y, Hildebrandt Y, Meyer S, Bartels K, Reinhard H, Lajmi N, Hegewisch-Becker S, Schilling G, Platzbecker U, Kobbe G, Schroeder T, Bokemeyer C, Kröger N
AM J HEMATOL. 2011;86(11):918-922.

Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma.
Atanackovic D, Panse J, Hildebrandt Y, Jadczak A, Kobold S, Cao Y, Templin J, Meyer S, Reinhard H, Bartels K, Lajmi N, Zander A, Marx A, Bokemeyer C, Kröger N
HAEMATOLOGICA. 2011;96(10):1512-1520.

Ganglioneuroblastoma infiltrating the bone marrow in an adult.
Bacher U, Christopeit M, Wiedemann B, Leuschner I, Haferlach T, Choschzick M
BRIT J HAEMATOL. 2011;153(5):544.

Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells.
Bacher U, Haferlach C, Alpermann T, Kern W, Schnittger S, Haferlach T
HAEMATOLOGICA. 2011;96(9):1284-1292.

Several lymphoma-specific genetic events in parallel can be found in mature B-cell neoplasms.
Bacher U, Haferlach T, Alpermann T, Kern W, Schnittger S, Haferlach C
GENE CHROMOSOME CANC. 2011;50(1):43-50.

Subclones with the t(9;22)/BCR-ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations.
Bacher U, Haferlach T, Alpermann T, Zenger M, Hochhaus A, Beelen D, Uppenkamp M, Rummel M, Kern W, Schnittger S, Haferlach C
BRIT J HAEMATOL. 2011;152(6):713-720.

Minimal residual disease diagnostics and chimerism in the post-transplant period in acute myeloid leukemia.
Bacher U, Haferlach T, Fehse B, Schnittger S, Kröger N
SCI WORLD J. 2011;11:310-319.

Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia.
Bacher U, Haferlach T, Schnittger S, Kreipe H, Kröger N
BRIT J HAEMATOL. 2011;153(2):149-167.

Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics.
Bacher U, Kern W, Alpermann T, Schnittger S, Kohlmann A, Klein H, Dugas M, Haferlach C, Haferlach T
LEUKEMIA. 2011;25(8):1361-1364.

Unusual course of myelodysplastic syndrome with presumed familial origin.
Bacher U, Ocheni S, Schafhausen P, Oyekunle A, Dierlamm J, Zander A, Bokemeyer C, Haferlach T, Kröger N
ACTA HAEMATOL-BASEL. 2011;126(4):234-237.

Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.
Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H, Hehlmann R, Hoffman R, Kiladjian J, Kröger N, Mesa R, McMullin M, Pardanani A, Passamonti F, Vannucchi A, Reiter A, Silver R, Verstovsek S, Tefferi A, LeukemiaNet E
J CLIN ONCOL. 2011;29(6):761-770.

Myogenic differentiation of mesenchymal stem cells co-cultured with primary myoblasts.
Beier J, Bitto F, Lange C, Klumpp D, Arkudas A, Bleiziffer O, Boos A, Horch R, Kneser U
CELL BIOL INT. 2011;35(4):397-406.

Expression of CD133 and other putative stem cell markers in uveal melanoma.
Berna-Thill M, Berna M, Grierson R, Reinhart I, Voelkel T, Piechaczek C, Galambos P, Jager M, Richard G, Lange C, Gehling U
MELANOMA RES. 2011;21(5):405-416.

B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia.
Binder M, Müller F, Jackst A, Lechenne B, Pantic M, Bacher U, Zu Eulenburg C, Veelken H, Mertelsmann R, Pasqualini R, Arap W, Trepel M
CANCER-AM CANCER SOC. 2011;117(9):1891-1900.

National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee.
Bishop M, Alyea E, Cairo M, Falkenburg J, June C, Kröger N, Little R, Miller J, Pavletic S, Porter D, Riddell S, van Besien K, Wayne A, Weisdorf D, Wu R, Giralt S
BIOL BLOOD MARROW TR. 2011;17(4):443-454.

Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL-positive CML cells.
Brassat U, Balabanov S, Bali D, Dierlamm J, Balabanov M, Hartmann U, Sirma H, Günes C, Wege H, Fehse B, Gontarewicz A, Dikomey E, Borgmann K, Brümmendorf T
EXP HEMATOL. 2011;39(1):62-66.

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.
Cavo M, Rajkumar S, Palumbo A, Moreau P, Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos M, Attal M, Sonneveld P, Boccadoro M, Anderson K, Richardson P, Bensinger W, Johnsen H, Kröger N, Gahrton G, Bergsagel P, Vesole D, Einsele H, Jagannath S, Niesvizky R, Durie B, Jesus S, Lonial S, Group I
BLOOD. 2011;117(23):6063-6073.

Do centrally pre-prepared solutions achieve more reliable drug concentrations than solutions prepared on the ward?
Dehmel C, Braune S, Kreymann K, Baehr M, Langebrake C, Hilgarth H, Nierhaus A, Dartsch D, Kluge S
INTENS CARE MED. 2011;37(8):1311-1316.

Gentherapie in Deutschland. Eine Einführung
Domasch S, Fehse B
2011. Gentherapie in Deutschland: Eine interdisziplinäre Bestandsaufnahme. Themenband des Gentechnologieberichts. Forum W - Wissenschaftlicher Verlag: 31-40.

Assessment of physiologic natural killer cell cytotoxicity in vitro.
Duske H, Sputtek A, Binder T, Kröger N, Schrepfer S, Eiermann T
HUM IMMUNOL. 2011;72(11):1007-1012.

Genetic Modifications – Possibilities and Limits of Gene Therapy
Fehse B
2011. Human Nature and Self Design. mentis Verlag Paderborn: 113-136.

Stand wissenschaftlicher und medizinischer Entwicklungen
Fehse B, Baum C, Schmidt M, Kalle C
2011. Gentherapie in Deutschland: Eine interdisziplinäre Bestandsaufnahme. Themenband des Gentechnologieberichts. Forum W - Wissenschaftlicher Verlag: 41-126.

Perspektivische Entwicklungen in der Stammzelltransplantation: Zelltherapie.
Fehse B, Lange C
2011. Allogene Stammzelltherapie – Grundlagen, Indikationen und Perspektiven.. Kröger N, Zander A (Hrsg.). 1.-3.. Aufl. Bremen: UNI-MED Bremen, London, Boston, 134-142.

Cytogenetic methods in chronic lymphocytic leukemia.
Haferlach C, Bacher U
Methods Mol Biol. 2011;730:119-130.

CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia.
Haferlach C, Bacher U, Kohlmann A, Schindela S, Alpermann T, Kern W, Schnittger S, Haferlach T
HAEMATOLOGICA. 2011;96(6):829-836.

Emergence of carbapenemases in Gram-negative bacteria in Hamburg, Germany.
Hentschke M, Goritzka V, Belmar Campos C, Merkel P, Ilchmann C, Lellek H, Scherpe S, Aepfelbacher M, Rohde H
DIAGN MICR INFEC DIS. 2011;71(3):312-315.

Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.
Hübel K, Fresen M, Salwender H, Basara N, Beier R, Theurich S, Christopeit M, Bogner C, Galm O, Hartwig R, Heits F, Lordick F, Rösler W, Wehler D, Zander A, Albert M, Dressler S, Ebinger M, Frickhofen N, Hertenstein B, Kiehl M, Liebler S, von Lilienfeld-Toal M, Weidmann E, Weigelt C, Lange F, Kröger N
BONE MARROW TRANSPL. 2011;46(8):1045-1052.

Acute monoblastic/monocytic leukemia and chronic myelomonocytic leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells.
Kern W, Bacher U, Haferlach C, Schnittger S, Haferlach T
LEUKEMIA LYMPHOMA. 2011;52(1):92-100.

The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.
Klyuchnikov E, Bacher U, Kröger N, Kazantsev I, Zabelina T, Ayuketang Ayuk F, Zander A
ANN HEMATOL. 2011;2011:974658.

Purification of CD4(+) T cells for adoptive immunotherapy after allogeneic hematopoietic stem cell transplantation.
Klyuchnikov E, Sputtek A, Slesarchuk O, Lioznov M, Stübig T, Bacher U, Amtsfeld G, Merle E, Reckhaus M, Fehse B, Wolschke C, Adjalle R, Ayuketang Ayuk F, Zander A, Kröger N
BIOL BLOOD MARROW TR. 2011;17(3):374-383.

Purification of CD4+ T cells for adoptive immunotherapy after allogeneic hematopoietic stem cell transplantation
Klyuchnikov E, Sputtek A, Slesarchuk O, Lioznov M, Stübig T, Bacher U, Amtsfeld G, Merle E, Reckhaus M, Fehse B, Wolschke C, Adjallé R, Ayuketang F, Zander A, Kröger N
BIOL BLOOD MARROW TR. 2011;17(3):374-83.

Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation.
Kobold S, Tams S, Luetkens T, Cao Y, Sezer O, Bartels B, Reinhard H, Templin J, Bartels K, Hildebrandt Y, Lajmi N, Marx A, Haag F, Bokemeyer C, Kröger N, Atanackovic D
Clin Dev Immunol. 2011;2011:302145.

Approaches to relapse after allogeneic stem cell transplantation.
Kröger N
CURR OPIN ONCOL. 2011;23(2):203-208.

Minimal residual disease following allogeneic hematopoietic stem cell transplantation.
Kröger N, Miyamura K, Bishop M
BIOL BLOOD MARROW TR. 2011;17(1):94-100.

Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma.
Kröger N, Zabelina T, Berger J, Duske H, Klyuchnikov E, Binder T, Stübig T, Hildebrandt Y, Atanackovic D, Alchalby H, Ayuketang Ayuk F, Zander A, Bacher U, Eiermann T
LEUKEMIA. 2011;25(10):1657-1661.

Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis.
Kröger N, Zabelina T, van Biezen A, Brand R, Niederwieser D, Martino R, Lim Z, Onida F, Schmid C, Garderet L, Robin M, van Gelder M, Marks R, Symeonidis A, Kobbe G, de Witte T
HAEMATOLOGICA. 2011;96(2):291-297.

Drug dosing and monitoring in obese patients undergoing allogenic stem cell transplantation.
Langebrake C, Bernhardt F, Baehr M, Kröger N, Zander A
INT J CLIN PHARM-NET. 2011;33(6):918-924.

Radiation rescue: mesenchymal stromal cells protect from lethal irradiation.
Lange C, Brunswig-Spickenheier B, Capallo-Obermann H, Eggert K, Gehling U, Rudolph C, Schlegelberger B, Cornils K, Zustin J, Spiess A, Zander A
PLOS ONE. 2011;6(1):14486.

Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients.
Lellek H, Waldenmaier D, Dahlke J, Ayuketang Ayuk F, Wolschke C, Kröger N, Zander A
MYCOSES. 2011;54(1):39-44.

Bone marrow-derived progenitor cells do not contribute to podocyte turnover in the puromycin aminoglycoside and renal ablation models in rats.
Meyer-Schwesinger C, Lange C, Bröcker V, Agustian P, Putri A, Lehmann U, Raabe A, Brinkmeyer M, Kobayashi E, Schiffer M, Büsche G, Kreipe H, Thaiss F, Becker J
AM J PATHOL. 2011;178(2):494-499.

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells
Michaelis M, Rothweiler F, Barth S, Cinatl J, van Rikxoort M, Löschmann N, Voges Y, Breitling R, von Deimling A, Rödel F, Riecken K, Fehse B, Mack E, Stiewe T, Doerr H, Speidel D, Cinatl J, Riecken K
CELL DEATH DIS. 2011;2:e243.

Thrombospondin-1 (TSP-1) in primary myelofibrosis (PMF) - a megakaryocyte-derived biomarker which largely discriminates PMF from essential thrombocythemia.
Muth M, Engelhardt B, Kröger N, Hussein K, Schlué J, Büsche G, Kreipe H, Bock O
ANN HEMATOL. 2011;90(1):33-40.

Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes.
Newrzela S, Cornils K, Heinrich T, Schläger J, Yi J, Lysenko O, Kimpel J, Fehse B, Dorothee V
MOL MED. 2011;17(11-12):1223-1232.

Molecular diagnostics, targeted therapy, and the indication for allogeneic stem cell transplantation in acute lymphoblastic leukemia.
Oyekunle A, Haferlach T, Kröger N, Klyuchnikov E, Zander A, Schnittger S, Bacher U
Adv Hematol. 2011;2011:154745.

Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Oyekunle A, Klyuchnikov E, Ocheni S, Kröger N, Zander A, Baccarani M, Bacher U
ACTA HAEMATOL-BASEL. 2011;126(1):30-39.

First-line matched related donor hematopoietic stem cell transplantation compared to immunosuppressive therapy in acquired severe aplastic anemia.
Peinemann F, Grouven U, Kröger N, Bartel C, Pittler M, Lange S
PLOS ONE. 2011;6(4):18572.

High-dose chemotherapy followed by autologous stem cell transplantation for metastatic rhabdomyosarcoma--a systematic review.
Peinemann F, Kröger N, Bartel C, Grouven U, Pittler M, Erttmann R, Kulig M
PLOS ONE. 2011;6(2):17127.

Cancer suicide gene therapy with TK.007: superior killing efficiency and bystander effect.
Preuß E, Muik A, Riecken K, Otte J, von Laer D, Fehse B
J MOL MED. 2011;89(11):1113-1124.

RGB marking facilitates multicolor clonal cell tracking.
Riecken K, Thomaschewski M, Warlich M, Volz T, Cornils K, Niebuhr B, Täger M, Lütgehetmann M, Pollok J, Stocking C, Dandri-Petersen M, Benten D, Fehse B
NAT MED. 2011;17(4):504-509.

Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT.
Robin M, Sanz G, Ionescu I, Rio B, Sirvent A, Renaud M, Carreras E, Milpied N, Mohty M, Beguin Y, Bordigoni P, de Witte T, Picardi A, Purtill D, Gluckman E, Kröger N, Rocha V
LEUKEMIA. 2011;25(1):75-81.

Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents.
Schmidt-Hieber M, Schwender J, Heinz W, Zabelina T, Kühl J, Mousset S, Schüttrumpf S, Junghanss C, Silling G, Basara N, Neuburger S, Thiel E, Blau I
HAEMATOLOGICA. 2011;96(1):142-149.

A copy number repeat polymorphism in the transactivation domain of the CEPBA gene is possibly associated with a protective effect against acquired CEBPA mutations: an analysis in 1135 patients with AML and 187 healthy controls.
Schnittger S, Bacher U, Eder C, Lohse P, Haferlach C, Kern W, Haferlach T
EXP HEMATOL. 2011;39(1):87-94.

Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
Schnittger S, Bacher U, Haferlach C, Alpermann T, Dicker F, Sundermann J, Kern W, Haferlach T
LEUKEMIA. 2011;25(4):615-621.

Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA.
Schnittger S, Bacher U, Haferlach C, Kern W, Alpermann T, Haferlach T
HAEMATOLOGICA. 2011;96(12):1799-1807.

Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia.
Schnittger S, Bacher U, Kern W, Alpermann T, Haferlach C, Haferlach T
LEUKEMIA. 2011;25(8):1297-1304.

Bioequivalence comparison of a new freezing bag (CryoMACS(®)) with the Cryocyte(®) freezing bag for cryogenic storage of human hematopoietic progenitor cells.
Sputtek A, Lioznov M, Kröger N, Rowe A
CYTOTHERAPY. 2011;13(4):481-489.

Gene therapy strategies: can we eradicate HIV?
van Lunzen J, Fehse B, Hauber J
Curr HIV/AIDS Rep. 2011;8(2):78-84.

Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease.
Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M, Ayuketang Ayuk F, Kiani A, Schwerdtfeger R, Vogelsang G, Kobbe G, Gramatzki M, Lawitschka A, Mohty M, Pavletic S, Greinix H, Holler E
BIOL BLOOD MARROW TR. 2011;17(1):1-17.

Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT.
Alchalby H, Badbaran A, Bock O, Fehse B, Bacher U, Zander A, Kröger N
BONE MARROW TRANSPL. 2010;45(9):1404-1407.

Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.
Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D, Bornhäuser M, Christian T, Baurmann H, Bethge W, Hildebrandt Y, Bacher U, Fehse B, Zander A, Kröger N
BLOOD. 2010;116(18):3572-3581.

Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis.
Alchalby H, Kröger N
Curr Hematol Malig Rep. 2010;5(2):53-61.

Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes.
Bacher U, Haferlach C, Kröger N, Schnittger S, Kern W, Wiedemann B, Zander A, Haferlach T
BIOL BLOOD MARROW TR. 2010;16(1):1-11.

Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies.
Bacher U, Haferlach C, Schnittger S, Kohlmann A, Kern W, Haferlach T
ANN HEMATOL. 2010;89(7):643-652.

Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML.
Bacher U, Haferlach T, Alpermann T, Zenger M, Kröger N, Beelen D, Kern W, Schnittger S, Haferlach C
BIOL BLOOD MARROW TR. 2010;16(12):1649-1657.

Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma.
Bacher U, Haferlach T, Kern W, Alpermann T, Schnittger S, Haferlach C
CANCER GENET CYTOGEN. 2010;203(2):169-175.

Detection of a t(4;14)(p16;q32) in two cases of lymphoma showing both the immunophenotype of chronic lymphocytic leukemia.
Bacher U, Haferlach T, Schnittger S, Weiss T, Burkhard O, Bechtel B, Kern W, Haferlach C
CANCER GENET CYTOGEN. 2010;200(2):170-174.

Gene expression profiling for diagnosis and therapy in acute leukaemia and other haematologic malignancies.
Bacher U, Kohlmann A, Haferlach T
CANCER TREAT REV. 2010;36(8):637-646.

Molecular genetics in acute myeloid leukemia.
Bacher U, Schnittger S, Haferlach T
CURR OPIN ONCOL. 2010;22(6):646-655.

Neue Wege der Stammzellforschung: Reprogrammierung von differenzierten Körperzellen
Beier H, Fehse B, Friedrich B, Götz M, Hansmann I, Hucho F, Köchy K, Müller-Röber B, Rheinberger H, Reich J, Robpers H, Schöler H, Schöne-Seifert B, Sperling K, Tanner K, Taupitz J, Wobus A
J Reprodmed Endokrinol. 2010;7:68-77.

Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Bishop M, Alyea E, Cairo M, Falkenburg J, June C, Kröger N, Little R, Miller J, Pavletic S, Porter D, Riddell S, van Besien K, Wayne A, Weisdorf D, Wu R, Giralt S
BIOL BLOOD MARROW TR. 2010;16(5):563-564.

Limited immune-modulating activity of porcine mesenchymal stromal cells abolishes their protective efficacy in acute kidney injury.
Brunswig-Spickenheier B, Boche J, Westenfelder C, Peimann F, Gruber A, Jaquet K, Krause K, Zustin J, Zander A, Lange C
STEM CELLS DEV. 2010;19(5):719-729.

An optimized assay for the enumeration of antigen-specific memory B cells in different compartments of the human body.
Cao Y, Gordic M, Kobold S, Lajmi N, Meyer S, Bartels K, Hildebrandt Y, Luetkens T, Ihloff A, Kröger N, Bokemeyer C, Atanackovic D
J IMMUNOL METHODS. 2010;358(1-2):56-65.

The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients.
Cao Y, Luetkens T, Kobold S, Hildebrandt Y, Gordic M, Lajmi N, Meyer S, Bartels K, Zander A, Bokemeyer C, Kröger N, Atanackovic D
EXP HEMATOL. 2010;38(10):860-867.

Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data.
Carreras E, Cahn J, Puozzo C, Kröger N, Sanz G, Buzyn A, Bacigalupo A, Vernant J
ANTICANCER RES. 2010;30(7):2977-2984.

Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning.
Casper J, Wolff D, Knauf W, Blau I, Ruutu T, Volin L, Wandt H, Schäfer-Eckart K, Holowiecki J, Giebel S, Aschan J, Zander A, Kröger N, Hilgendorf I, Baumgart J, Mylius H, Pichlmeier U, Freund M
J CLIN ONCOL. 2010;28(20):3344-3351.

Diagnosis of Toxoplasma gondii infection after allogeneic stem cell transplant can be difficult and requires intensive scrutiny.
Cavattoni I, Ayuketang Ayuk F, Zander A, Zabelina T, Bacher A, Cayiroglu E, Knospe V, Illies T, Aepfelbacher M, Richard G, Kröger N, Bacher U
LEUKEMIA LYMPHOMA. 2010;51(8):1530-1535.

Pilot study of rituximab plus donor-lymphocyte infusion to prevent or treat relapse in B-cell lymphoma after allogeneic stem cell transplantation.
Cavattoni I, Zabelina T, Ayuketang Ayuk F, Wolschke C, Bacher U, Zander A, Kröger N
LEUKEMIA LYMPHOMA. 2010;51(1):146-148.

Immunohistochemistry and molecular analyses in myeloid sarcoma of the breast in a patient with relapse of NPM1-mutated and FLT3-mutated AML after allogeneic stem cell transplantation.
Choschzick M, Bacher U, Ayuketang Ayuk F, Lebeau A
J CLIN PATHOL. 2010;63(6):558-561.

Mimicking the haematopoietic niche microenvironment provides a novel strategy for expansion of haematopoietic and megakaryocyte-progenitor cells from cord blood.
Deutsch V, Hubel E, Kay S, Ohayon T, Katz B, Many A, Zander A, Naparstek E, Grisaru D
BRIT J HAEMATOL. 2010;149(1):137-149.

Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).
Falini B, Macijewski K, Weiss T, Bacher U, Schnittger S, Kern W, Kohlmann A, Klein H, Vignetti M, Piciocchi A, Fazi P, Martelli M, Vitale A, Pileri S, Miesner M, Santucci A, Haferlach C, Mandelli F, Haferlach T
BLOOD. 2010;115(18):3776-3786.

Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells
Gieseke F, Böhringer J, Bussolari R, Dominici M, Handgretinger R, Müller I
BLOOD. 2010;116(19):3770-9.

Peptide length extension skews the minor HA-1 antigen presentation toward activated dendritic cells but reduces its presentation efficiency.
Hambach L, Aghai Z, Pool J, Kröger N, Goulmy E
J IMMUNOL. 2010;185(8):4582-4589.

Low physiologic oxygen tensions reduce proliferation and differentiation of human multipotent mesenchymal stromal cells
Holzwarth C, Vaegler M, Gieseke F, Pfister S, Handgretinger R, Kerst G, Müller I
BMC CELL BIOL. 2010;11:11.

Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT).
Hoogduijn M, Popp F, Grohnert A, Crop M, van Rhijn M, Rowshani A, Eggenhofer E, Renner P, Reinders M, Rabelink T, van der Laan L, Dor F, Ijzermans J, Genever P, Lange C, Durrbach A, Houtgraaf J, Christ B, Seifert M, Shagidulin M, Donckier V, Deans R, Ringden O, Perico N, Remuzzi G, Bartholomew A, Schlitt H, Weimar W, Baan C, Dahlke M
TRANSPLANTATION. 2010;90(2):124-126.

Tumour stromal cells derived from paediatric malignancies display MSC-like properties and impair NK cell cytotoxicity
Johann P, Vaegler M, Gieseke F, Mang P, Armeanu-Ebinger S, Kluba T, Handgretinger R, Müller I
BMC CANCER. 2010;10:501.

The role of multiparameter flow cytometry for disease monitoring in AML.
Kern W, Bacher U, Haferlach C, Schnittger S, Haferlach T
BEST PRACT RES CL HA. 2010;23(3):379-390.

Post-transplant immune reconstitution after unrelated allogeneic stem cell transplant in patients with acute myeloid leukemia.
Klyuchnikov E, Asenova S, Kern W, Kilinc G, Ayuketang Ayuk F, Wiedemann B, Lioznov M, Freiberger P, Zalyalov Y, Zander A, Kröger N, Bacher U
LEUKEMIA LYMPHOMA. 2010;51(8):1450-1463.

Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML)
Klyuchnikov E, Kröger N, Brummendorf T, Wiedemann B, Zander A, Bacher U
BIOL BLOOD MARROW TR. 2010;16(3):301-10.

Solid organ transplantation after allogeneic hematopoietic stem cell transplantation: a retrospective, multicenter study of the EBMT.
Koenecke C, Hertenstein B, Schetelig J, van Biezen A, Dammann E, Gratwohl A, Ganser A, Schleuning M, Bornhäuser M, Jacobsen N, Kröger N, Niederwieser D, de Witte T, Ruutu T
AM J TRANSPLANT. 2010;10(8):1897-1906.

Neurogenic transdifferentiation of human adipose-derived stem cells? A critical protocol reevaluation with special emphasis on cell proliferation and cell cycle alterations.
Kompisch K, Lange C, Steinemann D, Skawran B, Schlegelberger B, Müller R, Schumacher U
HISTOCHEM CELL BIOL. 2010;134(5):453-468.

Unrelated stem cell transplantation for patients with multiple myeloma.
Kröger N
CURR OPIN HEMATOL. 2010;17(6):538-543.

Questionable role of free light chain assay ratio to determine stringent complete remission in multiple myeloma patients.
Kröger N, Asenova S, Gerritzen A, Bacher U, Zander A
BLOOD. 2010;115(16):3413-3415.

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes.
Kröger N, Bacher U, Bader P, Böttcher S, Borowitz M, Dreger P, Khouri I, Macapinlac H, Macapintac H, Olavarria E, Radich J, Stock W, Vose J, Weisdorf D, Willasch A, Giralt S, Bishop M, Wayne A
BIOL BLOOD MARROW TR. 2010;16(9):1187-1211.

NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies.
Kröger N, Bacher U, Bader P, Böttcher S, Borowitz M, Dreger P, Khouri I, Olavarria E, Radich J, Stock W, Vose J, Weisdorf D, Willasch A, Giralt S, Bishop M, Wayne A
BIOL BLOOD MARROW TR. 2010;16(10):1325-1346.

Long-term follow-up of an intensified myeloablative conditioning regimen with in vivo T cell depletion followed by allografting in patients with advanced multiple myeloma.
Kröger N, Einsele H, Derigs G, Wandt H, Krüll A, Zander A
BIOL BLOOD MARROW TR. 2010;16(6):861-864.

Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation.
Kröger N, Shimoni A, Schilling G, Schwerdtfeger R, Bornhäuser M, Nagler A, Zander A, Heinzelmann M, Brand R, Gahrton G, Morris C, Niederwieser D, de Witte T
BRIT J HAEMATOL. 2010;148(2):323-331.

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
Kyle R, Durie B, Rajkumar S, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole D, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen W, Anderson K, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson P, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M, Group I
LEUKEMIA. 2010;24(6):1121-1127.

The MSCs' in vitro community: where to go?
Lange S, Zander A, Lange C
CTT-Cell Ther Transpl. 2010;1(4):1.

Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia.
Lim Z, Brand R, Martino R, van Biezen A, Finke J, Bacigalupo A, Beelen D, Devergie A, Alessandrino E, Willemze R, Ruutu T, Boogaerts M, Falda M, Jouet J, Niederwieser D, Kröger N, Mufti G, Witte D, Theo M
J CLIN ONCOL. 2010;28(3):405-411.

International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma.
Lokhorst H, Einsele H, Vesole D, Bruno B, Jesus S, Pérez-Simon J, Kröger N, Moreau P, Gahrton G, Gasparetto C, Giralt S, Bensinger W
J CLIN ONCOL. 2010;28(29):4521-4530.

Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia.
Luetkens T, Schafhausen P, Uhlich F, Stasche T, Akbulak R, Bartels B, Hildebrandt Y, Gontarewicz A, Kobold S, Meyer S, Gordic M, Bartels K, Lajmi N, Cao Y, Kröger N, Bokemeyer C, Brümmendorf T, Atanackovic D
LEUKEMIA RES. 2010;34(12):1647-1655.

Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC).
Miesner M, Haferlach C, Bacher U, Weiss T, Macijewski K, Kohlmann A, Klein H, Dugas M, Kern W, Schnittger S, Haferlach T
BLOOD. 2010;116(15):2742-2751.

MUTYH-associated polyposis - variability of the clinical phenotype in patients with biallelic and monoallelic MUTYH mutations and report on novel mutations.
Morak M, Laner A, Bacher U, Keiling C, Holinski-Feder E
CLIN GENET. 2010;78(4):353-363.

Influence of mannose-binding lectin genotypes and serostatus in allo-SCT: analysis of 131 recipients and donors
Neth O, Bacher U, Das P, Zabelina T, Kabisch H, Kroeger N, Ayuketang F, Lioznov M, Waschke O, Fehse B, Thiébaut R, Haston R, Klein N, Zander A
BONE MARROW TRANSPL. 2010;45(1):13-9.

Second Allogeneic Stem Cell Transplantation in a Patient with Hypoplastic Myelodysplastic Syndrome following a Primary Diagnosis of Aplastic Anaemia.
Ocheni S, Oyekunle A, Kröger N, Ayuketang Ayuk F, Klyuchnikov E, Arps S, Held K, Zabelina T, Adjalle R, Wolschke C, Zander A, Bacher U
ACTA HAEMATOL-BASEL. 2010;125(3):175-178.

Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma.
Pabst C, Zustin J, Jacobsen F, Luetkens T, Kröger N, Schilling G, Bokemeyer C, Sauter G, Atanackovic D, Marx A
EXP MOL PATHOL. 2010;89(2):175-181.

Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T- and B-cell depleted grafts in children
Pfeiffer M, Feuchtinger T, Teltschik H, Schumm M, Müller I, Handgretinger R, Lang P
HAEMATOLOGICA. 2010;95(8):1381-8.

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
Porter D, Alyea E, Antin J, DeLima M, Estey E, Falkenburg J, Hardy N, Kroeger N, Leis J, Levine J, Maloney D, Peggs K, Rowe J, Wayne A, Giralt S, Bishop M, van Besien K
BIOL BLOOD MARROW TR. 2010;16(11):1467-503.

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Porter D, Alyea E, Antin J, DeLima M, Estey E, Falkenburg J, Hardy N, Kröger N, Leis J, Levine J, Maloney D, Peggs K, Rowe J, Wayne A, Giralt S, Bishop M, van Besien K
BIOL BLOOD MARROW TR. 2010;16(11):1467-1503.

TK.007: A novel, codon-optimized HSVtk(A168H) mutant for suicide gene therapy.
Preuß E, Treschow A, Newrzela S, Brücher D, Riecken K, Felldin U, Alici E, Gahrton G, von Laer D, Dilber M, Fehse B
HUM GENE THER. 2010;21(8):929-941.

Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B-cell neoplasms.
Reindl L, Bacher U, Dicker F, Alpermann T, Kern W, Schnittger S, Haferlach T, Haferlach C
BRIT J HAEMATOL. 2010;151(1):25-36.

Chronic inflammatory bowel disease as key manifestation of atypical ARTEMIS deficiency
Rohr J, Pannicke U, Döring M, Schmitt-Graeff A, Wiech E, Busch A, Speckmann C, Müller I, Lang P, Handgretinger R, Fisch P, Schwarz K, Ehl S
J CLIN IMMUNOL. 2010;30(2):314-20.

Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells.
Rothweiler F, Michaelis M, Brauer P, Otte J, Riecken K, Fehse B, Doerr H, Wiese M, Kreuter J, Al-Abed Y, Nicoletti F, Cinatl J
NEOPLASIA. 2010;12(12):1023-1030.

Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML.
Schnittger S, Bacher U, Dicker F, Kern W, Alpermann T, Haferlach T, Haferlach C
GENE CHROMOSOME CANC. 2010;49(10):910-918.

Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up.
Shimoni A, Hardan I, Ayuketang Ayuk F, Schilling G, Atanackovic D, Zeller W, Yerushalmi R, Zander A, Kröger N, Nagler A
CANCER-AM CANCER SOC. 2010;116(15):3621-3630.

Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis.
Stahl T, Badbaran A, Kröger N, Klyuchnikov E, Zabelina T, Zeschke S, Schafhausen P, Schultz W, Asenova S, Smirnova A, Wolschke C, Ayuketang Ayuk F, Zander A, Fehse B, Bacher U
LEUKEMIA LYMPHOMA. 2010;51(10):1837-1843.

Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis
Stahl T, Badbaran A, Kröger N, Klyuchnikov E, Zabelina T, Zeschke S, Schafhausen P, Schultz W, Asenova S, Smirnova A, Wolschke C, Ayuketang F, Zander A, Fehse B, Bacher U
LEUKEMIA LYMPHOMA. 2010;51(10):1837-43.

Cell and virus genetics at the roots of gene therapy, retrovirology, and hematopoietic stem cell biology: Wolfram Ostertag (1937-2010).
Stocking C, Grez M, Fehse B, von Laer D, Itoh K, Prassolov V, Nowock J, Kühlcke K, Just U, Schröder T, Klump H, Schiedlmeier B, Grassman E, Meyer J, Li Z, Schambach A, Modlich U, Kustikova O, Galla M, Jürgen B, Zander A, Baum C
HUM GENE THER. 2010;21(11):1501-1503.

Highly efficient lentiviral transduction of phenotypically and genotypically characterized endothelial progenitor cells from adult peripheral blood.
Stockschlaeder M, Shardakova O, Riecken K, Stoldt V, Fehse B, Giers G, Scharf R
BLOOD COAGUL FIBRIN. 2010;21(5):464-473.

Infektionsdiagnostik in der Pneumologie
Strassburg A, Dalhoff K, Engelmann I, Ewig S, Herth F, Knobloch J, Rohde G, Sahly H, Schaaf B, Lange C
Pneumologie. 2010;64(5):291-9.

Mammary epithelial reconstitution with gene-modified stem cells assigns roles to Stat5 in luminal alveolar cell fate decisions, differentiation, involution, and mammary tumor formation.
Vafaizadeh V, Klemmt P, Brendel C, Riecken K, Doebele C, Britt K, Grez M, Fehse B, Desriviéres S, Groner B
STEM CELLS. 2010;28(5):928-938.

Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia.
Wiedemann B, Klyuchnikov E, Kröger N, Zabelina T, Stahl T, Zeschke S, Badbaran A, Ayuketang Ayuk F, Alchalby H, Wolschke C, Bokemeyer C, Fehse B, Zander A, Bacher U
EXP HEMATOL. 2010;38(12):1261-1271.

Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD.
Wolff D, Gerbitz A, Ayuketang Ayuk F, Kiani A, Hildebrandt G, Vogelsang G, Elad S, Lawitschka A, Socie G, Pavletic S, Holler E, Greinix H
BIOL BLOOD MARROW TR. 2010;16(12):1611-1628.

Phenotypic diversity in chondromyxoid fibroma reveals differentiation pattern of tumor mimicking fetal cartilage canals development: an immunohistochemical study.
Zustin J, Akpalo H, Gambarotti M, Priemel M, Rueger J, Lübke A, Reske D, Lange C, Püschel K, Lohmann C, Rüther W, Amling M, Alberghini M
AM J PATHOL. 2010;177(3):1072-1078.

Phenotypic diversity in chondromyxoid fibroma reveals differentiation pattern of tumor mimicking fetal cartilage canals development: an immunohistochemical study
Zustin J, Akpalo H, Gambarotti M, Priemel M, Rueger J, Luebke A, Reske D, Lange C, Pueschel K, Lohmann C, Rüther W, Amling M, Alberghini M
AM J PATHOL. 2010;177(3):1072-8.

Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells.
Atanackovic D, Hildebrandt Y, Jadczak A, Cao Y, Luetkens T, Meyer S, Kobold S, Bartels K, Pabst C, Lajmi N, Gordic M, Stahl T, Zander A, Bokemeyer C, Kröger N
HAEMATOLOGICA. 2009;*95*(5):785-793.

Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma.
Atanackovic D, Luetkens T, Hildebrandt Y, Arfsten J, Bartels K, Horn C, Stahl T, Cao Y, Zander A, Bokemeyer C, Kröger N
CLIN CANCER RES. 2009;15(4):1343-1352.

Comparison of the cytotoxicity of 4 preparations of anti-T-cell globulins in various hematological malignancies.
Ayuketang Ayuk F, Maywald N, Hannemann S, Larsen U, Zander A, Kröger N
ANTICANCER RES. 2009;29(4):1355-1360.

Antitumor effects of polyclonal antithymocyte globulins: focus on B-cell malignancies and multiple myeloma.
Ayuketang Ayuk F, Zander A, Kröger N
ANN HEMATOL. 2009;88(5):401-404.

Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis.
Bacher U, Asenova S, Badbaran A, Zander A, Alchalby H, Fehse B, Kröger N, Lange C, Ayuketang Ayuk F
CLIN EXP MED. 2009.

Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation.
Bacher U, Badbaran A, Fehse B, Zabelina T, Zander A, Kröger N
EXP HEMATOL. 2009;37(1):135-142.

Molecular determinants of prognosis in acute myeloid leukemia (AML) with normal karyotype.
Bacher U, Haferlach C
LEUKEMIA LYMPHOMA. 2009;50(9):1403-1405.

Interactive diagnostics in the indication to allogeneic SCT in AML.
Bacher U, Haferlach C, Schnittger S, Kern W, Kröger N, Zander A, Haferlach T
BONE MARROW TRANSPL. 2009;43(10):745-756.

The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes.
Bacher U, Haferlach T, Kern W, Weiss T, Schnittger S, Haferlach C
CANCER-AM CANCER SOC. 2009;115(19):4524-4532.

Safety of conditioning agents for allogeneic haematopoietic transplantation.
Bacher U, Klyuchnikov E, Wiedemann B, Kröger N, Zander A
EXPERT OPIN DRUG SAF. 2009;8(3):305-315.

The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia-a report from the German Registry covering the period from 1998 to 2004.
Bacher U, Klyuchnikov E, Zabelina T, Ottinger H, Beelen D, Schrezenmeier H, Ehninger G, Müller C, Berger J, Suttorp M, Kolb H, Kröger N, Zander A
ANN HEMATOL. 2009.

Gene expression profiling in acute myeloid leukaemia (AML).
Bacher U, Kohlmann A, Haferlach C, Haferlach T
BEST PRACT RES CL HA. 2009;22(2):169-180.

Current status of gene expression profiling in the diagnosis and management of acute leukaemia.
Bacher U, Kohlmann A, Haferlach T
BRIT J HAEMATOL. 2009;145(5):555-568.

Perspectives of gene expression profiling for diagnosis and therapy in haematological malignancies.
Bacher U, Kohlmann A, Haferlach T
Brief Funct Genomic Proteomic. 2009;8(3):184-193.

Molecular diagnostics in acute leukemias.
Bacher U, Schnittger S, Haferlach C, Haferlach T
CLIN CHEM LAB MED. 2009;47(11):1333-1341.

Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
Bacher U, Schnittger S, Kern W, Weiss T, Haferlach T, Haferlach C
ANN HEMATOL. 2009;88(12):1207-1213.

Outcome of transplantation for myelofibrosis.
Ballen K, Shrestha S, Sobocinski K, Zhang M, Bashey A, Bolwell B, Cervantes F, Devine S, Gale R, Gupta V, Hahn T, Hogan W, Kröger N, Litzow M, Marks D, Maziarz R, McCarthy P, Schiller G, Harry C, Roy V, Wiernik P, Horowitz M, Giralt S, Arora M
BIOL BLOOD MARROW TR. 2009;*16*(3):358-367.

Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1
Battula V, Treml S, Bareiss P, Gieseke F, Roelofs H, de Zwart P, Müller I, Schewe B, Skutella T, Fibbe W, Kanz L, Bühring H
HAEMATOLOGICA. 2009;94(2):173-84.

PKR activity is required for acute leukemic cell maintenance and growth: a role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation
Blalock W, Grimaldi C, Fala F, Follo M, Horn S, Basecke J, Martinelli G, Cocco L, Martelli A
J CELL PHYSIOL. 2009;221(1):232-41.

Identification of new target molecules PTK2, TGFBR2 and CD9 overexpressed during advanced bone marrow remodelling in primary myelofibrosis.
Bock O, Muth M, Theophile K, Winter M, Hussein K, Büsche G, Kröger N, Kreipe H
BRIT J HAEMATOL. 2009.

Outcome after allogeneic transplantation for adult acute myeloid leukemia patients exhibiting isolated or associated trisomy 8 chromosomal abnormality: a survey on behalf of the ALWP of the EBMT.
Chevallier P, Labopin M, Nagler A, Ljungman P, Verdonck L, Volin L, Zander A, Finke J, Socie G, Cordonnier C, Harousseau J, Mohty M, Rocha V
BONE MARROW TRANSPL. 2009;44(9):589-594.

Stem cell marking with promotor-deprived self-inactivating retroviral vectors does not lead to induced clonal imbalance.
Cornils K, Lange C, Schambach A, Brugman M, Nowak R, Lioznov M, Baum C, Fehse B
MOL THER. 2009;17(1):131-143.

5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis.
Czibere A, Bruns I, Kröger N, Platzbecker U, Lind J, Zohren F, Fenk R, Germing U, Schröder T, Gräf T, Haas R, Kobbe G
BONE MARROW TRANSPL. 2009;*45*(5):872-876.

Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group.
Dahlke M, Hoogduijn M, Eggenhofer E, Popp F, Renner P, Slowik P, Rosenauer A, Piso P, Geissler E, Lange C, Chabannes D, Mazzanti B, Bigenzahn S, Bertolino P, Kunter U, Introna M, Alessandro R, Capelli C, Perico N, Casiraghi F, Noris M, Gotti E, Seifert M, Riccardo S, Verspaget H, van Hoek B, Bartholomew A, Wekerle T, Volk H, Remuzzi G, Deans R, Lazarus H, Schlitt H, Baan C
TRANSPLANTATION. 2009;88(5):614-619.

Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival.
de Witte T, Brand R, van Biezen A, Mufti G, Ruutu T, Finke J, von Dem Borne P, Vitek A, Delforge M, Alessandrino P, Harlahakis N, Russell N, Martino R, Verdonck L, Kröger N, Niederwieser D
BRIT J HAEMATOL. 2009.

Dendritic cells: functional aspects of glycosylation and lectins
Erbacher A, Gieseke F, Handgretinger R, Müller I
HUM IMMUNOL. 2009;70(5):308-12.

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
Finke J, Bethge W, Schmoor C, Ottinger H, Stelljes M, Zander A, Volin L, Ruutu T, Heim D, Schwerdtfeger R, Kolbe K, Mayer J, Maertens J, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb H, Bertz H, Egger M, Grishina O, Socié G
LANCET ONCOL. 2009;10(9):855-864.

Diffusion-driven device for a high-resolution dose-response profiling of combination chemotherapy
Ganser A, Roth G, van Galen J, Hilderink J, Wammes J, Müller I, van Leeuwen F, Wiesmüller K, Brock R
ANAL CHEM. 2009;81(13):5233-40.

A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis.
Gupta V, Kröger N, Aschan J, Xu W, Leber B, Dalley C, Sabloff M, Lipton J, Messner H, Brune M
BONE MARROW TRANSPL. 2009.

Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment.
Haferlach C, Bacher U, Schnittger S, Weiss T, Kern W, Haferlach T
LEUKEMIA. 2009.

Discussion of the applicability of microarrays: profiling of leukemias.
Haferlach T, Bacher U, Kohlmann A, Haferlach C
Methods Mol Biol. 2009;509:15-33.

AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features.
Haferlach T, Kohlmann A, Klein H, Ruckert C, Dugas M, Williams P, Kern W, Schnittger S, Bacher U, Löffler H, Haferlach C
LEUKEMIA. 2009;23(5):934-943.

Second allogeneic stem cell transplantation in myeloid malignancies.
Hartwig M, Ocheni S, Asenova S, Wiedemann B, Zabelina T, Ayuketang Ayuk F, Kabisch H, Erttmann R, Kröger N, Zander A, Bacher U
ACTA HAEMATOL-BASEL. 2009;122(4):185-192.

Biclonal expansion and heterogeneous lineage involvement in a case of chronic myeloproliferative disease with concurrent MPLW515L/JAK2V617F mutation.
Hussein K, Bock O, Theophile K, Schlue J, Ballmaier M, Kröger N, Göhring G, Büsche G, Kreipe H
BLOOD. 2009;113(6):1391-1392.

Flow cytometric identification of acute myeloid leukemia with limited differentiation and NPM1 type A mutation: a new biologically defined entity.
Kern W, Haferlach C, Bacher U, Haferlach T, Schnittger S
LEUKEMIA. 2009;23(7):1361-1364.

Sensitising leukemic cells by targeting microenvironment.
Klyuchnikov E, Kröger N
LEUKEMIA LYMPHOMA. 2009;50(3):319-320.

Current status and perspectives of tyrosine kinase inhibitor treatment in the post-transplant period in patients with chronic myeloid leukemia (CML).
Klyuchnikov E, Kröger N, Brümmendorf T, Wiedemann B, Zander A, Bacher U
BIOL BLOOD MARROW TR. 2009.

Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia.
Klyuchnikov E, Schafhausen P, Kröger N, Brümmendorf T, Osanmaz O, Asenova S, Zabelina T, Ocheni S, Ayuketang Ayuk F, Zander A, Bacher U
ACTA HAEMATOL-BASEL. 2009;122(1):6-10.

Percutaneous intramyocardial stem cell injection in patients with acute myocardial infarction: first-in-man study.
Krause K, Jaquet K, Schneider C, Haupt S, Lioznov M, Otte K, Kuck K
HEART. 2009;95(14):1145-1152.

Endocardial electrogram analysis after intramyocardial injection of mesenchymal stem cells in the chronic ischemic myocardium.
Krause K, Schneider C, Lange C, Kokturk B, Boczor S, Geidel S, Salhi A, Alaser J, Zander A, Kuck K, Jaquet K
PACE. 2009;32(10):1319-1328.

JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation.
Kröger N, Alchalby H, Klyuchnikov E, Badbaran A, Hildebrandt Y, Ayuketang Ayuk F, Bacher U, Bock O, Kvasnicka M, Fehse B, Zander A
BLOOD. 2009;113(8):1866-1868.

Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma.
Kröger N, Badbaran A, Lioznov M, Schwartz S, Zeschke S, Hildebrandt Y, Ayuketang Ayuk F, Atanackovic D, Schilling G, Zabelina T, Bacher U, Klyuchnikov E, Shimoni A, Nagler A, Corradini P, Fehse B, Zander A
EXP HEMATOL. 2009;37(7):791-798.

Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation.
Kröger N, Brand R, van Biezen A, Zander A, Dierlamm J, Niederwieser D, Devergie A, Ruutu T, Cornish J, Ljungman P, Gratwohl A, Cordonnier C, Beelen D, Deconinck E, Symeonidis A, de Witte T
HAEMATOLOGICA. 2009;94(4):542-549.

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Kröger N, Holler E, Kobbe G, Bornhäuser M, Schwerdtfeger R, Baurmann H, Nagler A, Bethge W, Stelljes M, Uharek L, Wandt H, Burchert A, Corradini P, Schubert J, Kaufmann M, Dreger P, Wulf G, Einsele H, Zabelina T, Kvasnicka H, Thiele J, Brand R, Zander A, Niederwieser D, Witte d, Theo M
BLOOD. 2009;114(26):5264-5270.

HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen.
Kröger N, Zabelina T, Binder T, Ayuketang Ayuk F, Bacher U, Amtsfeld G, Lellek H, Schrum J, Erttmann R, Eiermann T, Zander A
BIOL BLOOD MARROW TR. 2009;15(4):454-462.

Retroviral insertion site analysis in dominant haematopoietic clones.
Kustikova O, Modlich U, Fehse B
Methods Mol Biol. 2009;506:373-390.

Platelet derived bFGF mediates vascular integrative mechanisms of mesenchymal stem cells in vitro
Langer H, Stellos K, Steingen C, Froihofer A, Schönberger T, Krämer B, Bigalke B, May A, Seizer P, Müller I, Gieseke F, Siegel-Axel D, Meuth S, Schmidt A, Wendel H, Müller I, Bloch W, Gawaz M
J MOL CELL CARDIOL. 2009;47(2):315-25.

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells.
Lioznov M, El-Cheikh J, Hoffmann F, Hildebrandt Y, Ayuketang Ayuk F, Wolschke C, Atanackovic D, Schilling G, Badbaran A, Bacher U, Fehse B, Zander A, Blaise D, Mohty M, Kröger N
BONE MARROW TRANSPL. 2009.

Concordance of assays designed for the quantification of JAK2V617F: a multicenter study.
Lippert E, Girodon F, Hammond E, Jelinek J, Reading N, Fehse B, Hanlon K, Hermans M, Richard C, Swierczek S, Ugo V, Carillo S, Harrivel V, Marzac C, Pietra D, Sobas M, Mounier M, Migeon M, Ellard S, Kröger N, Herrmann R, Prchal J, Skoda R, Hermouet S
HAEMATOLOGICA. 2009;94(1):38-45.

Reduced proliferation of CD34(+) cells from patients with acute myeloid leukemia after gene transfer of INPP5D.
Metzner A, Precht C, Fehse B, Fiedler W, Stocking C, Günther A, Mayr G, Jücker M
GENE THER. 2009;16(4):570-573.

Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.
Michaelis M, Rothweiler F, Klassert D, von Deimling A, Riecken K, Fehse B, Kammerer B, Doerr H, Cinatl J
CANCER RES. 2009;69(2):416-421.

Influence of mannose-binding lectin genotypes and serostatus in allo-SCT: analysis of 131 recipients and donors.
Neth O, Bacher U, Das P, Zabelina T, Kabisch H, Kröger N, Ayuketang Ayuk F, Lioznov M, Waschke O, Fehse B, Thiébaut R, Haston R, Klein N, Zander A
BONE MARROW TRANSPL. 2009.

Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation.
Ocheni S, Iwanski G, Schafhausen P, Zander A, Ayuketang Ayuk F, Klyuchnikov E, Zabelina T, Fiedler W, Schnittger S, Hochhaus A, Brümmendorf T, Kröger N, Bacher U
LEUKEMIA LYMPHOMA. 2009;50(4):551-558.

Outcome of allo-SCT for chronic myelomonocytic leukemia.
Ocheni S, Kröger N, Zabelina T, Zander A, Bacher U
BONE MARROW TRANSPL. 2009;43(8):659-661.

Syngenic graft-versus-chronic-myeloid-leukemia-effect?
Ocheni S, Schafhausen P, Bacher U, Fehse B, Kröger N
CTT-Cell Ther Transpl. 2009;1(3):66-68.

Pegfilgrastim compared to lenograstim after allogeneic peripheral blood stem-cell transplantation from unrelated donors.
Ocheni S, Zabelina T, Bacher U, Ayuketang Ayuk F, Zander A, Kröger N
LEUKEMIA LYMPHOMA. 2009;50(4):612-618.

Unrelated donor stem cell transplantation in acquired severe aplastic anemia: a systematic review.
Peinemann F, Grouven U, Kröger N, Pittler M, Zschorlich B, Lange S
HAEMATOLOGICA. 2009;94(12):1732-1742.

Successful unrelated donor stem cell transplantation for advanced myelofibrosis in an adult patient with history of orthotopic liver transplantation.
Perz J, Hegenbart U, Kröger N, Otto G, Ho A, Dreger P
HAEMATOLOGICA. 2009;94(4):594-596.

Diva-Fit: A step-by-step manual for generating high-resolution graphs and histogram overlays of flow cytometry data obtained with FACSDiva software
Riecken K, Fehse B
CTT-Cell Ther Transpl. 2009;1(4):1-4.

Lentiviral gene ontology (LeGO) vectors equipped with novel drug-selectable fluorescent proteins: new building blocks for cell marking and multi-gene analysis.
Riecken K, Mock U, Petrowitz B, Bartsch U, Fehse B
GENE THER. 2009.

Sleep disturbances and emotional distress in the acute course of hematopoietic stem cell transplantation.
Rischer J, Scherwath A, Zander A, Koch U, Schulz-Kindermann F
BONE MARROW TRANSPL. 2009.

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.
Saussele S, Lauseker M, Gratwohl A, Beelen D, Bunjes D, Schwerdtfeger R, Kolb H, Ho A, Falge C, Holler E, Schlimok G, Zander A, Arnold R, Kanz L, Dengler R, Haferlach C, Schlegelberger B, Pfirrmann M, Muller M, Schnittger S, Leitner A, Pletsch N, Hochhaus A, Hasford J, Hehlmann R
BLOOD. 2009;*115*(10):1880-1885.

Basic research and clinical applications of non-hematopoietic stem cells, 4-5 April 2008, Tubingen, Germany
Schäfer R, Dominici M, Müller I, Horwitz E, Asahara T, Bulte J, Bieback K, Le Blanc K, Bühring H, Capogrossi M, Dazzi F, Gorodetsky R, Henschler R, Handgretinger R, Kajstura J, Kluger P, Lange C, Luettichau I, Mertsching H, Schrezenmeier H, Sievert K, Strunk D, Verfaillie C, Northoff H
CYTOTHERAPY. 2009;11(2):245-55.

Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib.
Schafhausen P, Dierlamm J, Bokemeyer C, Brümmendorf T, Bacher U, Zander A, Schnittger S, Hochhaus A
CANCER GENET CYTOGEN. 2009;189(1):63-67.

Stehen kognitive Funktionen im Zusammenhang mit Angst, Depression und Posttraumatischer Belastungsstörung bei Brustkrebspatientinnen nach onkologischer Behandlung?
Schirmer L, Mehnert A, Scherwath A, Schleimer B, Schulz-Kindermann F, Zander A, Koch-Gromus U
Z PSYCHIATR PSYCH PS. 2009;57(1):33-42.

Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis.
Schnittger S, Bacher U, Haferlach C, Beelen D, Bojko P, Bürkle D, Dengler R, Distelrath A, Eckart M, Eckert R, Fries S, Knoblich J, Köchling G, Laubenstein H, Petrides P, Planker M, Pihusch R, Weide R, Kern W, Haferlach T
HAEMATOLOGICA. 2009;94(1):141-144.

Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera.
Schnittger S, Bacher U, Haferlach C, Geer T, Müller P, Mittermüller J, Petrides P, Schlag R, Sandner R, Selbach J, Slawik H, Tessen H, Wehmeyer J, Kern W, Haferlach T
HAEMATOLOGICA. 2009;94(3):414-418.

RQ-PCR based WT1 expression in comparison to BCR-ABL quantification can predict Philadelphia negative clonal evolution in patients with imatinib-treated chronic myeloid leukaemia.
Schnittger S, Bacher U, Kern W, Tschulik C, Weiss T, Haferlach C, Haferlach T
BRIT J HAEMATOL. 2009;146(6):665-668.

Donor lymphocyte infusions in amyloid light chain amyloidosis: induction of a "graft-versus-plasma cell-dyscrasia effect".
Schonland S, Kröger N, Wolschke C, Dreger P, Ho A, Hegenbart U
HAEMATOLOGICA. 2009;94(3):439-441.

Severe aplastic anaemia following leflunomide therapy.
Wüsthof M, Smirnova A, Bacher U, Kröger N, Zander A, Schuch G, Bokemeyer C
RHEUMATOLOGY. 2009.

CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D, Cao Y, Luetkens T, Panse J, Faltz C, Arfsten J, Bartels K, Wolschke C, Eiermann T, Zander A, Fehse B, Bokemeyer C, Kröger N
HAEMATOLOGICA. 2008;93(3):423-430.

Complement-dependent and complement-independent cytotoxicity of polyclonal antithymocyte globulins in chronic lymphocytic leukemia.
Ayuketang Ayuk F, Atassi N, Schuch G, Mina S, Fang L, Bokemeyer C, Fehse B, Zander A, Kröger N
LEUKEMIA RES. 2008;32(8):1200-1206.

Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuketang Ayuk F, Diyachenko G, Zabelina T, Panse J, Wolschke C, Eiermann T, Binder T, Fehse B, Erttmann R, Kabisch H, Bacher U, Kröger N, Zander A
EXP HEMATOL. 2008;36(8):1047-1054.

Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
Ayuketang Ayuk F, Diyachenko G, Zabelina T, Wolschke C, Fehse B, Bacher U, Erttmann R, Kröger N, Zander A
BIOL BLOOD MARROW TR. 2008;14(8):913-919.

Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation.
Ayuketang Ayuk F, Perez-Simon J, Shimoni A, Sureda A, Zabelina T, Schwerdtfeger R, Martino R, Sayer H, Alegre A, Lahuerta J, Atanackovic D, Wolschke C, Nagler A, Zander A, Miguel S, Kröger N, Kröger N
HAEMATOLOGICA. 2008;93(9):1343-1350.

Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.
Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S
BLOOD. 2008;111(5):2527-2537.

Minimal residual disease diagnostics in myeloid malignancies in the post transplant period.
Bacher U, Zander A, Haferlach T, Schnittger S, Fehse B, Kröger N
BONE MARROW TRANSPL. 2008;42(3):145-157.

Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation.
Benjamini O, Koren-Michowitz M, Amariglio N, Kröger N, Nagler A, Shimoni A
LEUKEMIA. 2008;22(10):1961-1963.

Abnormal expression of only the CD34 part of a transgenic CD34/herpes simplex virus-thymidine kinase fusion protein is associated with ganciclovir resistance.
Bennour E, Ferrand C, Rémy-Martin J, Certoux J, Gorke S, Qasim W, Gaspar H, Baumert T, Duperrier A, Deschamps M, Fehse B, Tiberghien P, Robinet E
HUM GENE THER. 2008;19(7):699-709.

Clinical application of a retroviral gene transfer protocol based on centrifugation-mediated vector preloading.
Fehse B
HUM GENE THER. 2008;19(6):655-658.

Insertional mutagenesis and clonal dominance: biological and statistical considerations.
Fehse B, Roeder I
GENE THER. 2008;15(2):143-153.

Analysis of sternotomy as treatment option for the resection of bilateral pulmonary metastases in pediatric solid tumors
Fuchs J, Seitz G, Ellerkamp V, Dietz K, Bosk A, Müller I, Warmann S, Schäfer J
J SURG ONCOL. 2008;17(4):323-30.

Initial report on a phase I clinical trial: Prevention and treatment of post-operative Acute Kidney Injury with allogeneic Mesenchymal Stem Cells in patients who require on-pump cardiac surgery.
Gooch A, Doty , Flores J, Toegel F, Reiss G, Lange C, Zander A, Zhang P, Westenfelder C
2008.

Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
Haferlach C, Bacher U, Tiu R, Maciejewski J, List A
CANCER GENET CYTOGEN. 2008;187(2):101-111.

The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers.
Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C
ANN HEMATOL. 2008;87(1):1-10.

Overexpression of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase inhibits GM-CSF-dependent colony formation of CD34+ hematopoietic progenitor cells.
Hoxha E, Fehse B, Ortmeyer G, Stocking C, Mayr G, Jücker M
LEUKEMIA LYMPHOMA. 2008;49(6):1206-1208.

WT1 protein expression in childhood acute leukemia
Kerst G, Bergold N, Gieseke F, Coustan-Smith E, Lang P, Kalinova M, Handgretinger R, Trka J, Müller I
AM J HEMATOL. 2008;83(5):382-6.

WT1 protein expression in slowly proliferating myeloid leukemic cell lines is scarce throughout the cell cycle with a minimum in G0/G1 phase
Kerst G, Bergold N, Viebahn S, Gieseke F, Kalinova M, Trka J, Handgretinger R, Müller I
LEUKEMIA RES. 2008;32(9):1393-9.

Safety of percutaneous dilational tracheostomy in hematopoietic stem cell transplantation recipients requiring long-term mechanical ventilation.
Kluge S, Baumann H, Nierhaus A, Kröger N, Meyer A, Kreymann K
J CRIT CARE. 2008;23(3):394-398.

Epigenetic modulation and other options to improve outcome of stem cell transplantation in MDS.
Kröger N
Hematology Am Soc Hematol Educ Program. 2008;60-67.

Choosing between stem cell therapy and drugs in myelofibrosis.
Kröger N, Mesa R
LEUKEMIA. 2008;22(3):474-486.

Efficient in vitro generation of adult multipotent cells from mobilized peripheral blood CD133+ cells
Kuçi S, Kuçi Z, Schmid S, Seitz G, Müller I, Dufke A, Leimig T, Murti G, Jurecic R, Schumm M, Lang P, Bruchelt G, Bader P, Klingebiel T, Niethammer D, Handgretinger R
Cell proliferation. 2008;41(1):12-27.

Retroviral integration site analysis in hematopoietic stem cells.
Kustikova O, Baum C, Fehse B
Methods Mol Biol. 2008;430:255-267.

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.
Lee S, Kukreja M, Wang T, Giralt S, Szer J, Arora M, Woolfrey A, Cervantes F, Champlin R, Gale R, Halter J, Keating A, Marks D, McCarthy P, Olavarria E, Stadtmauer E, Abecasis M, Gupta V, Khoury H, George B, Hale G, Liesveld J, Rizzieri D, Antin J, Bolwell B, Carabasi M, Copelan E, Ilhan O, Litzow M, Schouten H, Zander A, Horowitz M, Maziarz R
BLOOD. 2008;112(8):3500-3507.

Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques.
Lioznov M, Badbaran A, Fehse B, Bacher U, Zander A, Kröger N
BONE MARROW TRANSPL. 2008;41(10):913-916.

Transportation and cryopreservation may impair haematopoietic stem cell function and engraftment of allogeneic PBSCs, but not BM.
Lioznov M, Dellbrügger C, Sputtek A, Fehse B, Kröger N, Zander A
BONE MARROW TRANSPL. 2008;42(2):121-128.

Primary Cells As Feeder Cells For Coculture Expansion Of Human Hematopoietic Stem Cells From Umbilical Cord Blood A Comparative Study.
Magin A, Koerfer N, Partenheimer H, Lange C, Zander A, Noll T
STEM CELLS DEV. 2008.

Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy
McCubrey J, Sokolosky M, Lehmann B, Taylor J, Navolanic P, Chappell W, Abrams S, Stadelman K, Wong E, Misaghian N, Horn S, Bäsecke J, Libra M, Stivala F, Ligresti G, Tafuri A, Milella M, Zarzycki M, Dzugaj A, Chiarini F, Evangelisti C, Martelli A, Terrian D, Franklin R, Steelman L
Advances in enzyme regulation. 2008;48:113-35.

Mesenchymal stem cell therapy for degenerative inflammatory disorders
Müller I, Lymperi S, Dazzi F
Current opinion in organ transplantation. 2008;13(6):639-44.

Secretion of angiogenic proteins by human multipotent mesenchymal stromal cells and their clinical potential in the treatment of avascular osteonecrosis
Müller I, Vaegler M, Holzwarth C, Tzaribatchev N, Pfister S, Schütt B, Reize P, Greil J, Handgretinger R, Rudert M
LEUKEMIA. 2008;22(11):2054-61.

Resistance of mature T cells to oncogene transformation.
Newrzela S, Cornils K, Li Z, Baum C, Brugman M, Hartmann M, Meyer J, Hartmann S, Hansmann M, Fehse B, von Laer D
BLOOD. 2008;112(6):2278-2286.

EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT.
Ocheni S, Kröger N, Zabelina T, Sobottka I, Ayuketang Ayuk F, Wolschke C, Muth A, Lellek H, Petersen L, Erttmann R, Kabisch H, Zander A, Bacher U
BONE MARROW TRANSPL. 2008;42(3):181-186.

Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients.
Panse J, Friedrichs K, Marx A, Hildebrandt Y, Luetkens T, Barrels K, Horn C, Stahl T, Cao Y, Milde-Langosch K, Niendorf A, Kröger N, Wenzel S, Leuwer R, Bokemeyer C, Hegewisch-Becker S, Atanackovic D
BRIT J CANCER. 2008;99(6):930-938.

Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS).
Platzbecker U, Bornhäuser M, Germing U, Stumpf J, Scott B, Kröger N, Schwerdtfeger R, Böhm A, Kobbe G, Theuser C, Rabitsch W, Valent P, Sorror M, Ehninger G, Deeg H
BIOL BLOOD MARROW TR. 2008;14(11):1217-1225.

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.
Rawstron A, Orfao A, Beksac M, Bezdickova L, Brooimans R, Bumbea H, Dalva K, Fuhler G, Gratama J, Hose D, Kovarova L, Lioznov M, Mateo G, Morilla R, Mylin A, Omedé P, Pellat-Deceunynck C, Martin P, Petrucci M, Ruggeri M, Rymkiewicz G, Schmitz A, Schreder M, Seynaeve C, Spacek M, Tute d, Ruth M, Els V, Weston-Bell N, Owen R, Miguel S, Jesús F, Sonneveld P, Johnsen H
HAEMATOLOGICA. 2008;93(3):431-438.

Molecular characterisation of linezolid resistance in two vancomycin-resistant (VanB) Enterococcus faecium isolates using Pyrosequencing.
Saager B, Rohde H, Timmerbeil B, Franke G, Pothmann W, Dahlke J, Scherpe S, Sobottka I, Heisig P, Horstkotte M
EUR J CLIN MICROBIOL. 2008;27(9):873-878.

Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.
Schilling G, Hansen T, Shimoni A, Zabelina T, Pérez-Simón J, Simon-Perez J, Gutierrez N, Fiedler W, Liebisch P, Schwerdtfeger R, Bornhäuser M, Otterstetter S, Murga-Penas E, Dierlamm J, Ayuketang Ayuk F, Atanackovic D, Bacher U, Bokemeyer C, Zander A, San Miguel J, Miguel J, Nagler A, Kröger N
LEUKEMIA. 2008;22(6):1250-1255.

Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis.
Schnittger S, Bacher U, Haferlach C, Dengler R, Kröber A, Kern W, Haferlach T
LEUKEMIA. 2008;22(2):453-455.

A new case with rare e6a2 BCR-ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment.
Schnittger S, Bacher U, Kern W, Haferlach T, Hertenstein B, Haferlach C
LEUKEMIA. 2008;22(4):856-858.

The MADS transcription factor Mef2c is a pivotal modulator of myeloid cell fate.
Schüler A, Schwieger M, Engelmann A, Riecken K, Horn S, Müller U, Arnold M, Olson E, Stocking C
BLOOD. 2008;111(9):4532-4541.

Differences in proportion and dynamics of recipient hematopoiesis following hematopoietic cell transplantation in CML and IMF.
Siebolts U, Thiele J, Zander T, Ditschkowski M, Beelen D, Kröger N, Fehse B, Wickenhauser C
ONCOL REP. 2008;19(1):287-292.

Akt as a therapeutic target in cancer
Steelman L, Stadelman K, Chappell W, Horn S, Bäsecke J, Cervello M, Nicoletti F, Libra M, Stivala F, Martelli A, McCubrey J
EXPERT OPIN THER TAR. 2008;12(9):1139-65.

Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation.
Tichelli A, Passweg J, Wójcik D, Rovó A, Harousseau J, Masszi T, Zander A, Békássy A, Crawley C, Arat M, Sica S, Lutz P, Socié G
HAEMATOLOGICA. 2008;93(8):1203-1210.

Mesenchymal stromal cells: a novel treatment option for steroid-induced avascular osteonecrosis
Tzaribachev N, Vaegler M, Schaefer J, Reize P, Rudert M, Handgretinger R, Müller I
CAN MED ASSOC J. 2008;10(3):232-4.

A multicolor panel of novel lentiviral "gene ontology" (LeGO) vectors for functional gene analysis.
Weber K, Bartsch U, Stocking C, Fehse B
MOL THER. 2008;16(4):698-706.

Allogeneic stem cell transplantation in acute myeloid leukemia: establishment of indications on the basis of individual risk stratification.
Zander A, Bacher U, Finke J
DTSCH ARZTEBL INT. 2008;105(39):663-669.

Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up.
Zander A, Schmoor C, Kröger N, Krüger W, Möbus V, Frickhofen N, Metzner B, Berdel W, Koenigsmann M, Thiel E, Wandt H, Possinger K, Kreienberg R, Schumacher M, Jonat W
ANN ONCOL. 2008;19(6):1082-1089.

Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation.
Atanackovic D, Arfsten J, Cao Y, Gnjatic S, Schnieders F, Bartels K, Schilling G, Faltz C, Wolschke C, Dierlamm J, Ritter G, Eiermann T, Hossfeld D, Zander A, Jungbluth A, Old L, Bokemeyer C, Kröger N
BLOOD. 2007;109(3):1103-1112.

A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia.
Bacher U, Haferlach T, Kern W, Haferlach C, Schnittger S
HAEMATOLOGICA. 2007;92(6):744-752.

A case of chronic myeloproliferative syndrome followed by precursor T-cell acute lymphoblastic leukemia.
Bacher U, Haferlach T, Kern W, Harich H, Schnittger S, Haferlach C
CANCER GENET CYTOGEN. 2007;175(1):52-56.

Long-term safety of filgrastim (rhG-CSF) administration: application of haematopoietic growth factors in healthy individuals.
Bacher U, Zander A
BRIT J HAEMATOL. 2007;137(1):78-80.

Autologous stem cell transplantation in myelodysplastic syndromes.
de Witte T, Suciu S, Brand R, Muus P, Kröger N
SEMIN HEMATOL. 2007;44(4):274-277.

Farber disease: clinical presentation, pathogenesis and a new approach to treatment.
Ehlert K, Frosch M, Fehse N, Zander A, Roth J, Vormoor J
PEDIATR RHEUMATOL. 2007;5:15.

Modulation of Ca2+ entry and plasma membrane potential by human TRPM4b.
Fliegert R, Glassmeier G, Schmid F, Cornils K, Genisyuerek S, Harneit A, Schwarz J, Guse A
FEBS J. 2007;274(3):704-713.

Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma.
Gahrton G, Iacobelli S, Bandini G, Björkstrand B, Corradini P, Crawley C, Hegenbart U, Morgan G, Kröger N, Schattenberg A, Schönland S, Verdonck L, Volin L, de Witte T, Niederwieser D
HAEMATOLOGICA. 2007;92(11):1513-1518.

Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFNgammaR1 signaling and IDO expression
Gieseke F, Schütt B, Viebahn S, Koscielniak E, Friedrich W, Handgretinger R, Müller I
BLOOD. 2007;110(6):2197-200.

Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation.
Goekkurt E, Stoehlmacher J, Stueber C, Wolschke C, Eiermann T, Iacobelli S, Zander A, Ehninger G, Kröger N
ANTICANCER RES. 2007;27(6):4377-4380.

Insight into the molecular pathogenesis of myeloid malignancies.
Haferlach T, Bacher U, Haferlach C, Kern W, Schnittger S
CURR OPIN HEMATOL. 2007;14(2):90-97.

[Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)]
Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C
MED KLIN-INTENSIVMED. 2007;102(9):770-777.

Diagnostic pathways in acute leukemias: a proposal for a multimodal approach.
Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C
ANN HEMATOL. 2007;86(5):311-327.

Gene expression profiling for the diagnosis of acute leukaemia.
Haferlach T, Kohlmann A, Bacher U, Schnittger S, Haferlach C, Kern W
BRIT J CANCER. 2007;96(4):535-540.

Feasibility and outcome of reduced-intensity conditioning in haploidentical transplantation
Handgretinger R, Chen X, Pfeiffer M, Müller I, Feuchtinger T, Hale G, Lang P
ANN NY ACAD SCI. 2007;1106:279-89.

In vivo magnetic resonance imaging of iron oxide-labeled, arterially-injected mesenchymal stem cells in kidneys of rats with acute ischemic kidney injury: detection and monitoring at 3T
Ittrich H, Lange C, Tögel F, Zander A, Dahnke H, Westenfelder C, Adam G, Nolte-Ernsting C
J MAGN RESON IMAGING. 2007;25(6):1179-91.

In vivo magnetic resonance imaging of iron oxide-labeled, arterially-injected mesenchymal stem cells in kidneys of rats with acute ischemic kidney injury: detection and monitoring at 3T.
Ittrich H, Lange C, Tögel F, Zander A, Dahnke H, Westenfelder C, Adam G, Nolte-Ernsting C
J MAGN RESON IMAGING. 2007;25(6):1179-1191.

A new interphase fluorescence in situ hybridization approach for genomic rearrangements involving MLH1 and MSH6 in hereditary nonpolyposis colorectal cancer-suspected mutation-negative patients.
Koehler U, Grabowski M, Bacher U, Holinski-Feder E
CANCER GENET CYTOGEN. 2007;175(1):81-84.

Mini-Midi-Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation.
Kröger N
LEUKEMIA. 2007;21(9):1851-1858.

Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis.
Kröger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhäuser M, Reiter A, Zabelina T, Zander A, Fehse B
BLOOD. 2007;109(3):1316-1321.

Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
Kröger N, Thiele J, Zander A, Schwerdtfeger R, Kobbe G, Bornhäuser M, Bethge W, Schubert J, de Witte T, Kvasnicka H
EXP HEMATOL. 2007;35(11):1719-1722.

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.
Kropff M, Bisping G, Schuck E, Liebisch P, Lang N, Hentrich M, Dechow T, Kröger N, Salwender H, Metzner B, Sezer O, Engelhardt M, Wolf H, Einsele H, Volpert S, Heinecke A, Berdel W, Kienast J
BRIT J HAEMATOL. 2007;138(3):330-337.

Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways.
Kustikova O, Geiger H, Li Z, Brugman M, Chambers S, Shaw C, Pike-Overzet K, de Ridder D, Staal F, von Keudell G, Cornils K, Nattamai K, Modlich U, Wagemaker G, Goodell M, Fehse B, Baum C
BLOOD. 2007;109(5):1897-1907.

Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenerative medicine
Lange C, Cakiroglu F, Spiess A, Cappallo-Obermann H, Dierlamm J, Zander A
J CELL PHYSIOL. 2007;213(1):18-26.

CD34 modulates the trafficking behavior of hematopoietic cells in vivo.
Lange C, Li Z, Fang L, Baum C, Fehse B
STEM CELLS DEV. 2007;16(2):297-304.

Non-hematopoietic bone marrow cells for regenerative medicine.
Lange C, Tögel F, Jaquet K, Ittrich H, Westenfelder C, Zander A
2007. Stem cells and their potential for clinical application. Bilko et al. (Ed.) (Hrsg.). NATO ASI Series, .

Retransplantation with stem cells from mismatched related donors after graft rejection in pediatric patients
Lang P, Müller I, Greil J, Bader P, Schumm M, Pfeiffer M, Hoelle W, Klingebiel T, Heinzelmann F, Belka C, Schlegel P, Kremens B, Woessmann W, Handgretinger R
BLOOD CELL MOL DIS. 2007;40(1):33-9.

Insertional mutagenesis by replication-deficient retroviral vectors encoding the large T oncogene.
Li Z, Kustikova O, Kamino K, Neumann T, Rhein M, Grassman E, Fehse B, Baum C
ANN NY ACAD SCI. 2007;1106:95-113.

The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy.
Mehnert A, Scherwath A, Schirmer L, Schleimer B, Petersen-Ewert C, Schulz-Kindermann F, Zander A, Koch-Gromus U
PATIENT EDUC COUNS. 2007;66(1):108-118.

Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutations.
Metzner A, Horstmann M, Fehse B, Ortmeyer G, Niemeyer C, Stocking C, Mayr G, Jücker M
GENE THER. 2007;14(8):699-703.

Remarkable leukemogenic potency and quality of a constitutively active neurotrophin receptor, deltaTrkA.
Meyer J, Rhein M, Schiedlmeier B, Kustikova O, Rudolph C, Kamino K, Neumann T, Yang M, Wahlers A, Fehse B, Reuther G, Schlegelberger B, Ganser A, Baum C, Li Z
LEUKEMIA. 2007;21(10):2171-2180.

Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene.
Miletic H, Fischer Y, Litwak S, Giroglou T, Waerzeggers Y, Winkeler A, Li H, Himmelreich U, Lange C, Stenzel W, Deckert M, Neumann H, Jacobs A, von Laer D
MOL THER. 2007;15(7):1373-1381.

Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofixation after allogeneic stem cell transplantation.
Mösbauer U, Ayuketang Ayuk F, Schieder H, Lioznov M, Zander A, Kröger N
HAEMATOLOGICA. 2007;92(2):275-276.

Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation
Müller I, Kordowich S, Holzwarth C, Isensee G, Lang P, Neunhoeffer F, Dominici M, Greil J, Handgretinger R
BLOOD CELL MOL DIS. 2007;40(1):25-32.

[Magnetic resonance imaging of single SPIO labeled mesenchymal stem cells at 3 Tesla]
Peldschus K, Kaul M, Lange C, Nolte-Ernsting C, Adam G, Ittrich H
ROFO-FORTSCHR RONTG. 2007;179(5):473-479.

Progress in characterization, preparation and clinical applications of non-hematopoietic stem cells, 29-30 September 2006, Tübingen, Germany
Schäfer R, Dominici M, Müller I, Dazzi F, Bieback K, Godthardt K, Le Blanc K, Meisel R, Pochampally R, Richter R, Skutella T, Steinhoff G, Mitterberger M, Wendel H, Wiskirchen J, Handgretinger R, Northoff H
CYTOTHERAPY. 2007;9(4):397-405.

Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients.
Schnittger S, Bacher U, Haferlach C, Kern W, Haferlach T
LEUKEMIA. 2007;21(4):725-731.

JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML.
Schnittger S, Bacher U, Kern W, Haferlach C, Haferlach T
LEUKEMIA. 2007;21(1):183-184.

JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases.
Schnittger S, Bacher U, Kern W, Haferlach T, Haferlach C
LEUKEMIA. 2007;21(8):1843-1845.

Simplified protocol to isolate, purify, and culture expand mesenchymal stem cells.
Schrepfer S, Deuse T, Lange C, Katzenberg R, Reichenspurner H, Robbins R, Pelletier M
STEM CELLS DEV. 2007;16(1):105-107.

Cognitive function in the acute course of allogeneic hematopoietic stem cell transplantation for hematological malignancies.
Schulz-Kindermann F, Mehnert A, Scherwath A, Schirmer L, Schleimer B, Zander A, Koch-Gromus U
BONE MARROW TRANSPL. 2007;39(12):789-799.

Dualism of mixed chimerism between hematopoiesis and stroma in chronic idiopathic myelofibrosis after allogeneic stem cell transplantation.
Thiele J, Varus E, Siebolts U, Kvasnicka H, Wickenhauser C, Metz K, Beelen D, Ditschkowski M, Zander A, Kröger N
HISTOL HISTOPATHOL. 2007;22(4):365-372.

[Recovery of peripheral blood lymphocytes in patients with hematological diseases after allogenic non-relative transplantation of hemopoietic stem cells]
Vavilov V, Zander A, Afanas'iev B
TERAPEVT ARKH. 2007;79(7):44-47.

L1 is associated with favorable outcome in neuroblastomas in contrast to adult tumors.
Wachowiak R, Fiegel H, Kaifi J, Quaas A, Krickhahn A, Schurr P, Erttmann R, Schachner M, Kluth D, Sauter G, Izbicki J
ANN SURG ONCOL. 2007;14(12):3575-3580.

Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Weissinger E, Schiffer E, Hertenstein B, Ferrara J, Holler E, Stadler M, Kolb H, Zander A, Zürbig P, Kellmann M, Ganser A
BLOOD. 2007;109(12):5511-5519.

Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors.
Baum C, Kustikova O, Modlich U, Li Z, Fehse B
HUM GENE THER. 2006;17(3):253-263.

Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
Bornhäuser M, Kröger N, Schwerdtfeger R, Schafer-Eckart K, Sayer H, Scheid C, Stelljes M, Kienast J, Mundhenk P, Fruehauf S, Kiehl M, Wandt H, Theuser C, Ehninger G, Zander A
EUR J HAEMATOL. 2006;76(1):9-17.

Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation.
Dahlke J, Kröger N, Zabelina T, Ayuketang Ayuk F, Wolschke C, Renges H, Krüger W, Kruell A, Hinke A, Erttmann R, Kabisch H, Zander A
BONE MARROW TRANSPL. 2006;37(2):155-163.

The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes.
de Witte T, Brand R, van Biezen A, Delforge M, Biersack H, Or R, Meloni G, Bandini B, Sierra J, Kröger N, Gratwohl A, Niederwieser D
HAEMATOLOGICA. 2006;91(6):750-756.

Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma.
Donk v, Kröger N, Kröger N, Hegenbart U, Corradini P, Miguel S, Jesus F, Goldschmidt H, Perez-Simon J, Zijlmans M, Ayuketang Ayuk F, Montefusco V, Ayuk F, Oers v, Marinus H, Nagler A, Verdonck L, Lokhorst H
BLOOD. 2006;107(8):3415-3416.

Bovine herpesvirus 4 based vector interaction with liver cells in vitro and in vivo
Donofrio G, Martignani E, Poli E, Lange C, Martini F, Cavirani S, Cabassi C, Taddei S, Flammini C
J VIROL METHODS. 2006;136(1-2):126-36.

Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation.
Einsele H, Reusser P, Bornhäuser M, Kalhs P, Ehninger G, Hebart H, Chalandon Y, Kröger N, Hertenstein B, Rohde F
BLOOD. 2006;107(7):3002-3008.

Sensitive balance of suppressing and activating effects of mesenchymal stem cells on T-cell proliferation.
Fang L, Lange C, Engel M, Zander A, Fehse B
TRANSPLANTATION. 2006;82(10):1370-1373.

Cell growth and differentiation of different hepatic cells isolated from fetal rat liver in vitro.
Fiegel H, Bruns H, Höper C, Lioznov M, Kluth D
TISSUE ENG. 2006;12(1):123-130.

Fetal and adult liver stem cells for liver regeneration and tissue engineering.
Fiegel H, Lange C, Kneser U, Lambrecht W, Zander A, Rogiers X, Kluth D
J CELL MOL MED. 2006;10(3):577-587.

Retroviral vector insertions in T-lymphocytes used for suicide gene therapy occur in gene groups with specific molecular functions.
Giordano F, Fehse B, Hotz-Wagenblatt A, Jonnakuty S, Del Val C, Appelt J, Nagy K, Kuehlcke K, Naundorf S, Zander A, Zeller W, Ho A, Fruehauf S, Laufs S
BONE MARROW TRANSPL. 2006;38(3):229-235.

Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients.
Goekkurt E, Hoehn S, Wolschke C, Wittmer C, Stueber C, Hossfeld D, Stoehlmacher J
BRIT J CANCER. 2006;94(2):281-286.

Comparison of flow cytometry vs. a haematology cell analyser-based method to guide the optimal time-point for peripheral blood stem cell apheresis.
Gutensohn K, Magens M, Krüger W, Kröger N, Kühnl P
VOX SANG. 2006;90(1):53-58.

Increased alpha2,6-sialylation of surface proteins on tolerogenic, immature dendritic cells and regulatory T cells
Jenner J, Kerst G, Handgretinger R, Müller I
EXP HEMATOL. 2006;34(9):1212-8.

Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation.
Kröger N, Binder T, Zabelina T, Wolschke C, Schieder H, Renges H, Ayuketang Ayuk F, Dahlke J, Eiermann T, Zander A
TRANSPLANTATION. 2006;82(8):1024-1030.

Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
Kröger N, Brand R, van Biezen A, Cahn J, Slavin S, Blaise D, Sierra J, Zander A, Niederwieser D, de Witte T
BONE MARROW TRANSPL. 2006;37(2):183-189.

Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer.
Kröger N, Frick M, Gluz O, Mohrmann S, Metzner B, Jackisch C, Ko Y, Lindemann H, Meier C, Lohrmann H, Ruffert U, Hänel M, Bodenstein H, Neubauer A, Ehninger G, Wolf H, Kolbe K, Burock K, Zander A, Nitz U
J CLIN ONCOL. 2006;24(24):3919-3926.

Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
Kröger N, Milde-Langosch K, Riethdorf S, Schmoor C, Schumacher M, Zander A, Löning T
CLIN CANCER RES. 2006;12(1):159-168.

Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
Kröger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuketang Ayuk F, Wolschke C, Renges H, Dahlke J, Atanackovic D, Nagler A, Zander A
BONE MARROW TRANSPL. 2006;37(4):339-344.

Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.
Kröger N, Zabelina T, Ayuketang Ayuk F, Atanackovic D, Schieder H, Renges H, Zander A
EXP HEMATOL. 2006;34(6):770-775.

Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma.
Kröger N, Zagrivnaja M, Schwartz S, Badbaran A, Zabelina T, Lioznov M, Ayuketang Ayuk F, Zander A, Fehse B
EXP HEMATOL. 2006;34(5):688-694.

Hepatocytic differentiation of mesenchymal stem cells in cocultures with fetal liver cells.
Lange C, Bruns H, Kluth D, Zander A, Fiegel H
WORLD J GASTROENTERO. 2006;12(15):2394-2397.

Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects
Lang P, Pfeiffer M, Müller I, Schumm M, Ebinger M, Koscielniak E, Feuchtinger T, Föll J, Martin D, Handgretinger R
KLIN PADIATR. 2006;218(6):321-6.

Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Martino R, Parody R, Fukuda T, Maertens J, Theunissen K, Ho A, Mufti G, Kröger N, Zander A, Heim D, Paluszewska M, Selleslag D, Steinerova K, Ljungman P, Cesaro S, Nihtinen A, Cordonnier C, Vazquez L, López-Duarte M, Lopez J, Cabrera R, Rovira M, Neuburger S, Cornely O, Hunter A, Marr K, Dornbusch H, Einsele H
BLOOD. 2006;108(9):2928-2936.

Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM
Müller I, Kordowich S, Holzwarth C, Spano C, Isensee G, Staiber A, Viebahn S, Gieseke F, Langer H, Gawaz M, Horwitz E, Conte P, Handgretinger R, Dominici M
CYTOTHERAPY. 2006;8(5):437-44.

In vitro analysis of multipotent mesenchymal stromal cells as potential cellular therapeutics in neurometabolic diseases in pediatric patients
Müller I, Kustermann-Kuhn B, Holzwarth C, Isensee G, Vaegler M, Harzer K, Krägeloh-Mann I, Handgretinger R, Bruchelt G
EXP HEMATOL. 2006;34(10):1413-9.

Dynamic expression of LIM cofactors in the developing mouse neural tube.
Ostendorff H, Tursun B, Cornils K, Schlüter A, Drung A, Güngör C, Bach I
DEV DYNAM. 2006;235(3):786-791.

CD34(+)-selected stem cell boost for delayed or insufficient engraftment after allogeneic stem cell transplantation.
Oyekunle A, Koehl U, Schieder H, Ayuketang Ayuk F, Renges H, Fehse N, Zabelina T, Fehse B, Klingebiel T, Sputtek A, Zander A, Kröger N
CYTOTHERAPY. 2006;8(4):375-380.

Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up.
Oyekunle A, Kröger N, Zabelina T, Ayuketang Ayuk F, Schieder H, Renges H, Fehse N, Waschke O, Fehse B, Kabisch H, Zander A
BONE MARROW TRANSPL. 2006;37(1):45-50.

Hyaluronate and its receptors in bone marrow.
Schade U, Nehmann N, Horny H, Prehm P, Delpech B, Krüger W, Zander A, Schumacher U
ACTA HISTOCHEM. 2006;108(2):141-147.

Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects.
Scherwath A, Mehnert A, Schleimer B, Schirmer L, Fehlauer F, Kreienberg R, Metzner B, Thiel E, Zander A, Schulz-Kindermann F, Koch U
ANN ONCOL. 2006;17(3):415-423.

Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation.
Schönland S, Lokhorst H, Buzyn A, Leblond V, Hegenbart U, Bandini G, Campbell A, Carreras E, Ferrant A, Grommisch L, Jacobs P, Kröger N, Giorgio L, Russell N, Zachee P, Goldschmidt H, Iacobelli S, Niederwieser D, Gahrton G
BLOOD. 2006;107(6):2578-2584.

Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma.
van de Donk N, Kröger N, Hegenbart U, Corradini P, San Miguel J, Goldschmidt H, Perez-Simon J, Zijlmans M, Raymakers R, Montefusco V, Ayuketang Ayuk F, van Oers M, Nagler A, Verdonck L, Lokhorst H
BONE MARROW TRANSPL. 2006;37(12):1135-1141.

Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A
Zur Stadt U, Beutel K, Kolberg S, Schneppenheim R, Kabisch H, Janka G, Hennies H
HUM MUTAT. 2006;27(1):62-8.

Antithymocyte globulin induces complement-dependent cell lysis and caspase-dependent apoptosis in myeloma cells.
Ayuketang Ayuk F, Fang L, Fehse B, Zander A, Kröger N
EXP HEMATOL. 2005;33(12):1531-1536.

Untersuchungen zur Markierung von mesenchymalen Stammzellen mit unterschiedlichen superparamagnetischen Eisenoxidpartikeln und Nachweisbarkeit in der MRT bei 3T
Ittrich H, Lange C, Dahnke H, Zander A, Adam G, Nolte Ernsting C
ROFO-FORTSCHR RONTG. 2005;177(8):1151-63.

Reduction of myocardial scar size after implantation of mesenchymal stem cells in rats: what is the mechanism?
Jaquet K, Krause K, Denschel J, Faessler P, Nauerz M, Geidel S, Boczor S, Lange C, Stute N, Zander A, Kuck K
STEM CELLS DEV. 2005;14(3):299-309.

Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR
Kerst G, Kreyenberg H, Roth C, Well C, Dietz K, Coustan-Smith E, Campana D, Koscielniak E, Niemeyer C, Schlegel P, Müller I, Niethammer D, Bader P
BRIT J HAEMATOL. 2005;128(6):774-82.

Analysis of progenitor cell mobilization and erythropoietin plasma levels in patients with acute myocardial infarction
Krause K, Fehse B, Jaquet K, Lange C, Kyriazis K, Boczor S, Zander A, Kuck K
EXP CLIN CARDIOL. 2005;10(2):104-7.

Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma.
Kröger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A, Nagler A, Binder T, Eiermann T, Madrigal A, Schwerdtfeger R, Kiehl M, Sayer H, Beyer J, Bornhäuser M, Ayuketang Ayuk F, Zander A, Marks D
BRIT J HAEMATOL. 2005;129(5):631-643.

Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis.
Kröger N, Zabelina T, Schieder H, Panse J, Ayuk F, Stute N, Fehse N, Waschke O, Fehse B, Kvasnicka H, Thiele J, Zander A
BRIT J HAEMATOL. 2005;128(5):690-697.

Hepatocytic gene expression in cultured rat mesenchymal stem cells.
Lange C, Bassler P, Lioznov M, Bruns H, Kluth D, Zander A, Fiegel H
TRANSPL P. 2005;37(1):276-279.

Liver-specific gene expression in mesenchymal stem cells is induced by liver cells.
Lange C, Bassler P, Lioznov M, Bruns H, Kluth D, Zander A, Fiegel H
WORLD J GASTROENTERO. 2005;11(29):4497-4504.

High-potential human mesenchymal stem cells.
Lange C, Schroeder J, Stute N, Lioznov M, Zander A
STEM CELLS DEV. 2005;14(1):70-80.

Administered mesenchymal stem cells enhance recovery from ischemia/reperfusion-induced acute renal failure in rats
Lange C, Tögel F, Ittrich H, Clayton F, Nolte-Ernsting C, Zander A, Westenfelder C
KIDNEY INT. 2005;68(4):1613-7.

A comparison between three graft manipulation methods for haploidentical stem cell transplantation in pediatric patients: preliminary results of a pilot study
Lang P, Schumm M, Greil J, Bader P, Klingebiel T, Müller I, Feuchtinger T, Pfeiffer M, Schlegel P, Niethammer D, Handgretinger R
KLIN PADIATR. 2005;217(6):334-8.

Aldehyde dehydrogenase activity as a marker for the quality of hematopoietic stem cell transplants.
Lioznov M, Freiberger P, Kröger N, Zander A, Fehse B
BONE MARROW TRANSPL. 2005;35(9):909-914.

After major ABO-mismatched allogeneic hematopoietic progenitor cell transplantation, erythroid engraftment occurs later in patients with donor blood group A than donor blood group B.
Schetelig J, Breitschaft A, Kröger N, Zabelina T, Ebell W, Bornhäuser M, Haack A, Ehninger G, Salama A, Siegert W
TRANSFUSION. 2005;45(5):779-787.

Cytotoxic minor histocompatibility antigen HA-1-specific CD8+ effector memory T cells: artificial APCs pave the way for clinical application by potent primary in vitro induction
Schilbach K, Kerst G, Walter S, Eyrich M, Wernet D, Handgretinger R, Xie W, Rammensee H, Müller I, Bühring H, Niethammer D
BLOOD. 2005;106(1):144-9.

Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning.
Shimoni A, Kröger N, Zabelina T, Ayuketang Ayuk F, Hardan I, Yeshurun M, Shem-Tov N, Avigdor A, Ben-Bassat I, Zander A, Nagler A
LEUKEMIA. 2005;19(1):7-12.

Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation.
Thiele J, Kvasnicka H, Dietrich H, Stein G, Hann M, Kaminski A, Rathjen N, Metz K, Beelen D, Ditschkowski M, Zander A, Kröger N
HISTOL HISTOPATHOL. 2005;20(3):879-889.

Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms
Tögel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C
AM J PHYSIOL-RENAL. 2005;289(1):F31-42.

DHPLC based fraction collection of TCR-gamma rearrangements in childhood ALL: direct sequencing of products amplified by a single or a multiplex PCR approach
Zur Stadt U, Isbarn H, Schneppenheim R, Kabisch H
INT J ONCOL. 2005;27(2):547-52.

Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma.
Ayuketang Ayuk F, Shimoni A, Nagler A, Schwerdtfeger R, Kiehl M, Sayer H, Zabelina T, Zander A, Kröger N
LEUKEMIA. 2004;18(3):659-662.

Evidence for increased risk of secondary graft failure after in vivo depletion of suicide gene-modified T lymphocytes transplanted in conjunction with CD34+-enriched blood stem cells.
Fehse B, Ayuketang Ayuk F, Kröger N, Fang L, Kühlcke K, Heinzelmann M, Zabelina T, Fauser A, Zander A
BLOOD. 2004;104(10):3408-3409.

Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission.
Kiehl M, Kraut L, Schwerdtfeger R, Hertenstein B, Remberger M, Kröger N, Stelljes M, Bornhaeuser M, Martin H, Scheid C, Ganser A, Zander A, Kienast J, Ehninger G, Hoelzer D, Diehl V, Fauser A, Ringden O
J CLIN ONCOL. 2004;22(14):2816-2825.

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N, Perez-Simon J, Myint H, Klingemann H, Shimoni A, Nagler A, Martino R, Alegre A, Tomas J, Schwerdtfeger R, Kiehl M, Fauser A, Sayer H, Leon A, Beyer J, Zabelina T, Ayuketang Ayuk F, Miguel S, Jesus F, Brand R, Zander A
BIOL BLOOD MARROW TR. 2004;10(10):698-708.

Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation.
Kröger N, Schilling G, Einsele H, Liebisch P, Shimoni A, Nagler A, Perez-Simon J, Miguel S, Jesus F, Kiehl M, Fauser A, Schwerdtfeger R, Wandt H, Sayer H, Myint H, Zabelina T, Zabelina T, Dierlamm J, Hinke A, Zander A
BLOOD. 2004;103(11):4056-4061.

Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N, Shimoni A, Zagrivnaja M, Ayuketang Ayuk F, Lioznov M, Schieder H, Renges H, Fehse B, Zabelina T, Nagler A, Zander A
BLOOD. 2004;104(10):3361-3363.

Glycosylation and lectins-examples of immunesurveillance and immune evasion
Müller I, Jenner J, Handgretinger R, Riberdy J, Kerst G
HISTOL HISTOPATHOL. 2004;19(2):527-33.

Human gammadelta T cells from G-CSF-mobilized donors retain strong tumoricidal activity and produce immunomodulatory cytokines after clinical-scale isolation
Otto M, Barfield R, Iyengar R, Gatewood J, Müller I, Holladay M, Houston J, Leung W, Handgretinger R
HUM VACC IMMUNOTHER . 2004;28(1):73-8.

Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis.
Schetelig J, Bornhäuser M, Kiehl M, Schwerdtfeger R, Kröger N, Runde V, Zabelina T, Held T, Thiede C, Fauser A, Beelen D, Zander A, Ehninger G, Siegert W
BONE MARROW TRANSPL. 2004;33(5):483-490.

Autologous serum for isolation and expansion of human mesenchymal stem cells for clinical use
Stute N, Holtz K, Bubenheim M, Lange C, Blake F, Zander A
EXP HEMATOL. 2004;32(12):1212-25.

Influence of anti-thymocyte globulin as part of the conditioning regimen on immune reconstitution following matched related bone marrow transplantation.
Fehse N, Fehse B, Kröger N, Zabelina T, Freiberger P, Krüger W, Kabisch H, Erttmann R, Zander A
J Hematother Stem Cell Res. 2003;12(2):237-242.

Hepatic lineages isolated from developing rat liver show different ways of maturation.
Fiegel H, Kluth J, Lioznov M, Holzhüter S, Fehse B, Zander A, Kluth D
BIOCHEM BIOPH RES CO. 2003;305(1):46-53.

Liver-specific gene expression in cultured human hematopoietic stem cells.
Fiegel H, Lioznov M, Cortes-Dericks L, Lange C, Kluth D, Fehse B, Zander A
STEM CELLS. 2003;21(1):98-104.

Characterization of cell types during rat liver development.
Fiegel H, Park J, Lioznov M, Martin A, Jaeschke-Melli S, Kaufmann P, Fehse B, Zander A, Kluth D
HEPATOLOGY. 2003;37(1):148-154.

Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).
Kröger N, Einsele H, Wolff D, Casper J, Freund M, Derigs G, Wandt H, Schäfer-Eckart K, Wittkowsky G, Schmitz N, Krüger W, Zabelina T, Renges H, Ayuketang Ayuk F, Krüll A, Zander A
BONE MARROW TRANSPL. 2003;31(11):973-979.

Predictable and efficient retroviral gene transfer into murine bone marrow repopulating cells using a defined vector dose
Li Z, Schwieger M, Lange C, Kraunus J, Sun H, van den Akker E, Modlich U, Serinsöz E, Will E, von Laer D, Stocking C, Fehse B, Schiedlmeier B, Baum C
EXP HEMATOL. 2003;31(12):1206-14.

Receptor activator of nuclear factor kappaB ligand plays a nonredundant role in doxorubicin-induced apoptosis
Müller I, Pfister S, Grohs U, Zweigner J, Handgretinger R, Niethammer D, Bruchelt G
CANCER RES. 2003;63(8):1772-5.

Non-overt disseminated intravascular coagulation in patients during treatment with antithymocyte globulin for unrelated allogeneic hematopoietic stem cell transplantation.
Weber M, Kröger N, Langer F, Hansen A, Zabelina T, Eifrig B, Hossfeld D, Zander A
BONE MARROW TRANSPL. 2003;31(9):817-822.

Minor histocompatibility antigens on canine hemopoietic progenitor cells
Weber M, Lange C, Günther W, Franz M, Kremmer E, Kolb H
J IMMUNOL. 2003;170(12):5861-8.

ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML).
Zander A, Kröger N, Schleuning M, Finke J, Zabelina T, Beelen D, Schwerdtfeger R, Baurmann H, Bornhäuser M, Ehninger G, Fauser A, Kiehl M, Trenschel R, Ottinger H, Bertz H, Berger J, Kolb H, Schaefer U
BONE MARROW TRANSPL. 2003;32(4):355-361.

[Unrelated donor stem cell transplantation in children: low toxicity using a GvHD-prophylaxis regimen with CSA, MTX, metronidazole,iv-immunoglobulin and ATG]
Graf Finckenstein F, Zabelina T, Dürken M, Dahlke J, Kröger N, Krüger W, Janka-Schaub G, Erttmann R, Zander A, Kabisch H
KLIN PADIATR. 2002;214(4):206-211.

Binding of activated platelets to WBCs in vivo after transfusion.
Gutensohn K, Geidel K, Brockmann M, Siemensen M, Krueger W, Kröger N, Kuehnl P
TRANSFUSION. 2002;42(10):1373-1380.

Platelet function testing in apheresis products: flow cytometric, resonance thrombographic (RTG) and rotational thrombelastographic (roTEG) analyses.
Gutensohn K, Geidel K, Kröger N, Eifrig B, Crespeigne N, Kuehnl P
TRANSFUS APHER SCI. 2002;26(3):147-155.

Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia.
Hessling J, Kröger N, Werner M, Zabelina T, Hansen A, Kordes U, Ayuketang Ayuk F, Renges H, Panse J, Erttmann R, Zander A
BRIT J HAEMATOL. 2002;119(3):769-772.

Radiotherapy after high-dose chemotherapy and peripheral blood stem cell support in high-risk breast cancer.
Hoeller U, Juergen H, Kröger N, Krueger W, Jaenicke F, Alberti W
INT J RADIAT ONCOL. 2002;53(5):1234-1239.

Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality.
Kröger N, Sayer H, Schwerdtfeger R, Kiehl M, Nagler A, Renges H, Zabelina T, Fehse B, Ayuketang Ayuk F, Wittkowsky G, Schmitz N, Zander A
BLOOD. 2002;100(12):3919-3924.

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma.
Kröger N, Schwerdtfeger R, Kiehl M, Sayer H, Renges H, Zabelina T, Fehse B, Tögel F, Wittkowsky G, Kuse R, Zander A
BLOOD. 2002;100(3):755-760.

Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
Kröger N, Zabelina T, Guardiola P, Volker R, Sierra J, Anja V, Niederwieser D, Zander A, Theo D
BRIT J HAEMATOL. 2002;118(1):67-73.

In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors.
Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Rischewski J, Sonnenberg S, Ayuk F, Ayuketang Ayuk F, Schade U, Fiegel H, Erttmann R, Löliger C, Zander A
BONE MARROW TRANSPL. 2002;29(8):683-689.

Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin.
Kröger N, Zabelina T, Renges H, Krüger W, Kordes U, Rischewski J, Schrum J, Horstmann M, Ayuketang Ayuk F, Erttmann R, Kabisch H, Zander A
ANN HEMATOL. 2002;81(11):627-631.

Highly efficient retroviral gene transfer based on centrifugation-mediated vector preloading of tissue culture vessels.
Kühlcke K, Fehse B, Schilz A, Loges S, Lindemann C, Ayuketang Ayuk F, Lehmann F, Stute N, Fauser A, Zander A, Eckert H
MOL THER. 2002;5(4):473-478.

Reconstitution of mRNA editing in yeast using a Gal4-apoB-Gal80 fusion transcript as the selectable marker.
Lellek H, Welker S, Diehl I, Kirsten R, Greeve J
J BIOL CHEM. 2002;277(26):23638-23644.

Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease.
Schetelig J, Kröger N, Held T, Christian T, Krusch A, Zabelina T, Dubiel M, Rick O, Bornhäuser M, Ehninger G, Zander A, Siegert W
HAEMATOLOGICA. 2002;87(3):299-305.

Interleukin-10 modulation of alloreactivity and graft-versus-host reactions
Wang X, Lange C, Schulz U, Sviland L, Eissner G, Oliver K, Jackson G, Holler E, Dickinson A
TRANSPLANTATION. 2002;74(6):772-8.

T lymphocytes as targets of gene transfer with Moloney-type retroviral vectors.
Ayuketang Ayuk F, Zander A, Fehse B
CURR GENE THER. 2001;1(4):325-337.

Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation.
Fehse B, Chukhlovin A, Kühlcke K, Marinetz O, Vorwig O, Renges H, Krüger W, Zabelina T, Dudina O, Finckenstein F, Kröger N, Kabisch H, Hochhaus A, Zander A
J Hematother Stem Cell Res. 2001;10(3):419-425.

Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma.
Kröger N, Krüger W, Renges H, Zabelina T, Stute N, Jung R, Wittkowsky G, Kuse R, Zander A
BRIT J HAEMATOL. 2001;112(2):421-423.

A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N, Schetelig J, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander A
BONE MARROW TRANSPL. 2001;28(7):643-647.

Anti-thymocyte-globulin as part of the preparative regimen prevents graft failure and severe graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors.
Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Dürken M, Graf von Finkenstein F, Erttmann R, Kabisch H, Schafhausen P, Jaburg N, Löliger C, Zander A
ANN HEMATOL. 2001;80(4):209-215.

Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Kabisch H, Jaburg N, Löliger C, Krüll A, Zander A
BONE MARROW TRANSPL. 2001;27(4):349-354.

Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin.
Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Schafhausen P, Jaburg N, Löliger C, Schäfer P, Hinke A, Zander A
BRIT J HAEMATOL. 2001;113(4):1060-1071.

Noncutaneous varicella-zoster virus (VZV) infection with fatal liver failure in a child with acute lymphoblastic leukemia (ALL)
Müller I, Aepinus C, Beck R, Bültmann B, Niethammer D, Klingebiel T
Med Pediatr Oncol. 2001;37(2):145-7.

Extracorporeal plateletpheresis induces the interaction of activated platelets with white blood cells.
Gutensohn K, Alisch A, Krueger W, Kröger N, Kuehnl P
VOX SANG. 2000;78(2):101-105.

Quiescence of CD34-negative haematopoietic stem cells is mediated by downregulation of Cyclin B and no stat activation
Huss R, Gatsios P, Graeve L, Lange C, Eissner G, Kolb H, Thalmeier K, Heinrich P
CYTOKINE. 2000;12(8):1195-204.

Evidence of peripheral blood-derived, plastic-adherent CD34(-/low) hematopoietic stem cell clones with mesenchymal stem cell characteristics
Huss R, Lange C, Weissinger E, Kolb H, Thalmeier K
STEM CELLS. 2000;18(4):252-60.

In vitro-generated stem cell leukaemia showing altered cell cycle progression with distinct signalling of the tyrosine-phosphorylated rasGAP-associated p62(dok) protein
Huss R, Weissinger E, Lange C, Gatsios P, Eissner G, Kolb H, Diebold J, Heinrich P, Graeve L
J PATHOL. 2000;192(3):363-72.

Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, Del Valle F, Erttmann R, Kabisch H, Zander A
BONE MARROW TRANSPL. 2000;26(7):711-716.

Retroviral transduction of T lymphocytes for suicide gene therapy in allogeneic stem cell transplantation.
Kühlcke K, Ayuketang Ayuk F, Li Z, Lindemann C, Schilz A, Schade U M, Fauser A, Zander A, Eckert H, Fehse B
BONE MARROW TRANSPL. 2000;25(2):96-98.

Purification and molecular cloning of a novel essential component of the apolipoprotein B mRNA editing enzyme-complex.
Lellek H, Kirsten R, Diehl I, Apostel F, Buck F, Greeve J
J BIOL CHEM. 2000;275(26):19848-19856.

Low molecular thymic peptides stimulate human blood dendritic cells
Mayer G, Pohlmeyer K, Caliebe A, Heimueller E, Behnke B, Steimann G, Lange C, Beuth J
ANTICANCER RES. 2000;20(5A):2873-83.

Generation of functionally mature dendritic cells from the multipotential stem cell line FDCP-mix
Schroeder T, Strehl J, Lange C, Just U
BRIT J HAEMATOL. 2000;111(3):890-7.

Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirements.
Ayuketang Ayuk F, Li Z, Kühlcke K, Lindemann C, Schade U, Eckert H, Zander A, Fehse B
GENE THER. 1999;6(10):1788-1792.

Improved outcome in haemophagocytic lymphohistiocytosis after bone marrow transplantation from related and unrelated donors: a single-centre experience of 12 patients
Dürken M, Horstmann M, Bieling P, Erttmann R, Kabisch H, Löliger C, Schneider E, Hellwege H, Krüger W, Kröger N, Zander A, Janka G
BRIT J HAEMATOL. 1999;106(4):1052-8.

Rapid and efficient cloning of proviral flanking fragments by kanamycin resistance gene complementation
Fehse B, Kühlcke K, Langer A, Ostertag W, Lother H
NUCLEIC ACIDS RES. 1999;27(2):706-7.

Absence of APOBEC-1 mediated mRNA editing in human carcinomas.
Greeve J, Lellek H, Apostel F, Hundoegger K, Barialai A, Kirsten R, Welker S, Greten H
ONCOGENE. 1999;18(46):6357-6366.

Semi-automated flow cytometric analysis of CD34-expressing hematopoietic cells in peripheral blood progenitor cell apheresis products.
Gutensohn K, Carrero I, Krueger W, Kröger N, Schäfer P, Luedemann K, Kuehnl P
TRANSFUSION. 1999;39(11-12):1220-1226.

Hematopoietic reconstitution of syngeneic mice with a peripheral blood-derived, monoclonal CD34-, Sca-1+, Thy-1(low), c-kit+ stem cell line
Lange C, Kaltz C, Thalmeier K, Kolb H, Huss R
J Hematother Stem Cell Res. 1999;8(4):335-42.

Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow.
Zander A, Zabelina T, Kröger N, Renges H, Krüger W, Löliger C, Dürken M, Stockschläder M, de Wit M, Wacker-Backhaus G, Bielack S, Jaburg N, Rüssmann B, Erttmann R, Kabisch H
BONE MARROW TRANSPL. 1999;23(9):889-893.

Highly-efficient gene transfer with retroviral vectors into human T lymphocytes on fibronectin
Fehse B, Schade U, Li Z, Uhde A, Koch S, Goller B, Rüger R, Fehse N, Stockschläder M, Zander A
BRIT J HAEMATOL. 1998;102(2):566-74.

Inhibition of the apolipoprotein B mRNA editing enzyme-complex by hnRNP C1 protein and 40S hnRNP complexes.
Greeve J, Lellek H, Rautenberg P, Greten H
BIOL CHEM. 1998;379(8-9):1063-1073.

Dominant selection of hematopoietic progenitor cells with retroviral MDR1 co-expression vectors
Hildinger M, Fehse B, Hegewisch-Becker S, John J, Rafferty J, Ostertag W, Baum C
HUM GENE THER. 1998;9(1):33-42.

Interleukin 4 gene-defective mice reconstituted with wild-type bone marrow fail to produce normal immunoglobulin E levels
Lange C, Schüler T, Blankenstein T
J EXP MED. 1998;187(9):1487-93.

Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer.
Lehnert M, Mross K, Schueller J, Thuerlimann B, Kröger N, Kupper H
BRIT J CANCER. 1998;77(7):1155-1163.

Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review)
Müller I, Niethammer D, Bruchelt G
INT J MOL MED. 1998;1(2):491-4.

Loss of retroviral gene expression in bone marrow reconstituted mice correlates with down-regulation of gene expression in long-term culture initiating cells
Lange C, Blankenstein T
GENE THER. 1997;4(4):303-8.

Mobilisation kinetics of primitive haemopoietic cells following G-CSF with or without chemotherapy for advanced breast cancer
Baumann I, Swindell R, Van Hoeff M, Dexter T, de Wynter E, Lange C, Luft T, Howell A, Testa N
ANN ONCOL. 1996;7(10):1051-7.

Excision of specific DNA-sequences from integrated retroviral vectors via site-specific recombination
Bergemann J, Kühlcke K, Fehse B, Ratz I, Ostertag W, Lother H
NUCLEIC ACIDS RES. 1995;23(21):4451-6.

[The structure of the hemodynamic reactions to isometric loading in relation to the initial arterial pressure level]
Lioznova E, Lioznov M
Fiziol Cheloveka. 1994;20(2):73-79.

Timing of peripheral blood progenitor cell (PBPC) collections during recovery from chemotherapy supported by haematopoietic growth factor
Van Hoef M, Baumann I, Lange C, De Wynter E, Testa N, Howell A
LEUKEMIA. 1994;8(11):2020-1.

Dose-escalating induction chemotherapy supported by lenograstim preceding high-dose consolidation chemotherapy for advanced breast cancer. Selection of the most acceptable regimen to induce maximal tumor response and investigation of the optimal time to collect peripheral blood progenitor cells for haematological rescue after high-dose consolidation chemotherapy
Van Hoef M, Baumann I, Lange C, Luft T, de Wynter E, Ranson M, Morgenstern G, Yvers A, Dexter T, Testa N
ANN ONCOL. 1994;5(3):217-24.

Rapid haematological recovery after high-dose consolidation chemotherapy with peripheral blood progenitor cells (PBPC) as sole source of support collected at a single apheresis
Van Hoef M, Ranson M, Morgenstern G, Baumann I, Lange C, de Wynter E, Testa N, Howell A
BONE MARROW TRANSPL. 1994;13(6):839-40.

Haemopoietic cells mobilised into the circulation by lenograstim as alternative to bone marrow for allogeneic transplants
Baumann I, Testa N, Lange C, de Wynter E, Luft T, Dexter T, van Hoef M, Howell A
LANCET. 1993;341(8841):369.

[Experience with using cefoperazone in cancer patients after bone marrow transplantation]
Afanas'ev B, Zubarevskaia L, Shmidt A, Zabelina T
Antibiot Khimioter. 1992;37(8):14-15.

Metolazone in der Behandlung fortgeschrittener therapieresistenter dilatativer Kardiomyopathie
Kröger N, Szuba J, Frenzel H
MED KLIN-INTENSIVMED. 1991;86(6):305-8, 332.

[The nature of the changes in the systemic hemodynamic parameters under the combined action of vasoactive substances]
Lioznov M, Tkachenko B
Fiziol Zh SSSR Im I M Sechenova. 1991;77(4):24-33.

Metolazone for severe dilated cardiomyopathy refractory to conventional therapy
Kröger N, Szuba J, Buhl C, Pompecki R, Frenzel H
LANCET. 1990;335(8696):1031-2.

[Changes in arterial pressure during the joint action of vasoactive substances with unidirectional effects]
Lioznov M, Tkachenko B
Biull Eksp Biol Med. 1990;109(3):222-224.

[Character of arterial pressure changes under combined action of pressor and depressor agents]
Lioznov M, Tkachenko B
Biull Eksp Biol Med. 1990;109(1):13-15.

Nachweis von Neuroblastomzellen im Knochenmark durch "Southern-Blot" und "In situ-Hybridisierung" mit Hilfe einer NMYC-DNS-Probe
Kabisch H, Heinsohn S, Milde-Langosch K, Löning T, Bartl S, Erttmann R, Landbeck G
MONATSSCHR KINDERH. 1987;135(4):210-3.

[Therapy of patients with myeloid leukemia with small doses of cytosine arabinoside]
Patterson D, Kravtsova V, Petrova E, Zabelina T, Balaian L
TERAPEVT ARKH. 1987;59(12):81-86.

[Cloning of hematopoietic cells of patients with different forms of hematopoietic dysplasia in agar (clinico-cultural correlations)]
Afanas'ev B, Kulibaba T, Zabelina T, Lukasheva T, Smirnova G
TERAPEVT ARKH. 1982;54(8):97-103.

Proliferation and maturation of hemopoietic cells in adult patients with different forms of acute leukemia and chronic myeloid leukemia in agar and liquid cultures.
Afanasiev B, Elstner E, Saidali M, Zabelina T
Haematol Blood Transfus. 1981;26:251-254.

[Cloning of hematopoietic cells from patients with different variants of leukemia in a double-layer agar system]
Almazov V, Afanas'ev B, Kulibaba T, Smirnova G, Zabelina T
TERAPEVT ARKH. 1981;53(9):110-115.

[Treatment of autoimmune thrombocytopenic purpura with vincristine]
Bueva O, Afanas'ev B, Zabelina T, Petrov M, Kuznetsova A
TERAPEVT ARKH. 1981;53(11):80-84.

[Colony-forming capacity of the bone marrow cells in acute agranulocytosis]
Afanas'ev B, Postriganeva T, Shishkov A, Zaritski A, Zabelina T
Probl Gematol Pereliv Krovi. 1980;25(7):19-23.

[Proliferation and maturation of the hematopoietic cells in myelocytic leukemia in the stage of blast crisis]
Afanas'ev B, Sa Dali M, Zaritski A, Zabelina T, Mikha Lova T
Probl Gematol Pereliv Krovi. 1980;25(4):15-21.

[Cyclophosphan and prednisolone immunosuppressant therapy of a patient with hypoplastic anemia]
Postriganeva T, Afanas'ev B, Zaritski A, Sa Dali M, Zabelina T
TERAPEVT ARKH. 1980;52(9):108-110.

[Granulomonocytopoietic precursor cells in chronic myeloid leukemia]
Zabelina T, Afanas'ev B, Zaritski A, Razorenov L, Evert A
TERAPEVT ARKH. 1980;52(9):78-82.

[Colony-stimulating activity of the plasma from hematologically healthy persons]
Zaritski A, Afanas'ev B, Zabelina T, Gol'dman E, Postriganeva T
Probl Gematol Pereliv Krovi. 1980;25(2):15-18.

[Bone marrow cell colony-forming capacity in persons with benign leukopenia]
Afanas'ev B, Zaritski A, Zabelina T, Postriganeva T
Probl Gematol Pereliv Krovi. 1979;24(9):29-32.

[Colony-forming capacity of bone marrow cells in patients with various neutropenic conditions: hypoplastic anemia]
Afanas'ev B, Zaritski A, Zabelina T, Postriganeva T
TERAPEVT ARKH. 1979;51(3):76-85.

[Colony-forming capacity of the bone marrow cells in B12- and folic acid-deficiency anemias]
Afanas'ev B, Zaritski A, Zabelina T, Sa Dali M, Postiganeva T
Probl Gematol Pereliv Krovi. 1979;24(5):13-16.

[Regulation of granulo- and monocytic precursor cells in myeloma disease]
Zaritski A, Afanas'ev B, Gol'daman E, Zabelina T, Dubova F
Probl Gematol Pereliv Krovi. 1979;24(6):11-16.

[Regulation of granulo- and monocytic cell precursors in chronic lympholeukemia]
Zaritski A, Afanas'ev B, Gol'dman E, Zabelina T, Dubova F
Probl Gematol Pereliv Krovi. 1979;24(4):19-24.

[Bone marrow cell colony-forming capacity in various neutropenic conditions. Liver cirrhosis]
Afanal'ev B, Zaritski A, Shishkov A, Zabelina T, Postriganeva T
TERAPEVT ARKH. 1978;50(10):108-111.

[Treatment of idiopathic thrombopenia with vincristine]
Afanas'ev B, Zabelina T, Petrov M, Zaritski A
TERAPEVT ARKH. 1978;50(5):60-67.

The colony-forming ability of bone marrow in patients with different neutropenic states.
Almazov V, Afanasiev B, Zaritsky A, Zabelina T
HAEMATOLOGICA. 1977;62(5):490-505.

[Colony-forming capacity of the bone marrow and blood cells in vitro in different forms of acute leukemia]
Zabelina T, Afanas'ev B, Zaritski A, Postriganeva T, Sa Dali M
TERAPEVT ARKH. 1977;49(8):53-59.

Letzte Aktualisierung aus dem FIS: 24.10.2017 - 00:01 Uhr